The Role of Human Ubc9 During the Human Immunodeficiency Virus Replication Cycle by Bohl, Christopher R.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Dissertations and Theses in Biological Sciences Biological Sciences, School of 
9-2011 
The Role of Human Ubc9 During the Human Immunodeficiency 
Virus Replication Cycle 
Christopher R. Bohl 
University of Nebraska-Lincoln, cbohl1@hotmail.com 
Follow this and additional works at: https://digitalcommons.unl.edu/bioscidiss 
 Part of the Virology Commons 
Bohl, Christopher R., "The Role of Human Ubc9 During the Human Immunodeficiency Virus Replication 
Cycle" (2011). Dissertations and Theses in Biological Sciences. 34. 
https://digitalcommons.unl.edu/bioscidiss/34 
This Article is brought to you for free and open access by the Biological Sciences, School of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Dissertations and Theses in 
Biological Sciences by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
THE ROLE OF HUMAN UBC9 DURING THE HUMAN IMMUNODEFICIENCY 
VIRUS REPLICATION CYCLE 
 
by 
 
Christopher R. Bohl 
 
A DISSERTATION  
 
Presented to the Faculty of 
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Doctor of Philosophy 
 
Major: Biological Sciences 
 
Under the Supervision of Professor Charles Wood 
 
Lincoln, Nebraska 
 
September, 2011 
THE ROLE OF HUMAN UBC9 DURING THE HUMAN IMMUNODEFICIENCY 
VIRUS REPLICATION CYCLE 
Christopher R. Bohl, Ph.D. 
University of Nebraska, 2011 
Adviser: Charles Wood 
 
 Human immunodeficiency virus type 1 (HIV-1) is a retrovirus and the causative 
agent of the acquired immune deficiency syndrome (AIDS) pandemic.   The retrovirus 
replication cycle is divided into early infectious events, which involve the infection and 
integration of the viral DNA into target cell chromosomes; and late events, which involve 
the expression of viral genes and assembly of infectious virions.  To complete the 
replication cycle, HIV-1 utilizes various cellular pathways. 
 We identified the Ubc9 E2 SUMO conjugating enzyme as a HIV-1 Gag 
interaction partner.  When this interaction was disrupted in HIV-1 producer cells by Ubc9 
siRNA, the virus that was released from the cells was approximately 10-fold less 
infectious than virus released from control cells.  The decreased virion infectivity was 
found to be due to decreased levels of intracellular mature Env, which in turn decreased 
the amount of Env packaged into assembling virions.  Surprisingly, the defect in mature 
Env levels in Ubc9 knockdown cell was dependent upon Gag expression.  The 
mechanism of decreased mature Env in Ubc9 knockdown cells was examined and we 
found that gp120/gp41 appeared to be preferentially degraded at a post gp160 cleavage 
step, but before transport/association with the plasma membrane and lipid rafts.   The 
intracellular gp120 levels were restored when cells were treated with lysosome inhibitors, 
which suggested that the decreased intracellular Env stability is due to increased 
lysosomal degradation; however, inhibiting Env degradation did not restore Env 
packaging into assembled virions.  Since lysosomal degradation is linked with autophagy, 
we examined autophagy in Ubc9 knockdown cells and found that autophagy was 
increased approximately 3-fold compared to control cells.  Autophagy inhibitors were 
unable to block autophagy, and we were unable to determine if increased lysosomal 
degradation of gp120 was occurring through an autophagy dependent or independent 
mechanism. 
 We have also examined the potential role of Ubc9 during the HIV-1 early 
infectious events.  Decreased LTR driven gene expression was detected following the 
infection of Ubc9 knockdown cells with VSV-G pseudotyped HIV-1 virions.  These 
results suggested that Ubc9 plays a functional role during the early events of the HIV-1 
replication cycle at a post-entry step. 
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Chapter I 
Introduction and literature review 
Human immunodeficiency virus 
 
Human immunodeficiency virus type-1 (HIV-1) is the etiological agent of 
acquired immune deficiency syndrome (AIDS), a disease that progressively depletes the 
immune system over a long period of time, due to the infection and death of the host’s 
primary lymphocytes, leading to complications with opportunistic infections or 
malignancies that result in death.  The World Health Organization and the United Nations 
Program on HIV/AIDS estimate that there are 33.3 million people worldwide infected 
with HIV.  Since the start of the pandemic, it is estimated that 60 million people have 
been infected, with approximately 25 million deaths related to AIDS.  While progress has 
been made in the fight against the AIDS epidemic through the implementation of 
educational programs and an increased accessibility of anti-retroviral drugs, there was 
still an estimated 2.6 million new infections in 2009 (362). 
HIV-1 is a human retrovirus and is a member of the Retroviridae family.  It is 
classified as a lentivirus (genera) based on the organization of the viral genome and 
particle morphology.  Retroviruses are enveloped, plus-stranded RNA viruses that 
replicate via a DNA intermediate.  This replication strategy is a defining characteristic of 
the Retroviridae family. The viral genome is packaged into virion particles as a dimer of 
plus-strand, linear RNA (vRNA).  Upon receptor-mediated attachment and entry into a 
target cell, the core of the virus in released into the cytoplasm where the vRNA is reverse 
transcribed by viral proteins into linear DNA (vDNA).  The vDNA is then shuttled to the 
nucleus where it is covalently integrated into the host cell genome by the viral integrase, 
 2 
aided by host proteins.  The host transcription/translation machinery expresses the viral 
genes.  Taking advantage of the various cellular pathways, the viral proteins assemble 
and release new virions (reviewed in 71, 112, 114). 
Virion structure 
  The mature HIV-1 virion is a spherical particle with a centrally located cone-
shaped core. The virions are heterogeneous in size with a mean diameter of 
approximately 135-145 nm (42, 120).  The core is also heterologous in size and shape 
with an average length and diameter of approximatley103 nm and 52 nm respectively 
(377) (Fig. 1a).  The core encapsulates the viral ribonucleoprotein complex consisting of 
the vRNA coated with the viral nucleocapsid protein, the replication enzymes reverse 
transcriptase and integrase, protease, Nef, and Vpr (107, 191, 377).  The virion is coated 
with a host derived lipid envelope.  The viral envelope is derived from the plasma 
membrane of the virus producer cell, however the viral envelope is enriched in 
cholesterol, sphingomyelins, glycphingolipids, saturated phosphoglycerolipids and 
phosphoinositides, ceramide, GM3, phosphatidylinositol 4,5-bisphosphate [PI(4,5)P(2)], 
and is more highly ordered compared to the plasma membrane of the viral producing 
cells (7, 52, 225).  The mature viral glycoproteins, homotrimers of gp120/gp41 
heterodimers, are inserted into the viral envelope and protrude from the surface of the 
virus along with other host derived membrane proteins (194, 195, 277, 317, 327).  It is 
estimated that fewer that 10 glycoprotein timers are present on a virion (62, 408).  The 
matrix proteins are located directly beneath the lipid membrane.  A number of host 
proteins are both selectively packaged and randomly packaged into virions.  The location 
of these proteins within the virion are unknown, but it is likely that the majority are either 
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associated with the outside of the capsid core, or in the intravirion space between the core 
and the matrix shell (2, 63, 377) (Fig. 1b). 
Viral genome and transcriptional regulation 
The HIV-1 is classified as a complex retrovirus because it encodes a number of 
regulatory, and accessory proteins.  The HIV-1 genome contains 9 open reading frames 
that encode for a number of structural and non-structural proteins (Fig. 2).  Identical viral 
long terminal repeats (LTRs) flank the viral genome and encode the cis-acting elements 
involved in regulating viral gene expression.  The 5’-LTR contains the majority of the 
host transcription factor binding sites that regulate the transcriptional activation of RNA 
Polymerase II.  These are primarily located within the 5’-U3 region.  The transcription 
start site located at the boundary between U3-Repeat (R) regions (reviewed in 170).  The 
R region also contains the transactivating responsive sequence (TAR) that enhances 
transcription from the viral promoter through interactions with the viral Tat accessory 
protein (reviewed in 300).  The 3’-LTR contains the cis-acting sequences that are 
responsible for the 3’-end processing and polyadenylation of the vRNA and are located at 
the boundary between the 5’-R-U5 regions (72).  Approximately half of the vRNA is 
spliced within the nucleus by the host RNA splicing machinery creating more than 40 
different mRNA species.  The majority of these alternatively spliced vRNAs are used in 
the expression of Env and viral accessory proteins (160, 301, 345).  The unspliced and 
partially spliced vRNAs are exported to the cytoplasm through the interactions of the 
viral accessory protein Rev and the cis acting sequence Rev response element (RRE) in 
the Env gene (reviewed in 295), and are used for Gag and Gag-Pol expression or 
packaging into assembling virions. 
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Viral proteins and function 
 
Gag 
 
The gag gene encodes the major viral structural protein Gag.  Gag is translated 
from full-length unspliced vRNA on cytoplasmic ribosomes.  The HIV-1 Gag protein is a 
55 kDa polyprotein precursor that encodes all the necessary functional domains/motifs to 
drive the assembly and release of virus like particles (VLPs) in the absence of all other 
viral proteins.  The Gag protein undergoes a viral protease-dependent maturation event 
where Gag is systematically cleaved into the mature, infectious virion proteins during, or 
shortly after release from the cell.  The Gag polyprotein is cleaved into: matrix (MA), 
capsid (CA), spacer peptide 2 (SP2), nucleocapsid (NC), spacer peptide 1 (SP1), and p6.  
The functional domains within Gag are located through the Gag protein and have various 
functional roles during assembly.  The membrane binding-domain (M-domain) is located 
in the N-terminus of MA, and functions by regulating the targeting and binding of Gag to 
specific host cell membranes.  The interaction domain (I-domain) sequences are found 
within the CA and NC domains and function in Gag-Gag interactions and 
multimerization that leads to the assembly of immature virions.  The late domain(s) (L-
domain) is located within p6 and facilitates the budding and release of newly assembled 
virions by interacting with components of the endosomal sorting complex required for 
transport (ESCORT) pathway (reviewed in 363, 375).  Sequences within p6 are also 
responsible for the packaging of the viral accessory protein Vpr (189).  The Gag protein 
is responsible for the binding and packaging of the full-length genomic vRNA through 
interactions with the Psi packaging sequences in the vRNA and zinc-finger motifs within 
NC (Gag function reviewed in 113, 352, 387).  
 5 
 
Replication enzymes (Protease, Reverse transcriptase, and Integrase) 
 
The pol gene encodes for three essential viral enzymes protease, reverse 
transcriptase, and integrase.  The pol proteins are expressed as a Gag-Pol fusion 
polyprotein through a -1 frame shift that occurs near the c-terminus of Gag and occurs 
approximately 5-10% of the time (161).  The pol encoded proteins are packaged into 
assembling virions through interactions within the I-domains within the Gag sequences of 
Gag-Pol.  The viral protease (PR) is encoded in the 5’ end of the pol gene.  PR is a small 
(10 kDa) homodimeric aspartic protease and it is essential for virion infectivity (188).  
The mechanism of protease auto-activation is not well understood, however dimerization 
is essential for the creation of the active site.  The viral Protease is activated during or 
shortly after virion budding and is responsible for the cleavage maturation of Gag and 
Gag-Pol into the various infectious proteins found within the mature virion.  PR-
dependent maturation of Gag is accompanied with a morphological change in the virion. 
Nef is also cleaved by PR and may play a role in virion infectivity in T-cells (46, 283).  
PR is one of the targets of anti-retroviral drug treatment in patients (reviewed in 380). 
 Reverse Transcriptase (RT) is the second protein encoded in pol.  Reverse 
Transcriptase is the viral RNA-dependent DNA polymerase.  The functional RT is a 
heterodimers of two subunits (p66/51), which differ only in the presence or absence of 
the RNase H domain.  Interestingly, the two subunits fold into distinctly different 
structures, with only the p66 contributing to the enzymatic activity (150, 206).  The p51 
subunit appears to play a structural role and may be involved with binding of the 
tRNA3
lys
 primer.  RT initiates the synthesis of minus-strand DNA using tRNA3
lys
 that is 
base paired to the primer binding sequence within the vRNA.  After the RT synthesizes 
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vDNA, the RNase H domain degrades the vRNA template.  As RT reaches the end of the 
5’-vRNA, the RT complex transfers to the 3’ end of the vRNA where the R regions base 
pair and minus-strand vDNA synthesis continues.  The RNase H resistant, polypurine 
tract is then used by the RT complex as a primer to extend the 3’-plus-strand vDNA.  The 
remaining RNA is degraded by RNase H, and the plus-strand vDNA is transferred to the 
5’-end of the vDNA where it base pairs with complementary sequences and continues 
vDNA synthesis (Fig. 3) (reviewed in 71).  RT has low intrinsic fidelity that leads to 
nucleotide misincorporation during the vDNA synthesis.  These nucleotide 
misincorporations lead to high genomic variability among viruses.  The viral genome also 
undergoes multiple recombination/cross over events during reverse transcription, 
increasing genetic variability (212).  Because RT is unique to the viral genome, it is also 
a major target for anti-retroviral drug treatments (reviewed in 324, 366). 
 Integrase is the last protein encoded by pol.  The integrase functions to assist the 
nuclear import of the pre-integration complex (PIC), and to covalently insert the vDNA 
into the host chromosome.  The Integrase protein accomplishes this through two different 
catalytic activities carried out by two different integrase complexes.  Integrase forms 
dimers on the ends of the vDNA at each LTR.  The dimer processes the 3’-end of the 
LTRs through an endonucleotide cleavage and removal of a dinucleotide from the 3’-end 
from each of the LTRs.  The ends of the vDNA are brought together and the integrase 
dimers form a tetramer, the functional integration complex (61).  The tetrameric integrase 
then facilitates the vDNA strand transfer and integration into the host chromosome.  
Weak palindromic consensus sequences have been identified at integrations sites 
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suggesting that there are preferred integration sites within the host genome.  Integrase is 
also a target for anti-retroviral drug treatment (132, 393) Integrase reviewed in 71, 82). 
Envelope glycoprotein 
The env gene encodes the viral glycoprotein (Env) and is responsible for virion 
attachment and entry into a target.  Env translated from a singly spliced vRNA in the 
endoplasmic reticulum (ER) as a precursor protein (gp160).  The gp160 is highly N-
glycosylated and forms timers in the ER.  As gp160 trafficks out of the ER and through 
the Golgi complex, the glycans are modified into complex sugars and the gp160 trimers 
are cleaved by Furin in the trans-Golgi complex (TGN) into the mature fusogenic forms 
(trimers of gp120 and gp41 heterodimers).  The mature Env trafficks through the cellular 
secretory system to the plasma membrane (PM) where it is incorporated into the 
assembling virions, or endocytosed and recycled back to the TGN, or degraded in the 
lysosome.  The gp120 surface subunit (SU) functions by binding and attaching the virion 
to the surface of a target cell through specific interactions with the viral receptor (CD4) 
and co-receptor(s) (CXCR4 and CCCR5).  The interaction of the co-receptor of the 
variable loop 3 (V3 loop) of gp120 directs cell tropism.  T-tropic viruses that infect T-
cells utilize CCCR4, while M-tropic viruses that infect primary macrophage utilize 
CCCR5 as a co-receptor.  The gp120 subunit is highly variable among isolates in both 
sequence and amino acids length, leading to variations in stability, receptor binding 
affinity, and antibody neutralization. The gp120 is non-covalently bound to gp41, and is 
often shed from the cell.  The gp41 transmembrane subunit (TM) is anchored in lipid 
membranes through a transmembrane domain and contains a long C-terminal cytoplasmic 
tail (CT) that mediates packaging into the assembling virion and limits cell surface 
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expression through endocytosis.  The gp41 mediates the fusion of the viral lipid envelope 
through interactions with the target cell PM and N-terminal fusogenic peptide leading to 
the release of the viral core into the cytoplasm (reviewed in 58, 116).  Env functions in 
viral replication are also targets for anti-retroviral drug treatment (356). 
Accessory proteins (Vif, Vpu, Vpr, Nef, Tat, and Rev)  
The vif gene encodes a small 23 kDa multifunction protein that is associated with 
the nucleus, host cell membranes, and is essential for viral replication in primary T-cells 
(reviewed in 71). Virion infectivity factor (Vif) is translated from a singly spiced vRNA 
and is packaged into assembling virions through interactions with Gag at levels similar to 
the Pol products (39, 50, 109, 219).  Vif forms multimers and has been implicated to be 
involved in virion assembly by increasing Env incorporation into virions by regulating 
PR activation, Gag processing, core stability, and morphology.  However the mechanisms 
of these functions is unknown (35, 148, 268, 337, 396).  Vif is most well known for its 
function in preventing the incorporation of the host restriction factor apoplipoprotein B 
mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G or A3G) and 
APOBEC3F (A3F) by targeting them for degradation through the ubiquitin dependent 
proteasomal pathway (247, 399).  When packaged into virions, A3G and A3F inhibit 
viral reverse transcription and introduce G to A hypermutations into the viral genome 
during the early steps of infection of a target cell (reviewed in 127, 235). 
The vpu gene encodes a small 16 kDa protein that functions to down regulate host 
factors from the cell surface.  Vpu is translated from a singly spliced vRNA, and is a 
type-1 integral membrane protein that forms multimers (232).  Vpu functions to down 
regulate the expression of cellular CD4, which is thought to increase Env incorporation 
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due to decreased premature Env-CD4 interactions within the cell as Env trafficks to 
assembly sites at the plasma membrane.  Vpu interacts with the CT of CD4 in the ER and 
targets it for degradation through the ubiquitin dependent proteasomal pathway (reviewed 
in 235).   Vpu has also been demonstrated to increase virion release from the cell, 
however the mechanism was not understood until recently (130, 184, 348, 397).  It was 
recently discovered that Vpu binds the host protein tetherin, a newly identified host 
restriction factor that blocks the release of virions from the plasma membrane and targets 
it for degradation in the lysosome.  The degradation mechanism is not fully elucidated, 
but proteasomal degradation has also been shown to be involved (94, 158, 237). 
The vpr gene encodes a small 15 kDa multifunctional protein that plays important 
roles in a number of steps of the HIV-1 life cycle.  Vpr is translated from a singly spliced 
vRNA.  Vpr is packaged into the assembling virions through interactions with Gag, at 
approximately a 1-10 ratio (73).  Vpr is encapsulated inside the mature viral core and is 
part of the pre-integration complex (PIC).  One of its functions is to facilitate the nuclear 
import of the PIC into the nucleus of non-dividing cells (296, 297).  Vpr appears to use 
various cellular mechanisms to localize to the nucleus, however it appears to do so in a 
unique manner that is independent of the classical NLS and M9 nuclear import pathways 
(162, 164). Vpr has been demonstrated to interact with importin-!, which was suggested 
to mediate the nuclear import of Vpr (179).  It has also been shown that Vpr interacts 
directly with nuclear pore proteins, however mutations that disrupt those interactions 
block perinuclear localization, but did not block import into the nucleus (367).   Vpr has 
also been implicated in upregulation of LTR driven transcription, immune dysfunction, 
apoptosis, neurotoxicity, and G2 cycle arrest (5, 9, 293, 372, reviewed in 187, 235). 
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The nef gene encodes a small 27 kDa myristoylated multifunctional protein that is 
translated from a doubly spliced vRNA.  The HIV-1 negative factor (NEF) has been 
jokingly referred to as “not enough function”, as it has been found to interact with a 
number of host factors and plays various roles during multiple steps of the viral 
replication cycle.  Nef localizes primarily to the paranuclear regions and to the PM.   Nef 
has many functions and has been demonstrated to play a critical role in HIV-1 
pathogenesis.  Individuals infected with Nef deleted HIV-1 progress at a much slower 
rate than those that are infected with viruses that encode a functional nef gene, however 
the mechanisms involved are not well understood (reviewed in 108, 129).  Nef also 
functions to down regulate the surface expression of CD4 and major histocompatibility 
complex-I (MHC-I).  Nef has been shown to interact with the CT of CD4 causing its 
clathrin dependent endocytosis and degradation in the lysosome (57, 291, 292).  The 
mechanism resulting in the down regulation of surface MHC-I by Nef is unclear and 
there was evidence to suggest that Nef increased endocytosis from the plasma membrane 
and blocked the transport of MHC-I from the TGN to the PM (133, 205, 227, 332, 351).  
Nef has also found to mediate cell signaling and activation (102, 208, 229, 288). 
The tat gene encodes a 15 kDa protein that is essential for HIV-1 replication (81).   
The viral trans-activator of transcription (Tat) is a multifunctional protein and primarily 
located in the nucleus, but can also be secreted from the cell (53).  Tat forms homodimers 
(111), and binds the trans-activating response element (TAR) stem-loop structure within 
the 5’-vRNA and enhances LTR-directed translation by hundreds to thousands fold (140, 
256, 314, 339).  Tat interacts with various host factors in the RNA Polymerase II 
complex and increases vRNA transcription by enhancing both initiation and elongation of 
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host transcriptional complexes  (reviewed in 40).  Tat has also been shown to be involved 
in the upregulation of host genes, apoptosis, and neurotoxicity (reviewed in 300). 
 The rev gene encodes a 19 kDa phosphoprotein that is essential for expression of 
the viral structural proteins.  The viral regulator of expression of virion proteins (Rev) is 
absolutely required for the cytoplasmic export and accumulation of full-length unspliced 
and singly spliced vRNA.  Monomers of Rev are imported into the nucleus and bind the 
rev response element (RRE), a cis-acting sequence that forms stem loop (236, 238).  It 
then multimerizes, forming a large RNA-protein complex containing Rev and various 
host proteins, then shuttles out of the nucleus along with the vRNA (reviewed in 295).  
The RRE is located in the env intron, and is present in full-length and singly spliced 
vRNA (238).  Rev has also been demonstrated to increase the half-life and the translation 
of RRE containing RNAs (13, 78, 103, 234) 
HIV-1 life cycle 
The HIV-1 life cycle is a multi-step process that requires approximately 24 hours 
to complete one replication cycle (defined as the time it takes to infect a new target cell 
and the subsequent production of new virions).  The average generation time in infected 
individuals (defined as the time from release of an infectious virion, infection of a new 
target cell and subsequent release of the next generation of virus particles) is 
approximately 2.6 days (145).  The HIV-1 life cycle is divided into two multi-step events, 
early and late events.  Early events encompass the step from virus attachment through 
integration of the provirus, while late events involve the transcription/translation of viral 
genes that culminates in the assembly and release of the newly infectious virions. 
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Early events 
Early infectious events of the HIV-1 life cycle begin by the attachment of the 
virus to the target cell (helper T-cells and macrophage) through interactions between the 
host CD4 and viral Env subunit gp120.   After attachment and interaction with the host 
CD4, gp120 undergoes subtle conformational changes that allow the V3 loop of gp120 to 
engage the viral co-receptors (host CXCR4 and CCR5).  This is followed by large 
conformational change in gp120 and gp41, where the fusogenic peptide in gp41 is 
inserted into the target cell membrane.  Through further conformational changes, gp41 
brings the host and viral lipid membranes into close proximity where they undergo lipid 
mixing and fusion of the two membranes.  Interestingly, DC-sign and !4"7, expressed on 
the surface of dendritic and natural killer cells respectively, can also bind HIV-1 gp120 
and are involved in trans-infection of target cells in the lymph tissue of an infected 
individual (68, 123).  HIV-1 Env mediated fusion takes approximately one hour to 
complete (121, 154).  The fusion of the virus at the plasma membrane releases the viral 
core into the cytoplasm where it undergoes rearrangement to form the reverse 
transcription complex (RTC).  The RTC is transported to the cytoplasmic side of the 
nucleus where the viral RNA reverse transcription into viral DNA is completed (vDNA).  
The RTC undergoes another rearrangement to become the PIC and is transported into the 
nucleus (reviewed in 373).  In the nucleus, the vDNA is intergraded into the host 
chromosome directed by the viral integrase and cellular factors.  Integrated proviruses 
can be detected within 3 hours post infection (43).  During these early events, the virus 
can both utilize, and evade, host proteins in order to its replication cycle (reviewed in 
202, 262, 349, 373). 
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Late events 
 The viral genes are expressed from the integrated provirus using the host 
transcriptional and translational machinery.  HIV-1 gene expression is biphasic (Rev 
dependent and Rev-independent).  The double spliced accessory proteins (Tat, Rev, and 
Nef) are the first proteins to be expressed from a newly integrated provirus.  The 
expression of Tat greatly increases the LTR-directed expression by biding the TAR 
region of the viral RNA and increasing both the initiation and elongation complexes of 
host RNA Pol II.  As Rev levels increase in the cell, Rev binds the RRE in full-length and 
singly spiced vRNAs and shuttles them to the cytoplasm for translation before they can 
further spliced in the nucleus by the host splicing factors (295).  The predominant viral 
structural proteins are expressed from the full-length and singly spliced vRNAs.   
Gag (Pr55) and Gag-Pol (Pr160) are translated in the cytoplasm from full-length 
unspliced vRNA and traffics through a poorly defined route to the site of assembly on the 
PM.  Gag is co-translationally modified at the N-terminal glycine residue and is essential 
for the correct targeting of Gag to the PM (44, 131, 265, 407).  Gag trafficking to the PM 
occurs quickly after translation, and can be detected at the PM within 5 minutes after Gag 
synthesis (276).  The myristate is sequestered inside the MA domain within Gag and only 
becomes exposed when phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) binds a 
highly basic region within MA.  The exposure of the myristate has been hypothesized to 
target Gag to lipid rafts within minutes after binding the PM (217, 276, 316).  Lipid rafts 
are microdomains that have been shown to be important microdomains in the plasma 
membrane that facilitates virion assembly and release, however tetraspanin enriched 
membranes have also been implicated to be the site of virion assembly (reviewed in 273, 
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369, 370).  The intracellular route that Gag takes to the plasma membrane is not well 
defined, however a number of cellular proteins have been identified to play important 
roles in Gag intracellular stability and trafficking to the correct assembly site. 
As Gag is trafficked through the cytoplasm to the site of assembly, it functions to 
specifically bind and package the viral genome through the zinc-finger motifs in NC and 
interactions with the host protein Staufen (255) 
Once trafficked to the PM, Gag forms high-order multimers through interactions 
between the I-domains of Gag and Gag-Pol proteins at the plasma membranes (85, 149, 
153, 200). Multimerization with Gag-Pol ensures the packaging of the replicative 
enzymes into the assembling virions and initiates the capsid assembly process.  After the 
viral and cellular factors are correctly trafficked to the PM and virion assembly is 
initiated through Gag multimerization, the ribonucleic protein complex is retained at the 
assembly site as the nascent virion is assembled and released from the cell surface 
through a process called budding.  The budding and release of progeny virions occurs 
simultaneously with capsid assembly and utilize the host vacuolar protein sorting 
pathway through direct interactions between tumor susceptibility gene 101 (TSG101) or 
ALIX and the L-domain within p6 of Gag (122, 347).  During or shortly after release, the 
immature virion core containing approximately 2100 Gag proteins (42) undergoes viral 
protease-dependent cleavage maturation where the Gag proteins are cleaved into their 
infectious virion associated forms to facilitate infection of new target cells  (Gag function 
reviewed in 113, 352, 387). 
During the virion assembly process, Gag must also interact with the mature viral 
Env glycoprotein and package it into the assembling virions.  The Env gp160 is highly 
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glycosylated with N-linked high mannose sugars, interacts with ER chaperones and 
quickly folds, forms disulfide bonds, and becomes competent to bind CD4 within 15 
minutes after synthesis. Trimers of gp160 are assembled approximately 30 minutes after 
synthesis, and are trafficked to the Golgi apparatus within 80 minutes of synthesis (48, 
98, 104, 204, 279).  As gp160 trafficks through the Golgi, the glycans are extensively 
modified and gp160 is cleaved by a host protease into its mature forms (gp120 and gp41) 
(23, 106, 281, 321, 343).  Env continues through the secretory pathway where it is 
inserted into the plasma membrane at approximately 2 hours after synthesis.  If Env is not 
packaged into assembling virions, it is quickly endocytosed through interactions with AP-
1 or AP-2 with the endocytosis signals in the CT of gp41 in a clathrin dependent manner, 
and can be recycled back to the trans-Golgi network through interactions with Tip47, or 
degraded in the lysosome (29, 30, 49, 271, 385). 
The mechanism of Env packaging is not well understood and published data 
indicates that sequences with the MA domain of Gag interact with sequences within the 
CT of Env to facilitate the active packaging of Env into the assembling virions (reviewed 
in 167).  Interestingly, many of the host factors that have been identified to be involved in 
intracellular Gag trafficking are also involved with intracellular trafficking of Env.  
Microscopy studies that showed virion components localizing and assembling into 
vesicles that contained cellular markers for late endosomes/MVBs led many in the field 
to hypothesize that virion assembly occurred in, or was initiated at the membranes of 
endocytic vesicles (266, 275, 287).  This also led people to hypothesize that Gag may 
first interact with Env that is localized in the endosomal pathway and this interaction 
leads to selective packaging of Env into assembling virions because both proteins had 
 16 
been previously demonstrated to utilize the endocytic pathway during virion assembly.  
Strengthening this hypothesis, a gp41 tail interacting protein with the molecular weight of 
47 kDa (Tip47) was identified as a linker protein that physically linked the MA domain 
of Gag with the CT of Env.  Over expression of Tip47 led to increased Env packaging 
into virions, while the knockdown of Tip47 expression with siRNA led to decreased Env 
packaging that resulted in decreased virion infectivity (20, 224). 
Interestingly, a few years later, published data indicated that the intracellular 
vesicles that were visualized and hypothesized to be sites of assembly were not late 
endosomes, but were deep invaginations of the plasma membrane that were also enriched 
in CD63, a commonly cellular used marker for late endosomes.  Because of the 
sectioning technique and the enrichment of CD63, the virion assembly sites were 
mistakenly identified as late endosome/multivesicular bodies (MVBs)(84, 176, 378).  
While these data refute the hypothesis that HIV-1 assembles in/at late endosomes, it did 
not offer any insights as to where Gag and Env first interact which then led to packaging. 
 While the accessory proteins are not essential for virion assembly, they do have 
important functions that optimize virion production and infectivity.  During assembly, 
Nef and Vpu function to down regulate the cellular expression of CD4.  Down regulation 
of CD4 was hypothesized to decrease premature CD4/Env interactions, which optimize 
Env trafficking through the secretory pathway to the assembly site.  It was also 
hypothesized to increase virion release from virus producing cells by inhibiting unwanted 
virion attachment to the producer cell through interaction between surface CD4 and 
newly synthesizes virions.  While Nef has been attributed many functions, one of the 
important functions is to decrease the cell surface expression of MHC-I.  The down 
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regulation of MHC-I is hypothesized to be a mechanism to avoid immune detection and 
clearance of virus producing cells by cytotoxic T-cells in an infected individual.  Vif and 
Vpu function to down regulate host restriction factors and reduce their detrimental affect 
on virion assembly and subsequent replication.  Vif degrades and prevents the packaging 
of APOBEC host proteins, while Vpu degrades cellular tetherin and prevents it from 
blocking virion release.  The combined functions of the 15 proteins expressed by HIV-1 
work efficiently together in a consorted effort to recapitulate the HIV-1 lifecycle while 
the infected individual’s immune system tries to block their function and clear the 
infection from the body. 
Host factors that are involved in virion assembly 
 
As detailed above, the HIV-1 virion assembly pathway is a complex process that 
requires the intricate trafficking of viral and cellular proteins that culminates in the 
assembly and release of infectious virions.  Viral proteins optimize the assembly process 
through the utilization of host factors. Identifying and understanding important virus:host 
interactions could potentially identify new pathways that could be pursued to develop 
new antivirals that interrupt important virus/host interactions.  Because Gag plays such an 
essential role in the assembly pathway, it has been extensively studied in efforts to 
identify cellular pathways that are important in facilitating Gag function.  
A number of host factors have been identified to be functionally important in 
trafficking Gag to the assembly site on the PM.  Members of the kinesin motor family 
(KIF4A, KIF3A and KIF3C) have been implicated in intracellular Gag trafficking and 
virion assembly (15, 41, 242).  Kinesin proteins function to regulate the movement of 
various intracellular components along the microtubule network.  KIF4A was 
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demonstrated to decrease Gag stability and VLP release when KIF4A expression was 
knocked down with siRNA.  It was found that in KIF4A knockdown cells, Gag 
trafficking to the PM was blocked and Gag accumulated at large perinuclear sites named 
Gag perinuclear clusters (GPC).  This data suggested that KIF4A was involved in 
trafficking Gag from this intermediate, intracellular trafficking site to the PM.  
Knockdown of KIF3A and KIF3C by siRNA inhibited the release of VLPs and infectious 
virus respectively, but the mechanism was not further characterized. 
The expression of suppressor of cytokine signaling-1 (SOCS1), an E3 ubiquitin 
ligase, was found to be upregulated in T-cells during HIV-1 infection.  It has also been 
shown to function in Gag stability and trafficking through the cytoplasm.  SOCS1 was 
found to directly bind the MA domain of Gag and colocalize with Gag at perinuclear 
punctate sites.  The overexpression of SOCS1 increased Gag stability and viral assembly 
and release, while depletion of SOCS1 by siRNA caused decreased Gag stability and 
viral assembly and release.  It was also observed that in SOCS1 knockdown cells, Gag 
formed large perinuclear clusters, similar to GPCs and displayed decreased stability.  
However, these perinuclear clusters co-localized with lysosome markers and Gag 
stability was restored with the use of lysosome inhibitors indicating that they are 
functionally different than the previously identified GPCs.  This data suggested that 
SOCS1 is involved in Gag trafficking and stability by trafficking Gag to the PM and 
preventing its degradation in the lysosome (315). 
The E3 ubiquitin ligase hPOSH, has been shown to be important for targeting Gag 
from the TGN to the PM.  The hPOSH was identified in a siRNA screen directed against 
components of the ubiquitin pathway in an effort to identify proteins that were important 
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for ubiquitin dependent HIV-1 virion release (331).  Interestingly, hPOSH was found to 
localize to the cytoplasmic side of the TGN and depletion of endogenous hPOSH by 
siRNA decreased Gag localization at the plasma membrane and increased localization to 
the TGN.  It was found that the E3 ligase activity was important for the altered trafficking 
of Gag, however they were not able to detect differences in the ubiquitination state of 
Gag in the presence or absence of hPOSH, which led to the hypothesis that hPOSH 
functions by indirectly affecting Gag trafficking to the PM, by directly affecting the 
trafficking of vesicles that contained or were associated with Gag (8). 
Interesting, many components involved in proteins sorting though the secretory 
and endocytic pathway are involved in proper Gag trafficking to the assembly site. 
Members of the Ras superfamily that are responsible for the regulation of vesicular 
transport pathways have been identified to be important in Gag trafficking and in virion 
assembly and release.  Rab9 is a GTPase that facilitates vesicular trafficking from late 
endosomes to the TGN through interactions with p40 (90).  Rab11A is GTPase that 
facilitates vesicular trafficking from the TGN to the PM (60).  Rab9 and Rab11A 
knockdown with siRNA resulted in significantly decreased HIV-1 replication.  It was 
also observed that Gag displayed increased localization to CD63+ late endosomes in 
Rab9 knockdown cells, which suggested that the decreased replication in Rab9 
knockdown cells was due to decreased virion assembly and release due to increased 
sequestration of Gag in late endosomes caused by altered trafficking of Gag (260). 
Various subunits of the Adaptor Complexes AP-1 (51), AP-2 (19), and AP-3 (93) 
have all been implicated in facilitating intracellular Gag trafficking. The AP-1 complex is 
required for the bi-directional proteins sorting and trafficking between the TGN and 
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endosomes (270).  The AP-1 complex has also been implicated in protein trafficking 
from the TGN, or early endosomes to late endosomes or lysosomes (286, 306).  The µ1A 
subunit of the AP-1 complex was found to interact with the MA domain within Gag and 
depletion of µ1A expression by siRNA significantly reduced virion release, however no 
differences in virion infectivity were observed.  Interestingly, over expression of µ1A led 
to increased virion release (51). 
The µ2 subunit of the AP-2 adaptor complex, which directs clathrin dependent 
endocytosis, has been reported to interact with Gag at the MA-CA interface.  It was 
found that virion release was increased when a trans-dominant negative µ2 subunit was 
overexpressed, however those virions were less infectious due to decreased Env 
packaging.  Gag trafficking to the PM was found to altered in the presence of the trans-
dominant negative µ2.  Gag appeared to target to fewer, but larger clusters at the 
periphery of the PM compared to cells without the trans-dominant negative µ2, which 
showed small but distinct areas of Gag localization on the PM (19).  Interestingly, 
clathrin has recently been shown to interact with the IN domain in Gag-Pol and 
specifically packaged into virions.  Knockdown of clathrin by shRNA led to decreased 
specific virion infectivity, however the mechanism is not known (298). 
The AP-3 # subunit was found to interact with the N-terminus of the MA domain 
in Gag.  The function of AP-3 is not well defined.  It is involved in protein sorting and 
trafficking to the lysosome, however whether it functions in the sorting from TGN to the 
lysosomes, or from endosomes to lysosomes is controversial (286).  Knockdown of the 
AP-3 complex using siRNAs specific for the various subunits of AP-3 showed that the 
AP-3 complex is important for Gag trafficking through the cell.  Gag showed altered 
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trafficking to the PM, late endosome/MVBs, and diffuse intracellular staining patterns in 
AP-3 knockdown cells or when a trans-dominant negative AP-3 # subunit was over 
expressed in HIV-1 producing cells (93). 
The Golgi-localized $–ear containing Arf binding proteins (GGA) and ADP 
ribosylation factors (ARF) are involved in protein sorting and tracking from the TGN and 
endosomes.  GGA proteins are recruited to membranes and function through interactions 
with various members of the ARF protein family.  Knockdown of GGA2 or GGA3 in 
virus producing cell increased the amount of virion release, while overexpression of 
GGA1, GGA2, or GGA3 decreased Gag binding to the membrane and virion release, 
which suggest that the GGA proteins are negative regulators of HIV-1 assembly.  
Interestingly, it was also found that over expression of GGA1 causes defects in gp160 
processing and led to decreased levels of intracellular gp120 and increased levels of 
intracellular gp160.  Knockdown of Arf 1,3,5 and 6 with siRNA, or overexpression of 
trans-dominant negative forms of Arf 1,3 and 5 led to decreased virion assembly and 
release (174). 
The soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) machinery has been shown to be important for HIV-1 virion production (173, 
253).  SNARE machinery is involved in the catalysis of fusion events between 
intracellular vesicles/membranes and are required at each step of the endocytic and 
exocytic trafficking pathways (383).  Knockdown of N-ethylmaleimide-sensitive factor 
(NSF) and !-soluble NSF attachment protein (SNAP), or overexpression of a NSF trans-
dominant negative mutant led to decreased virion production and correlated with 
decreased Gag localization at the plasma membrane.  Disruption of the SNARE 
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machinery also blocked Env trafficking and cleavage, which resulted in decreased virion 
infectivity (173).  The mechanism of how the SNARE machinery stimulates virion 
production is not fully understood. 
Once trafficked to the assembly site, Gag initiates the assembly of the virion 
capsid through multimerization.  The ATP-binding cassette protein family E (ABCE1), 
has been shown to interact with Gag through the basic residues in the NC domain and 
play an important role in virion assembly.  Mutations that inhibited interactions with 
ABCE1 were blocked in the early stages of immature capsid assembly, thus preventing 
virion assembly.  ABCE1 was hypothesized to function as a Gag chaperone that mediated 
Gag multimerization and subsequent virion assembly (218). 
CD81 has also been implicated as playing an important role during virion 
assembly.  CD81 is a tetraspanin that is part of the tetraspanin-enriched microdomain in 
the PM and can also be found in late endosomes/MVBs (101).  CD81 is highly enriched 
at assembly sites and virological synapses (169).  Gag and CD81 have been shown to 
form intracellular complexes, and when CD81 expression on the cell surface was down 
regulated, either by shRNA or incubation with CD81 antibodies, virion release was 
decreased.  Interestingly, this release was accompanied with a change in Gag staining 
patterns on the PM (less clustered puncta) and an increase in virion infectivity.   
The budding and release of progeny virions occurs simultaneously with capsid 
assembly and utilize the host vacuolar protein sorting pathway through direct interactions 
between TSG101 or ALIX and the L-domain within p6 of Gag.  TSG101 and ALIX are 
members of the ESCRT-1 complex and have been shown to be essential in virus budding 
from the cell surface (122, 347).  TSG101 and ALIX have also been shown to interact 
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with the components of the ESCRT-3 complex, which was also found to be essential in 
facilitating budding from the plasma membrane (reviewed in 66, 294, 340). 
The host protein Staufen has been implicated to play a role in the selective 
packaging of vRNA during the assembly pathway (56, 255).  It has been found that 
Staufen selectively binds the genomic vRNA and interacts with Gag cytoplasmic 
complex through the NC domain.   Staufen knockdown with siRNA led to decreased 
specific virion infectivity by approximately 50% compared to virions produced in normal 
cells (56, 255).  This finding was supported by, a recently published report indicating that 
Gag/RNA interactions occur in the cytoplasm and involves Gag dimers or low-order 
multimers (200). 
Ubc9, SUMOylation, and Retroviruses 
Several laboratories including ours have published data that has demonstrated that 
the host SUMOylation pathway plays an important role during the viral life cycle.  Ubc9 
was first identified as a retrovirus interacting partner in yeast two-hybrid screen using a 
HeLa cDNA library and the full-length Gag protein (Pr78) of Mason-Pfizer monkey virus 
(MPMV) as the bait protein.  It was demonstrated that Ubc9 and Pr78 interacted through 
sequences within the capsid (p27) domain of Gag (376).  Even though a functional role 
for Ubc9 in the MPMV replication cycle was not elucidated, our laboratory has expanded 
the studies to HIV-1.  We demonstrated that Ubc9 and HIV-1 Gag (Pr55) interacted in 
vitro and in vivo and mapped the interaction to the NC-p6 domain within Gag.  We 
discovered that in Ubc9 knockdown cells, the amount of mature virions released into the 
medium was unchanged, which indicated that the general functions of Gag were not 
disrupted, however specific infectivity was decreased approximately 10-fold compared to 
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virions produced in control cells.  We used immunoblotting to assay the virion 
composition and found that the defective virions contained less mature Env 
(gp120/gp41).  Pseudotyping experiments with VSV-G restored virion infectivity, 
indicating that the defect was primarily due to deficiencies in Env packaging and entry of 
target cells, and not due to disruptions in the function of the HIV-1 core or replicative 
enzymes during early infection events. Env production was examined in the Ubc9 
knockdown cells and it revealed that intracellular mature Env levels were decreased.  
Unexpectedly, the mechanism of decreased intracellular Env levels was found to be 
dependent upon Gag expression, which suggested that the interaction between Gag and 
Ubc9 somehow stabilized intracellular Env levels.  Pulse chase data suggested that the 
decreased levels of intracellular Env was likely due to decreased stability of mature Env 
in Ubc9 knockdown cells.  We also found that the overexpression of the trans-dominant 
negative, catalytically inactive Ubc9 mutant (C93A) did not negatively affect virion 
infectivity, which suggested that the SUMO conjugating activity was not involved with 
Ubc9 dependent decreased infectivity.  We published this data in 2009 in the Journal of 
Virology (159).   
During this time, Gurer et al. published data demonstrating that HIV-1 p6 
interacted with Ubc9 and SUMO-1.  They showed that the major Ubc9 binding site was 
at or near the lysine at position 27 (K27).  A GFP-p6 fusion protein could be 
SUMOylated at K27 at low levels in vivo if SUMO-1 was overexpressed.  SUMOylation 
of GFP-p6 was prevented when the lysine at position 27 was mutated to arginine (K27R). 
The K27R mutation in the context of NL4-3 appeared to be unaffected during virion 
assembly, however they showed that if SUMO-1 was overexpressed in HIV-1 producer 
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cells, the completion of reverse transcription was inhibited in target cells.  Interestingly, 
unconjugated SUMO-1 was found in the virion when overexpressed in producer cells, 
however they were not able to detect SUMOylated viral proteins in the virion.  The K27R 
mutant relieved the block in target cells when SUMO-1 was overexpressed in the 
producer cells, however the mechanism of how the overexpression of SUMO-1 led to 
changes in reverse transcription are not fully understood (137). The phenotype that we 
observed was different from that of Gurer et al.  This may be due to differences in 
experimental procedures, or as we had hypothesized previously, only a small amount of 
Gag may be needed to interact with Ubc9 to carry out its functional role during HIV-1 
assembly (159).   This interaction may be occurring through a second binding site within 
Gag, as K27R does not completely inhibit Ubc9 interactions (unpublished data). 
Another group, Martinez et al. published data demonstrating that when the 
expression of KIF4, a microtubule motor protein, was knocked down using siRNA, Gag 
stability and trafficking to the plasma membrane was disrupted.  Gag trafficking appeared 
to be blocked at the early intermediate step at an intracellular site where they 
characterized as GPCs.  Using a Myc-tagged Ubc9 construct from our laboratory, they 
showed that Myc-Ubc9 and SUMO-1 were co-localized to the GPCs with Gag in KIF4 
knockdown cells (242). 
Very recently, a French group reported that HIV-1 Integrase is SUMOylated in 
vitro and in vivo when SUMO-1, SUMO-2, or SUMO-3 were overexpressed in cells 
expressing HIV-1 Integrase.  Mutations of three lysines at position 46, 136, and 244 lead 
to decreased SUMOylation of Integrase and was found to correlate to defects in provirus 
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integration, suggesting that Ubc9 and SUMOylation are involved in the early events 
during HIV-1 infection (401).   
Interestingly, Ubc9 and SUMOylation have also been found to be important 
during the early infectious events of a murine retrovirus.  Yueh et al. reported that 
Moloney murine leukemia virus (MuLV) capsid (p30) protein interacted with Ubc9 and 
PIASy (E3-SUMO ligase).  Mutations of lysine residues near the Ubc9 binding domain 
blocked p30 SUMOylation and correlated with a defect in replication at an early 
infectious step after reverse transcription of the vRNA, before targeting to the nucleus 
(400).  This phenotype is different from what Gurer et al. and Zamborlini et al. described, 
which indicated that different viruses may utilize Ubc9 and SUMOylation differently. 
Ubc9 and SUMOylation 
 
 Ubc9 is a small protein of approximately 18 kDa, it is constitutively expressed in 
every cell type, and is the only E2 small ubiquitin-like modifier (SUMO) conjugase 
identified to date (192).  Ubc9 plays an essential role in regulating various aspects of 
cellular function and replication through SUMO-dependent and SUMO-independent 
mechanisms (142, 261). The SUMOylation pathway involves a series of enzymatic steps 
that is analogous to the ubiquitin pathway that results in the covalent attachment of 
SUMO to target proteins. Ubc9 has considerable sequence similarity and adopts a 
similarly folded structure as an E2 ubiquitin conjugase (358).  Ubc9 is responsible for 
target recognition of proteins to be SUMOylated, but it is through the interaction with the 
E3 SUMO ligases that facilitates target specificity in the covalent attachment of SUMO 
to target proteins.   
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SUMOylation occurs through an isopeptide bond between the C-terminal glycine 
of SUMO and the lysine side chain of the target protein in an ATP dependent manner.  In 
vitro, Ubc9 is able to covalently attach SUMO to the target protein in the absence of an 
E3 SUMO ligase (88, 248, 272).  The cysteine at position 93 is essential in the enzymatic 
activity of Ubc9 and the amino acids that surround the active site have been found to bind 
directly to the putative SUMOylation motif (22, 322, 355).  The putative SUMOylation 
motif is %KXE/D, where % is a hydrophobic amino acid and X is any amino acid (309).  
However this motif alone is not the only contributing factor in SUMOylation, non-
canonical SUMOylation motifs have also been reported, and it is not known how the non-
consensus sites are recognized by Ubc9 (67 reviewed in 124, 141, 166).   
Interestingly, Ubc9 itself has been found to be SUMOylated at a non-consensus 
site that modulates Ubc9 target interactions and SUMOylation by causing a 
conformational change in Ubc9, which creates a new binding surface for altered 
interactions with target proteins (186).  The regulation of SUMOylation of target proteins 
has also been previously hypothesized to involve the phosphorylation, ubiquitination, 
and/or acetylation state of the target protein (Ubc9 and SUMOylation reviewed in 124, 
141, 166, 325, 384, 405).  Ubc9 was often found to be involved in the SUMOylation of a 
number of cellular proteins, but Ubc9 can also function in SUMO-independent 
mechanisms.  Lu/BCAM (75), androgen receptor (54), MEKK1, type I TNF-alpha 
receptor (318), GLUT4 (220), RNA helicase A (11), glucocorticoid receptors (181), Vsx-
1 (199), SOX4 (282), and HHV-6 IE2 (357) have been demonstrated to require Ubc9 
binding for their function and correct intracellular targeting, but are not targets for SUMO 
modification. 
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Ubc9 and SUMOylation in autophagy regulation 
 
Autophagy is a degradation/recycling pathway that turns over long-lived protein, 
damaged organelles, and cellular cytoplasmic factors.  Old or damaged organelles and the 
surrounding cytoplasm are engulfed in a double, or multi-membrane vesicle known as the 
autophagosome, which fuses with lysosomes to form autophagolysosomes.  The contents 
of the autophagolysosome are degraded and recycled for anabolic cellular metabolism. 
Autophagy is highly regulated, but can be quickly upregulated over basal levels in 
response to cellular stress, starvation, activation of the cell signaling pathways, or by 
infection of a pathogen.  The formation of an autophagic vacuole requires a sequential 
cascade of various protein-protein interactions and protein-lipid interactions leading to 
the formation of the double membraned autophagic vacuole.  The upregulation of 
autophagy is commonly initiated by cellular stress through inhibition of the mTOR kinase 
activities, however other pathways have been demonstrated to regulate autophagy.  
Changes in the levels of reactive oxygen species (17, 33, 38, 92, 228, 328, 365), increase 
in free intracellular Ca
2+ 
(89, 151), altered cell signaling through the MEK/ERK 
pathways (198, 364, 371), activation of phosphorylation pathways (PKA, PKB, PKC, and 
AMPK) (12, 45, 77, 165, 209, 214, 249, 344), or toll-like receptor signaling (196, 197, 
278, 305, 359) have all been demonstrated to be involved in the upregulation of 
autophagy.  Interestingly many of the alternative activation pathways converge at some 
point with the SUMOylation pathways, either directly or indirectly (1, 6, 24, 37, 136, 
165, 180, 198, 223, 226, 353, 365).  Even though SUMOylation of various proteins 
within these regulation pathways have been demonstrated (HIF-1 and HIF-2, MDM2, 
P53, tissue transglutaminase 2, eE2F, MEK, c-Jun, Smad4, transforming growth factor–
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beta), the SUMOylation of these proteins have not been analyzed with regards to their 
roles during the regulation of autophagy (6, 24, 37, 59, 180, 198, 223, 310, 353, 365).  
Given the far- reaching functions of Ubc9 and SUMOylation in cellular function, it is 
likely that Ubc9 and SUMOylation play important roles in autophagy regulation.  To our 
knowledge, there are no reports demonstrating that Ubc9 or SUMOylation have an effect 
on the proteins that are involved with autophagic vesicle elongation or fusion with the 
lysosome (Atg3, Atg4, Atg5, Atg7, Atg9, Atg12, Atg16, Atg18, or LC3) (autophagy 
reviewed in 95, 230, 231, 252, 289). 
Research aims 
 The aim of this research is to expand the functional studies, which began with 
identification of Ubc9 as a binding partner of M-PMV Gag, to HIV-1 and examine if 
Ubc9 plays a functional role in the HIV-1 life cycle.  In this dissertation we demonstrated 
that Ubc9 is a binding partner of HIV-1 Gag and that Ubc9 is important during the late 
events of the virus life cycle.  We demonstrated that Ubc9 plays an important role during 
the replicative HIV-1 life cycle.  Using siRNA specific for Ubc9, we found that 
knockdown of Ubc9 in HIV-1 producer cells led to decreased specific infectivity of the 
released virions.  The decreased infectivity was due to a decrease in intracellular gp120 
levels.  The lower levels of gp120 were demonstrated to be due to enhanced selective 
degradation of intracellular gp120 in the lysosome, which occurred in a Gag dependent 
manner.  It was also discovered that autophagy was upregulated in Ubc9 knockdown 
cells.  Whether an induction of autophagy directly leads to an increase in lysosomal 
degradation of gp120 needs to be further elucidated. 
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Figures and Figure legends 
Figure 1 
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Figure 1.  HIV-1 virion morphology.  (a) Thin-section transmission electron microscopy 
of HIV-1 virions.  The cone-shaped core, lipid envelope, and virion glycoproteins are 
visible (259).  (b) Schematic of known protein localization of various viral and host 
components within the virion. 
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Figure 2 
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Figure 2.  HIV-1 Genome, genomic landmarks, and viral transcripts.  Proviral DNA 
genomic map was designed from the modification of HXB2CG proviral sequences 
(GenBank: AF033819.3)(71, 304).  Transcriptional start site and open reading frame 
(ORF) within the proviral sequence and nucleotide positions are labeled.  The 
transcriptional start and stop sites are located at the boundary between the 5’-U3-R and 
3’-R-U5 regions respectively.  The primer biding site (PBS), Rev response element 
(RRE), and the polypurine tract (PPT) are identified.  The predominant splice donor (SD) 
and splice acceptor (SA) sites utilized by the host splicing machinery are labeled.  The 
full-length genomic vRNA and predominant spliced vRNA transcripts and the ORFs 
encoding Env and accessory proteins are shown.  The vRNAs contain a 5’-7-
methylguanylate cap and 3’-polyadenylated tail.  The site of the  -1 frame shift that 
produces Gag-Pol is identified as a zigzag arrow on the full-length genomic vRNA.  Viral 
protease-dependent cleavage sites with Gag and Gag-Pol are identified as black arrows.  
White arrows identify cellular host protease-dependent cleavage sites within Gag, Gag-
Pol, and Env.  Post-translational modification of viral proteins are identified with 
symbols; myristoylation is identified as a circled upper-case M, phosphorylation is 
identified as a circled upper-case P, and glycosylation is depicted as upper-case Y. 
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Figure 3 
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Figure 3.  Reverse transcription of the vRNA to vDNA.  (a) The tRNA3
lys
 binds the 
vRNA in through complementary sequences within the PBS.  (b) RT uses the tRNA 
primer to initiate the synthesis of minus-strand DNA  (first strong stop DNA).  (c) The 
RNase H activity of the p66 subunit of RT degrades the vRNA from the vRNA/DNA 
hybrid.  (d) The RT/first strong stop complex is transferred to the 3’-end of the vRNA  
(first strand transfer) where it base pairs through complimentary sequences with in the 
terminal repeat region  (R-region).  (e) Complementary vDNA is synthesized.  (f) The 
vRNA template is degraded, with the exception of a RNase H resistant, PPT.   (g) The 
PPT is used by the RT complex as a primer to extend the 3’-plus-strand vDNA.  (h) The 
remaining RNA is degraded by RNase H.  (i) The plus-strand vDNA is transferred to the 
5’-end of the vDNA (second strand transfer) where it base pairs with complementary 
sequences within the PBS. (j) The vDNA synthesis is continued, completing the synthesis 
of vDNA.  Genomic sequences are not drawn to scale. 
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Chapter II 
 
 
 
Human Ubc9 contributes to the production of fully infectious 
HIV-1 virions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data from this chapter was published in the Journal of Virology, October 2009, p. 
10448-10459, Vol. 83, No. 7. 
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Abstract 
Ubc9 was identified as a cellular protein that interacts with the Gag protein of Mason-
Pfizer monkey virus.  We show here that Ubc9 also interacts with the HIV-1 Gag 
protein and their interaction is important for virus replication.  Gag was found to co-
localize with Ubc9 predominantly at perinuclear puncta.  While cells in which Ubc9 
expression was suppressed with RNAi produced normal numbers of virions, these 
particles were 8-10 fold less infectious than those produced in the presence of Ubc9.  
The nature of this defect was assayed for the dependence on Ubc9 during viral 
assembly, trafficking, and Env incorporation.  The Gag-mediated assembly of virus 
particles and protease-mediated processing of Gag and Gag-Pol were unchanged in the 
absence of Ubc9.  However, the stability of the cell associated Env glycoprotein was 
decreased and Env incorporation into released virions was altered.  Interestingly, 
overexpression of the Ubc9 trans-dominant negative mutant C93A, which is a defective 
E2-SUMO-1 conjugase, suggests that this activity may not be required for interaction 
with Gag, virion assembly, or infectivity.  This finding demonstrates that Ubc9 plays an 
important role in the production of infectious HIV-1 virions. 
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Introduction 
Production of infectious HIV-1 particles is a coordinated series of poorly defined 
events wherein the virus takes advantage of cellular components to target its structural 
proteins and genomic RNAs to common sites on cellular membranes.  This co-
localization drives the assembly of immature capsids, packaging of the diploid viral 
genomic RNA, incorporation of viral glycoproteins and virion-associated proteins, and 
viral budding/release.  The major structural component of the immature HIV-1 core is the 
Gag polyprotein.  Gag is synthesized on cytoplasmic ribosomes as a 55 kDa polyprotein, 
Pr55Gag, and is co- or post-translationally myristylated.  Expression of Gag alone is 
sufficient for assembly and release of non-infectious virus-like particles.  However, 
infectivity of HIV-1 can only be attained by inclusion of the receptor-binding Env 
glycoproteins (gp120 and gp41) and the pol-encoded enzymes (protease, PR; reverse 
transcriptase, RT; and integrase, IN).  PR is essential for the cleavage of the Gag 
polyprotein into the structural proteins, NH2 - MA (p17, the membrane-associated, matrix 
protein), CA (p24, the major capsid protein), SP1 (spacer peptide 1, also known as p2), 
p7 (NC, the nucleocapsid protein), SP2 (spacer peptide 2, also known as p1), and p6-
COOH (113, 387), to form the mature, infectious virion.  The cleavage of the precursor 
polyprotein has been the target of the highly effective protease inhibitor class of 
antiretrovirals. 
 Gag-mediated packaging of viral enzymes, structural proteins (e.g. Gag-Pol 
polyprotein, mature Env glycoproteins, Vpu, Vpr, Vif), the viral RNAs, and cellular 
components (e.g. Cyclophilin A (110) and Lysyl-tRNA) are necessary for the production 
of infectious particles (113, 118, 387).  Since these molecules are synthesized in different 
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cellular compartments, it is imperative that cellular pathways traffic these components to 
common assembly sites on infected cell membranes.  Cell fractionation, 
immunohistochemistry, electron and fluorescent microscopy studies have shown that Gag 
assembles and buds almost exclusively from the plasma membrane in primary CD4+ T 
cells and in most cell lines such as HeLa, 293 and COS-1 cells (143, 147, 275, 360).  
However, a significant but minor portion of Pr55 in T-cells can also be found associated 
with late endosomes (LE) (134).  These observations led to the postulation that most of 
Pr55Gag buds primarily from the plasma membrane, but a portion of the polyprotein may 
fail to bud and cycles off the plasma membrane into the LE (139). Alternatively, it has 
been suggested that Gag is initially targeted to the LE/multivesicular bodies (MVB) 
compartments and is subsequently transported to the plasma membrane (134, 264, 290, 
303, 336).  Consistent with the latter hypothesis, further studies have shown that Gag co-
localizes with LE/MVB marker proteins in infected/transfected cells and is packaged into 
released virions (193, 287).  Studies have shown that the membranes of these intracellular 
structures are contiguous with the plasma membrane (84, 176, 378) and HIV-1 may 
utilize these tetraspanin enriched microdomains as assembly sites (84, 168).  The current 
model is that HIV-1 assembles and buds from specialized regions of the plasma 
membrane in most, if not all cell types. 
 The intracellular trafficking pathways of the viral structural proteins must 
converge at common sites to allow the requisite assembly interactions to occur.  
However, the intracellular location of these interactions and the temporal or spatial 
regulation of these events are not well defined.  Gag and Gag-Pol proteins are transported 
through the cytoplasm to cellular membranes by poorly understood processes that likely 
 40 
involve components of the cellular cytoskeletal system.  The viral glycoproteins are 
synthesized on rough endoplasmic reticulum (RER) and are co-translationally 
translocated into the ER lumen as gp160 precursor proteins.  The gp160 molecules are 
heavily N and O-linked glycosylated concomitant with trimerization prior to being 
transported to the Golgi apparatus for oligosaccharide maturation.  During transport from 
the cis-medial Golgi to the cell surface, gp160 is likely cleaved by Furin in the medial 
trans Golgi (138, 254), yielding the mature surface (SU, gp120) and transmembrane (TM, 
gp41) glycoproteins.  However, other proteases may also be involved (155, 269, 392). 
 It is hypothesized that Env trimers interact with Gag at budding sites, yet 
biochemical and genetic evidence suggest that the initial Gag-Env interactions, whether 
direct or indirect, occur prior to their arrival at the final assembly sites (221, 222, 323, 
335).  In fact, Tip47, a tail interacting protein involved in retrograde transport of cellular 
factors from endosomes to the trans-golgi network (TGN), was found to be required for 
Env packaging.  This model suggests that during retrograde transport to the TGN, Env 
comes into contact with Gag on endosomes with Tip47 directly facilitating Gag and Env 
interaction.  This complex is then targeted to the final assembly site on the plasma 
membrane (224). 
Coordinated trafficking of Gag, Gag-Pol, and Env requires interactions with 
cellular proteins.  A number of host factors such as, AP-1 (51), AP-2 (19), AP-3 (93), 
Rab9 (260), POSH (8), PI(4,5)P2 (274), Tip47 (224), SOCS1 (315), Arf proteins (174), 
and KIF4 (241) are found to interact directly with HIV-1 structural proteins, promoting 
proper intracellular trafficking and driving virion assembly.  Ubc9, an E2 SUMO 
conjugating enzyme (333), was found to interact with several different retroviral proteins, 
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but its function during virus replication is unclear.  Ubc9 was shown to interact with the 
full-length Gag protein of Mason-Pfizer monkey virus (M-PMV) near the nuclear 
membrane, suggestive of a possible function for Ubc9 during virus assembly (376).  In 
contrast, Ubc9 was subsequently shown to interact with and SUMOylate the CA protein 
of Moloney murine leukemia virus (MoMuLV) (400).  Unlike the observations made 
with M-PMV, an interaction between the full-length MLV Gag protein and Ubc9 was not 
observed in the yeast two-hybrid assay.  Biochemical and genetic analyses suggested the 
MLV CA-Ubc9 interaction is required during the early stages of replication, post-reverse 
transcription. 
Finally, Ubc9 was shown to interact with the HIV-1 p6
gag
 protein in yeast and 
SUMOylate a p6-GFP fusion protein in mammalian cells.  Overexpression of SUMO-1 
resulted in the packaging of free SUMO-1 into HIV-1 virions and was shown to cause a 
5-fold decrease in infectivity by these virions when compared to virions produced in 
control cells.  It was found that the defect in infectivity of wild-type (wt) HIV-1 virions 
produced in the presence of overexpressed SUMO-1 occurred during a post-entry step 
(137), and suggests that SUMOylation of p6 negatively regulates HIV-1 infectivity 
during an early infectious event.  Interestingly, mutation of the SUMOylation site, in the 
context of an infectious provirus, had no apparent effect on virus replication in normal 
cells.  However, unlike wt HIV-1, the SUMOylation mutant did not exhibit a defect in 
virion infectivity when SUMO-1 was overexpressed in producer cells.  Thus, the role of 
SUMOylation on p6 function is still not clear. 
Recently it was reported that GagGFP co-localizes with myc-Ubc9 at Gag 
perinuclear clusters (GPCs) in the absence of KIF4 (241), a kinesin family motor protein.  
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Blocking KIF4 function resulted in Gag accumulation at GPCs, inhibiting Gag 
trafficking, stability, and subsequent release.  However, neither an interaction between 
Ubc9 and full-length Pr55 nor SUMOylation of Pr55 by Ubc9 during assembly was 
examined in the previous report.  In this study, we further investigated the role of Ubc9 
during HIV-1 replication.  We demonstrated that; a) Ubc9 interacts with Pr55, b) Ubc9 
and C93A Ubc9, a trans-dominant negative mutant (354), co-localize with Gag at 
perinuclear sites, c) Ubc9 is crucial during the late stages of replication to produce 
infectious particles, and d) the E2 SUMO conjugation activity of Ubc9 does not appear to 
be a prerequisite for its effect during the late stages of the HIV-1 life cycle. 
Materials and Methods 
Cell lines and bacterial strains.  TZM-bl indicator cells were obtained from the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-
bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.  HeLa and 293T cells 
were obtained from the American Type Culture Collection.  Escherichia coli BL21 
(DE3) cells were used for expression of GST and GST-Ubc9 (376). 
Plasmids.  The infectious HIV-1 proviral clone pNL4-3, and non-infectious clone pNL4-
3-!E-EGFP were obtained from the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH: pNL4-3 from Dr. Malcolm Martin (4) and pNL4-3-!E-
EGFP (Cat# 11100) from Drs. Haili Zhang, Yan Zhou, and Robert Siliciano (403).  The 
pLTR EnvNL4-3 construct encoding HIV-1 Envelope was created by introducing an EcoRI 
site pNL4-3 at position 823.  The 4920 bp EcoRI (nt 823 and 5743) fragment was 
removed and the remaining vector was religated. The plasmids pCMVGAGPOL-RRE-R 
and pCMVrev, encoding HIV-1 Gag and Rev respectively, were a kind gift from Dr. 
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David Rekosh (University of Virginia, Charlottesville, VA) (213, 342).  The in vitro Gag 
expression plasmids pTM/55BAM, pGPG1-39G1, pGPG1-15G1, pGPG1-41G1, pGPG1-
17G1, pGPG1-24G1 were a kind gift from Dr. Paul Spearman (Emory University, 
Atlanta, GA) (341).  The plasmid pHyg-VSV-G encoding VSV-G was a kind gift from 
Dr. Asit Pattnaik (University of Nebraska-Lincoln, Lincoln, NE). 
Plasmids pET41c+ (Novagen), pET Ubc9, pCMV-Tag3A, and pCMV Myc-Ubc9 have 
been previously described (376).  Myc-C93A was created by PCR based site directed 
mutagenesis of Myc-Ubc9 by mutating nucleotides 276 and 277 to cytosine and guanine 
respectively in the Ubc9 ORF.  The plasmid pEGFP-SUMO-1 encoding an EGFP-
SUMO-1 fusion protein was a kind gift from Dr. Yongsok Kim (182) 
RNA interference (RNAi) and DNA transfections.  Synthetic, double-stranded siRNAs 
with 3’ dTdT overhangs, corresponding to nucleotides 86-104 of the Ubc9 open reading 
frame were purchased from Dharmacon and are similar to those previously described 
(216).  Fluorescent, non-silencing 21 base pair double-stranded RNA (Qiagen) was used 
as a control RNA (Ctr. RNA).  293T cells were transfected twice with RNAs, at 0 and 24 
hrs, using Lipofectamine 2000 reagent (Invitrogen) as per manufacturer’s protocol.  After 
an additional 24 hrs, cells were transfected with either plasmid pNL4-3, pLTR EnvNL4-3, 
pNL4-3 !Env-EGFP, or pNL4-3-!E-EGFP with pHyg-VSV-G.  Plasmids 
pCMVGAGPOL-RRE-R and pCMVrev were co-transfected into HeLa cells using 
Fugene 6 (Roche) as per manufacturer’s suggestions.   
GST pull-down assays.  pTM/55BAM, pGPG1-39G1, pGPG1-15G1, pGPG1-41G1, 
pGPG1-17G1, and pGPG1-24G1 were used to express [
35
S] methionine-cysteine 
radiolabled wt Gag and Gag deletion mutants using the TNT Coupled Reticulocyte 
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Lysate System (Promega).  GST-Ubc9 (pET Ubc9) and GST (pET41c+) were expressed 
in and purified from E.coli as previously described.  Radiolabeled Gag or Gag deletion 
mutants were incubated with equimolar concentrations of GST or GST-Ubc9, 
immobilized on glutathione beads and pull-down assays were carried out as previously 
described (376). 
Viral infectivity assays.  Virus released into the culture media from transfected cells was 
quantified by determining the amount of released p24 by immunoblotting.  TZM-bl 
indicator cells were infected with equivalent amounts of viruses (normalized to p24 
content).  The number of infected cells in this single round infectivity assay was 
determined by staining for "–galactosidase activity at 36 hrs post infection as previously 
described (183). 
Antibodies.  Anti-Ubc9 (H-81) rabbit polyclonal antibodies (pAb), anti-Actin goat pAb, 
anti-Cyclophilin A pAb, HIV-1 anti-gp41 (10E9) monoclonal antibodies (mAb), and 
HRP-conjugated chicken anti-goat pAb were purchased from Santa Cruz Biotechnology, 
Inc.  The following rabbit, goat, and mouse anti-HIV-1 antibodies: anti-p24 mAb 24-2, 
gp41 mAb 2F5, HIV-1sf2 p24 pAb, HIV-1 gp160/120 goat pAb H3T, HIV-1HXB2 Vif 
pAb, HIV-1NL4-3 Vpu pAb, and Vpr pAb were obtained from the NIH AIDS research and 
reference reagent program.  Anti-SUMO-1 #12783 rabbit polyclonal antibodies, a kind 
gift from Dr. Van Wilson (Texas A&M University System Health Science Center, 
College Station, TX), were previously described (313).  HRP-conjugated goat anti-rabbit 
and HRP-conjugated sheep anti-human antibodies were purchased from Amersham 
Pharmacia Biotech.  Cy5 conjugated donkey anti-mouse and Cy2 conjugated donkey 
anti-rabbit sera were purchased from Jackson Immunoresearch Laboratories.  Pooled 
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AIDS patient serum and pooled normal human serum were obtained from a patient 
cohort. 
Immunoblotting analysis.  Media from transfected cells were harvested and virions 
were purified from medium by pelleting through a 20% sucrose cushion (34).  Pelleted 
virions and cells were solublized directly in 2X protein sample buffer (PSB), separated by 
SDS-PAGE and analyzed by immunoblotting.  For immunoblot detection of 
SUMOylated proteins, transfected cells were lysed as previously described (16) with 
SUMO lysis buffer containing 20mM Iodoacetamide and NEM.  Lysates were separated 
by SDS-PAGE, transferred to a PVDF membrane (GE Healthcare), and analyzed by 
immunoblotting. 
Viral RNA extraction and real time PCR.  Viral RNA (vRNA) was extracted from 
equal numbers of virions (normalized by p24 content) and reverse transcribed (34).  Viral 
cDNA was quantified by real time PCR (iCyclerIQ, Bio Rad) using previously described 
primers (74). 
Cell viability assay.  Viability of Ubc9 siRNA transfected cells and control cells was 
assayed using BD ApoAlert Annexin V & Apo 2.7-PE kit (BD Biosciences) as per 
manufacturer’s protocol.  Annexin-EGFP V staining and Propidium Iodide uptake was 
measured using BD FACSCalibur (BD Biosciences).   
Confocal microscopy.  Transfected 293T cells were cultured on sterile cover slips 
treated with poly-L-lysine in 35mm culture dishes.  Cell were fixed at room temperature 
in 4% paraformaldehyde in PBS for 20 minutes and permeabilized with 0.2% TX-100 in 
PBS for 5 minutes.  Fixed cells were processed and stained as previously described (34).  
Cover slips were mounted on slides and analyzed by confocal microscopy (Olympus 
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FV500 and upright BX Olympus florescence microscope).  Proteins in transfected cells 
were detected using the following antibodies: Pr55, anti-p24 mAb, Env, anti-gp41 mAb 
10E9, Ubc9, anti-Ubc9 pAbs.  Fluorescent Cy5-conjugated donkey anti-mouse and Cy2-
conjugated donkey anti-rabbit antibodies were used as secondary antibodies. Anti-Ubc9 
antibodies were not able to detect endogenous Ubc9 in this assay.  Consequently, Cy2 
background antibody staining and any potential low level, endogenous Ubc9 staining 
signals were reduced to undetectable levels; such that, the fluorescent signals detected 
were due to exogenous protein expression only.  0.3-um Z-sections were analyzed using 
Flowview imaging software (Olympus). 
Metabolic labeling and immunoprecipitation.  Transfected 293T cells were pulse 
labeled for 45 min with 300 "Ci [
35
S]methionine-cysteine (>1000Ci/mmol, NEN).  The 
labeling media were removed and the cells were chased for 2 and 4 hours in normal 
growth media.  The cell culture supernatants were then collected, clarified by 
centrifugation (13,800 xg/1 min), and adjusted to 1X lysis buffer (320).  Cells were lysed 
with 1X lysis buffer containing protease inhibitors (Roche) and centrifuged to remove 
cellular debris.  Viral proteins were immunoprecipitated (IP) with a pooled patient serum, 
separated by SDS-PAGE, and visualized by fluorography. For co-immunoprecipitation 
experiments, transfected HeLa cells were lysed with GTN buffer containing 0.1% BSA 
(376).  Cell lysates were centrifuged to remove cellular debris, Ubc9-Gag complexes 
were immunoprecipitated with anti-Ubc9 antibodies that recognizes both endogenous 
Ubc9 and Myc-Ubc9, and the complexes were detected by immunoblotting using anti-
p24 sera. 
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Quantitation of gp160 processing efficiency.  Autoradiograms were scanned using a 
Fluor-S
TM
 system.  The accompanying Discovery Series Quantity One
TM
 software 
(BioRad) was used to quantitate the intensities of the bands corresponding to gp160 and 
gp120 from the scanned images.  The molar equivalence of each protein was calculated 
by dividing the band intensity by the number of methionines for each protein (gp160 and 
gp120 contain 14 and 9 methionines, respectively).  To calculate the percent of gp160 
cleaved into gp120 in Env-only expressing cells, the molar equivalence of gp120 was 
divided by the total molar equivalence of Env (gp120 and gp160). 
Results 
HIV-1 Gag interacts with hUbc9.  While we have shown that Ubc9 interacts with the 
full-length Gag protein of M-PMV, others have not detected an interaction with the full-
length Gag proteins from other retroviruses.  However, a Gag cleavage product, p6, was 
identified as a Ubc9 binding partner and target for SUMOylation (137).  Furthermore, 
recent work shows that HIV-1 GagGFP is targeted to a vesicle containing Ubc9 and 
SUMO-1 early in the assembly pathway, suggesting that Ubc9 may play a role during the 
assembly process (241).  To test if an interaction between Ubc9 and HIV-1 Pr55 could be 
detected in vitro, Pr55 was translated in vitro in the presence of [
35
S] methionine.  GST-
tagged-Ubc9 was expressed in E. coli and purified using glutathione-agarose beads.  The 
Gst-Ubc9 bound beads were mixed with in vitro translated Pr55.  Bound proteins were 
eluted and examined by SDS-PAGE and fluorography (Fig. 1a).  While GST control 
beads showed no detectable binding to Pr55, the GST-Ubc9 beads efficiently bound Pr55 
under conditions previously used to detect Ubc9-M-PMV Gag interactions. The 35 kDa 
band that was pulled down with Gst-Ubc9 is a peptide produced during the in vitro 
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transcription reaction from the use of an internal ATG as the translation start site.  This 
peptide could contain the Gag/Ubc9 binding site.  Gst-Ubc9 pull-down assays using a 
panel of Gag deletion mutants (Fig. 1b) showed that the Ubc9 binding site on Pr55 is 
located within the carboxy-terminal NC-p2-p6 region, since only clones pGPG1-39G1 
and pGPG1-15G1 retained the ability to be pulled down by Gst-Ubc9 (Fig. 1c).  These 
results were consistent with previous observations that the p6 domain of Pr55 contains a 
Ubc9 binding site (137) and demonstrated that the MA-CA-p1 regions of Pr55 do not 
contain any additional major Ubc9 binding sites.   
Co-immunoprecipitations confirmed Ubc9 and Gag interact in vivo (Fig. 2a).  
pNL4-3 or Pr55 was expressed in HeLa cells alone or with Myc-tagged Ubc9.  At 48 hrs 
post-transfection, cells were lysed using the same buffer as used in the GST pulldowns 
and incubated with either polyclonal anti-Ubc9 antibodies or with preimmune rabbit sera.  
Immunoblots using anti-p24 sera indicated that while the control preimmune sera did not 
precipitate Pr55, anti-Ubc9 antibodies co-immunoprecipitated Pr55.  The overexpression 
of Myc-tagged Ubc9 only increased the amount of Pr55 pulled down by about 30%.  The 
small increase in the amount of Gag pulled down when Ubc9 was overexpressed was not 
unexpected as Ubc9 interactions with target proteins were shown to be transient and 
weak (215). 
To further substantiate Ubc9-Pr55 interactions in cells, immunofluorescence 
assays were utilized to examine Ubc9 and Gag subcellular localization.  293T cells were 
transfected with either Myc-Ubc9 expression plasmid alone (Fig 2b-d) or co-transfected 
with pNL4-3 and Myc-Ubc9 (Fig. 2e-j).  Cells were processed 48 hrs post transfection 
and examined by confocal microscopy.  Myc-Ubc9 staining occurred in the nucleus, 
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throughout the cytoplasm, in areas near the plasma membrane [Fig. 2b-d, e, and h (white 
arrows)], and as distinct foci juxtaposed to the nuclear membrane [Fig. 2b-d, e and h 
(yellow arrows)].  In cells co-transfected with Myc-Ubc9 and pNL4-3 (Fig. 2e-j), HIV-1 
Gag stained the cytoplasm, plasma membrane, and at perinuclear foci (Fig. 2f).  HIV-1 
Gag and Ubc9 co-localized in HIV-1 expressing cells (Fig. 2g) in a similar pattern that 
was observed with M-PMV Gag and Ubc9 in infected cells (376) and is similar to what 
was observed recently for HIV-1 GagGFP (241).  Gag was also observed to co-localize 
with Ubc9 in the cytoplasm near the plasma membrane and at perinuclear foci (Fig. 2g).  
In an effort to identify the Gag-Ubc9 co-localization site and determine whether Ubc9 
and Env also co-localize, we stained for both Env and Ubc9.  Env and Ubc9 did not seem 
to co-localize (Fig. 2h-j) and certainly not at the same punctate perinuclear site observed 
between Gag and Ubc9 (yellow and white arrows).  Furthermore, these results suggest 
that the Ubc9/Gag foci observed in this study are not in the ER, golgi, or post-golgi 
vesicles, all cellular organelles that Env is known to occupy.  These results are similar to 
what Martinez et al. reported, where they describe a similar subcellular site containing 
Gag, Ubc9, and SUMO-1 (44), 
Ubc9 is important for the production of infectious HIV-1 particles.  Having 
determined that Ubc9 interacts with the full-length HIV-1 Gag protein, we sought to 
further elucidate the role of Ubc9 in the production of replication competent HIV-1 
particles by ascertaining whether infectious virions could be produced in the absence of 
Ubc9 expression.  To achieve this, 293T cells were transfected twice with either a non-
silencing control RNA (Ctr. RNA) or a Ubc9-specific silencing RNA (Ubc9 RNAi) at 24 
hr intervals followed by transfection with wt HIV-1 proviral DNA (pNL4-3) after an 
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additional 24 hrs. The effects of Ubc9 RNAi transfection on Ubc9 expression, cell 
viability, virus production, and viral infectivity were assayed at 72 hrs post-initial RNA 
transfection.  As shown in figure 3a, Ubc9 expression was reduced to almost undetectable 
levels in cells transfected with Ubc9 RNAi as compared to cells transfected with the Ctr. 
RNA.  The levels of controls, p53 and Actin, remained constant in all samples, 
demonstrating the specificity of Ubc9 silencing.  Because Ubc9 is required to sustain 
cellular replication (142), we examined cell viabilities at 72 h post-transfection when 
media containing virions were collected.  Flow cytometry quantifying propidium iodide 
incorporation, Annexen V staining, and trypan blue exclusion (data not shown) assays 
demonstrated that greater than 97% of control RNA and Ubc9 RNAi transfected cells 
were viable when the virions were harvested (Fig. 3b). 
To examine whether Ubc9 is important during virus assembly and release, cell-
free virions released into culture supernatants from transfected cells were pelleted, lysed, 
and analyzed by Western blots.  We found that Ubc9 expression is not required for virus 
assembly, budding, or Pr55 processing since equivalent amounts of p24 were released 
from cells as pelletable virus particles in the presence or absence of Ubc9 expression 
(Fig. 3c).  These virions also contained equivalent amounts of reverse transcriptase (data 
not shown).  The effect of Ubc9 depletion on virion infectivity was analyzed by using 
equivalent amounts of virions (normalized to p24 content) released from these cells in 
single-round infectivity assays using TZM-bl reporter cells to quantify the number of 
infectious events relative to virions produced in the presence of Ubc9.  Virions released 
from cells that did not express detectable levels of Ubc9 were on average 10-fold less 
infectious than those virions released from cells expressing normal levels of Ubc9 (Fig. 
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3d).  The average viral titer for cells transfected with no RNA, Ctr. RNA, and Ubc9 
RNAi were 3750, 4083, and 367, respectively.  These results are the first to demonstrate 
that while Ubc9 has no effect on Gag synthesis, processing, or assembly into virions, its 
expression in the producer cells is important for the generation of infectious HIV-1 
virions.  
Ubc9 is important for the correct production and packaging of viral components.  
We initially anticipated that Ubc9 must be packaged into HIV-1 virions to achieve full 
infectivity.  However, this scenario appears unlikely since we and others (63) were 
unable to detect Ubc9 or SUMO-1 in HIV-1 particles released from cells even when myc-
Ubc9 was overexpressed in the producer cells (data not shown).  Our results (Fig 3c) 
demonstrated that the interaction between Gag and Ubc9 is not required for Gag release 
and processing, but is important for infectivity (Fig 3d).  Therefore, Ubc9 must influence 
Gag-mediated biosynthesis, the packaging of other viral components, or the inclusion of 
cell-derived viral inhibitors.  The deficiency in assembly of released virions was 
identified by comparing the composition of replication defective virions harvested from 
Ubc9 knock-down cells to fully-infectious HIV-1 from normal and control RNA 
transfected cells.   
As shown, Ubc9 expression was not required for packaging of the vRNA (Fig. 
4a), the HIV-1 accessory proteins Vpr, Vpu, and Vif, or the cellular protein Cyclophilin 
A (Fig.4b).  In contrast, virions produced in the absence of Ubc9 expression contained 
significantly lower amounts of Env glycoproteins (gp120, and gp41) than virions 
produced from cells transfected with pNL4-3 alone or with pNL4-3 and control RNA 
(Fig. 4c). Env production was assayed in these producer cells and it was found that cells 
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transfected with pNL4-3 and Ubc9 RNAi contained similar amounts of the Env precursor 
protein gp160, but exhibited a decrease in gp120 and gp41 levels when compared to 
those that were transfected with pNL4-3 alone or with pNL4-3 and Ctr. RNA (Fig. 4d). 
The changes observed in gp120 expression and packaging were unexpected and 
suggested that the decrease in virion infection may be due to the inability of the virions to 
attach and enter a nascent cell; however, the SUMOylation pathway has also been 
implicated during early infectious events of HIV-1 (137) and MLV (400).  Gurer et al. 
had previously shown that overexpression of SUMO-1 in producer cells leads to a 
decrease in HIV-1 virion infectivity and was attributed to a defect during an early step of 
reverse transcription of the viral genome.  Similarly, Yueh et al. reported that point 
mutations of lysines (K202 and K220) that block the SUMOylation of the capsid protein 
of MLV also resulted in a defect at an early infectious event, albeit at a post reverse 
transcription step. 
To examine the possibility that the decrease in virion infectivity could be 
attributed to defects that occurred during post-entry events, we assayed the ability of 
VSV-G pseudotyped HIV-1 cores to complete early infection events and nascent viral 
gene expression.  These experiments allowed us to examine early events independently 
from any potential defects in entry caused by the decreased Env packaging in the absence 
of Ubc9 expression.  Virion infectivity was carried out as before using TZM-bl indicator 
cells.  As shown in figure 4e, the decreased expression of Ubc9 by RNAi had no affect on 
the infectivity of the pseudotyped HIV-1 cores.  This data indicated the defect observed 
with virions produced in the absence of Ubc9 expression is not due to a defect during 
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early post-entry events, but is likely the result of the virions’ inability to enter a 
susceptible cell as a result of the decreased amount of Env packaged. 
Ubc9 contributes to viral glycoprotein stability in the presence of Gag expression.  
Immunoblot data that examined viral proteins at steady state levels showed a significant 
decrease in the amount of gp120/gp41 in the transfected cells and in the amount of Env 
packaged into the virions.  The decrease in gp120 in the producer cells suggested that this 
could be due to a defect in gp160 maturation, a decrease in stability of gp120, or a fewer 
number of mature virions being endocytosed in the absence of Ubc9 expression.  A 
defect in gp160 maturation was less likely, as immunoblot data (Fig. 4d) did not show the 
increase in gp160 expression levels at steady state, which was expected if gp160 was not 
undergoing cleavage during maturation.  Therefore, pulse chase experiments were carried 
out to further examine these possibilities and to access Env stability in the absence of 
Ubc9 expression. Equivalent amounts of Env and Gag proteins were synthesized in all 
samples (Fig. 5a).  However, a 90% reduction of Ubc9 expression resulted in an 
approximately 2-fold decrease in the amount of cell-associated gp120 (Fig. 5a and c).  
This reduction in cell-associated gp120 was not due to a defect in gp160 processing or an 
increased release of gp120 into the media (Fig. 5a and b).  When pulse-labeled Gag 
proteins were chased, the levels of cell-associated Pr55 decreased as virus-associated p24 
increased at the same rates regardless of the Ubc9 expression levels.  The amount of cell 
associated p25/p24 did not change relative to the control cells, indicating that the 
decrease in cell-associated gp120 is not due to decreased endocytosis of mature virions.   
The amount of gp120 packaged into particles released from Ubc9 RNAi treated 
cells was also approximately 2-fold less than the particles released from control cells. 
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This is consistent with what was observed in the amounts of cell-associated gp120. The 
small amount of gp120 that was detected in Ubc9 RNAi transfected cells and released 
into the media was probably from cells that were not transfected with the Ubc9 RNAi. 
These data suggest that Ubc9 plays an important role on gp120 levels in the virus 
producing cells, either directly or indirectly, resulting in decreased packaging of gp120 
into the released virions. 
Ubc9 has been reported to interact with a variety of cellular proteins affecting 
subcellular location, function, and stability (250).  Some of these proteins share similar 
biosynthetic pathways as HIV-1 Env and are found in organelles known to be utilized by 
Env during the late virion assembly pathway (75, 325, 389).  Because Ubc9 has been 
shown to act directly upon cellular glycoproteins utilizing the secretory pathway, pulse 
chase experiments that assayed Env stability were done in the absence of Gag expression 
to rule out the possibility that Ubc9 was directly acting upon Env.  This was carried out 
by using a pNL4-3 that was modified to express Env glycoproteins in the absence of Pr55 
by deleting the gag and pol genes.  293T cells were transfected with this construct (LTR 
EnvNL4-3) either alone or with the Ctr. RNA or Ubc9 siRNA.  Env processing kinetics and 
stability were examined by pulse-chase experiments at 24 hrs post transfection.  
Surprisingly, in the absence of gag, pretreatment of cells with Ubc9 RNAi had no effect 
on the amount of gp160 that was synthesized and processed or on the kinetics and 
efficiency of processing gp160 into gp120 and gp41 (Fig. 6).  We concluded from these 
experiments that Ubc9, in the absence of Gag, does not play a significant role either in 
gp160 cleavage, trafficking through the secretory pathway to the TGN, or in gp120 
stability. Together these results demonstrate that Ubc9 functions during the virus 
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assembly process, which is required for full infectivity, and suggest that Ubc9 is involved 
in the processing and packaging of mature Env glycoproteins. 
Ubc9 functions independently of its E2 SUMO conjugase activity.  Ubc9 is the only 
E2 SUMO-conjugating enzyme identified (124) and many of the Ubc9 interacting 
partners are substrates for SUMOylation.  However, there is an increasing number of 
reports which demonstrate that Ubc9 also functions in a SUMO conjugase independent 
manner (11, 55, 181, 199, 282, 318, 357).  To determine whether Ubc9 SUMO conjugase 
activity is involved or required for its interaction with Gag and if it affects viral 
infectivity, we tested the effect of the overexpression of a trans-dominant negative 
mutant, C93A, that has no E2 SUMO conjugase activity (354).  293T cells were co-
transfected with equal amounts of EGFP-SUMO-1 and pCMV-Tag3A (empty vector), 
EGFP-SUMO-1 and Myc-C93A, or with pCMV-Tag3A alone to confirm that Myc-C93A 
acts as a trans-dominant negative.  Endogenous SUMO-1 is the limiting factor for 
SUMOylation (87), thus overexpression of exogenous EGFP-SUMO-1 proteins greatly 
increases the amount of SUMOylated proteins detected by immunoblot. A 4-fold 
overexpression of Myc-C93A over endogenous Ubc9 lead to approximately a 70% 
decrease in the global amount of EGFP-SUMOylated proteins.  Quantitation of the 80 
kDa band demonstrated a 90% decrease when compared to the control (Fig. 7a).  This 
result suggests that overexpression of Myc-C93A can inhibit SUMOylation effectively. 
To examine if the SUMOylation activity of Ubc9 is important for HIV-1 
infectivity, 293T cells were co-transfected with pNL4-3 and either pCMV-Tag3A (Fig. 
7b, set 1), Myc-Ubc9 (Fig. 7b, set 2), or Myc-C93A (Fig. 7b, set 3).  As expected, 
immunoblot analysis of whole cell lysates and virions pelleted from the medium of 
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transfected cells shows that the overexpression of either Ubc9 or C93A had no effect on 
virion budding, maturation, or release (Fig. 7b).  We then further examined whether the 
virions produced in the presence of C93A mutant displayed decreased infectivity.  As in 
previous experiments, the released virions were normalized for p24 content and equal 
amounts of virions were used to infect TZM-bl indicator cells.  In contrast to the loss of 
virion infectivity observed in the absence of Ubc9, overexpression of C93A and 
inhibition of SUMOylation in the producer cells had little effect on virion infectivity 
when compared to control samples (Fig. 7c).  In addition, Gag trafficked normally to 
perinuclear sites and co-localized with C93A Ubc9 (yellow and white arrows)(Fig. 7d).  
Collectively, these results suggest that Ubc9 may function independently of its E2 SUMO 
conjugating activity during the late stages of the HIV-1 life cycle.  
Discussion 
In this study we have shown that Ubc9 interacts with the full-length HIV-1 Gag 
protein and have demonstrated for the first time that Ubc9 plays a role during the late 
stages of virus replication and its expression in HIV-1 producing cells is important for 
conferring full infectivity to the nascent virus stock.  Our results indicate that Ubc9 
influences the stability and incorporation of mature Env into budding particles and may 
function during the HIV-1 assembly process in a SUMO-independent manner.  These 
conclusions are supported by the following: i) Ubc9-Gst fusion proteins can interact with 
in vitro translated Gag through its NC-p6 domain; ii) Gag-Ubc9 complexes can be co-
immunoprecipitated from cell lysates; iii) Gag, Ubc9, and trans-dominant negative C93A 
co-localize to discrete locations in the cytoplasm; iv) overexpression of Ubc9 or C93A 
does not affect virion infection, v) Ubc9 silencing leads to impaired virion infectivity; vi) 
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Ubc9 silencing has no effect on Gag assembly, budding, and processing or on Gag-
mediated packing of the viral RNAs, Vif, Vpr, Vpu, or the cellular protein Cyclophilin A; 
vii) Ubc9 is important for proper Env stability and incorporation of mature Env 
glycoproteins into virion particles when Env is expressed in the context of wt HIV-1 
replication; and viii) Ubc9 and Env do not appear to co-localize at the distinct perinuclear 
foci that contain Ubc9 and Gag. 
While most studies that have characterized Env processing and stability were 
carried out in Env-only expression systems, our data suggested that in the context of wt 
HIV-1, Gag and Ubc9 are important for Env stability and incorporation into nascent 
virions.  It was unexpected that the knockdown of a Gag interacting partner would cause 
a change in Env stability and packaging, but it was even more so to find that this 
phenotype was directly tied to the presence or absence of Gag expression.  While many 
have speculated that Env trimers interact with Gag at budding sites, biochemical and 
genetic evidence suggests that the initial Gag-Env interactions, whether direct or indirect, 
occur prior to their arrival at the assembly sites (86, 221, 222, 224, 280). 
The mechanism of how Gag influences gp120 stability in the absence of Ubc9 has 
not been elucidated, but our data suggests the Gag/Ubc9 complex could interact/affect 
Env after it has passed through the trans-golgi, possibly in secretory vesicles, plasma 
membrane, or recycling endosomes.  Our data suggest that Ubc9 is not involved directly 
with Env processing, as gp160 processing and gp120 stability are normal in the absence 
of Gag and Ubc9 and Env and Ubc9 do not strongly co-localize at the same subcellular 
compartments.  Although the majority of Ubc9/Gag co-localization is at perinuclear foci, 
which may be the Ubc9/SUMO-1 positive cellular structures where GPCs transiently 
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traffic through during an early stage of assembly (44), co-localization was observed in 
areas adjacent to plasma membrane with both Ubc9 and C93A as well.  It is possible that 
this area is a functional subcellular site of interaction between Ubc9 and Gag.  The close 
proximity of this co-localization site to the plasma membrane and the physical distance 
from the distinct perinuclear foci containing Gag and Ubc9, suggests that Ubc9 may also 
function at a later stage of assembly.  A stage where Gag has already trafficked through 
assembly intermediates and has been targeted to and is in close proximity to the plasma 
membrane, possibly at virus assembly sites. 
The trafficking of Gag to the sites of Ubc9 colocalization is most likely very 
transient as overexpression of Myc-Ubc9 greatly increases the amount of Gag 
localization to perinuclear sites containing Ubc9, but does not lead to a change in the 
amount of Gag released into the media as virions.  If Gag trafficking to sites of Ubc9 
colocalization were not transient or Gag trafficking to assembly sites slowed, we would 
have expected a difference between the amount of virions released from cells when Ubc9 
or C93A were overexpressed.  However, this phenotype was not observed suggesting 
very transient Gag trafficking through the sites of Ubc9 colocalization.  The full extent of 
how Ubc9 functions during the HIV-1 life cycle is still not well understood and it may be 
involved with various steps during assembly. 
Ubc9 is an E2 SUMO conjugase that is part of the cytoplasmic portion of the 
nuclear pore complex (402).  It appears to localize to distinct, yet undefined perinuclear 
regions, the secretory pathway, and is also free in the cytoplasm (241, 325, 376, 389).  
Ubc9, through its SUMOylation activity, is involved in the targeting of transcription 
factors, cellular receptors, and viral proteins (reviewed in 124, 146, 250)).  However, 
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there are a number of reports in the literature demonstrating Ubc9 functions in a SUMO 
independent manner.  Androgen receptor (55), MEKK1, type I TNF-alpha receptor (318), 
GLUT4 (220), RNA helicase A (11), glucocorticoid receptors (181), Vsx-1 (199), SOX4 
(282), and HHV-6 IE2 (357) require Ubc9 binding for their function and correct 
intracellular targeting, but they are not targets for SUMO-1 modification. 
Our experiments with the dominant negative C93A support a model where Ubc9 
functions as an essential binding partner of Gag in the late HIV-1 life cycle, but may do 
so independently of its SUMOylation conjugation function.  If SUMOylation was 
important during the late stages of the HIV-1 life cycle, we would have expected to see a 
difference in virion infectivity with the trans-dominant C93A mutant as compared to 
virions produced in control cells, yet little difference was observed.  This model is 
supported by data reported by Gurer et al. where the mutant HIV-1K27R displayed no 
defects in virion assembly, even though it contained a mutated version of an in vivo 
SUMOylation site within p6.  We have attempted to detect SUMOylated Gag or other 
viral proteins in both cell lysates and released virions under steady state levels and when 
Ubc9 and SUMO-1 have been overexpressed, but have been unsuccessful.  It is 
interesting to note that p6 (K27R) showed diminished Ubc9 binding in yeast (137), but 
the mutation did not abolish its interaction with Ubc9 completely.  Because of this, we 
carried out GST-Ubc9 pull down experiments with K27R in the context of Pr55 and 
found that p6 (K27R) can still interact with Ubc9 in vitro (data not shown).  This result 
suggests that there is more than one Ubc9 binding site within Gag or mutation of lysine 
27 in p6 is not enough to completely abolish Ubc9 binding. 
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In this study we mainly focused on the effects of Ubc9 on the late events of the 
viral life cycle in producer cells.  Even though Ubc9 is not packaged into virions under 
steady state levels or when Ubc9 is overexpressed (data not shown), it has been reported 
that SUMO-1 plays a role during the early infectious events of HIV-1 (137, 400) and may 
regulate various steps within the retrovirus life cycle.  To further understand mechanisms 
of how Ubc9 is functioning in the HIV-1 life cycle, studies following Gag and Env 
trafficking in the absence of Ubc9 are currently underway.  We are also investigating 
whether Ubc9 directly plays a role during the early infectious events of HIV-1 in target 
cells after entry.  Our data shows that Ubc9 plays an important role during HIV-1 
replication and we have identified another protein/pathway that could potentially be 
developed into novel anti-retrovirals. 
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Figures and Figure Legends 
 
Figure 1 
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Figure 1:  HIV-1 Gag proteins interact with Ubc9 in vitro.  (a) GST-Ubc9 pull-down 
assay. [
35
S] Methionine-labeled, in vitro translated Pr55 was incubated in GTN buffer 
with GST-bound glutathione beads or GST–Ubc9 bound beads.  As a loading control, 
1/10 of the amount of Pr55 added to the GST pull down reactions was loaded directly.  
Bound proteins were eluted with PSB and separated by SDS–PAGE.  The radio-labeled 
proteins were visualized by phosphor-imaging.  (b) Mapping the Ubc9 binding domain 
within HIV-1 Gag.  (c) GST-Ubc9 pull-down assays using wt Gag and the Gag deletion 
mutants were done as described above. 
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Figure 2 
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Figure 2:  HIV-1 Gag proteins interact with Ubc9 in vivo.  (a) Co-immunoprecipitation 
of endogenous Ubc9 and HIV-1 Gag.  HeLa cells were either mock transfected (lane 1 
and 5); co-transfected with pCMVGAGPOL-RRE-R and pCMVrev (lane 2 and lane 4); 
co-transfected with pCMVGAGPOL-RRE-R, pCMVrev and pCMV Myc-Ubc9 (lane 3); 
or transfected with pNL4-3 (lane 6).  Cells were lysed with GTN buffer and 
immunoprecipitated (IP) with anti-Ubc9 (lane 1, 2, 3, 5 and 6) or preimmune sera (lane 
4), and analyzed by immunoblotting using anti-p24 antibodies.  (b-g) Gag and Ubc9 co-
localize at distinct perinuclear puncta and areas near the plasma membrane.  293T cells 
were transfected with Myc-Ubc9 (b-d) or co-transfected with pNL4-3 and Myc-Ubc9 
expression plasmid (e-j).  Cells were fixed and processed for immunofluorescence with 
(b-d) anti-Ubc9 pAb, (e-g) anti-p24 mAb and anti-Ubc9 pAb (h-j), anti-Ubc9 pAb and 
10E9 anti-Env mAb.  Cy5-conjugated donkey anti-mouse and Cy2-conjugated donkey 
anti-rabbit antibodies were used as secondary antibodies.  Co-localization was examined 
by confocal microscopy using 0.3-um optical-sections.  Representative medial sections 
are shown.  Yellow arrows indicate Ubc9 and Gag co-localization at perinuclear puncta.  
White arrows indicate areas of Ubc9 and Gag co-localization near the plasma membrane.  
Scale bar represents 10 "m. 
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Figure 3 
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Figure 3:  Ubc9 is important for the production of infectious HIV-1 virions.  (a) Ubc9 
expression can be suppressed by RNA silencing.  293T cells were transfected with either 
control RNA (Ctr. RNA) or Ubc9 siRNA.  A second transfection with RNAs was 
performed 24 hrs later. Cells were lysed in PSB, separated by SDS PAGE, and protein 
expression levels were analyzed by immunoblotting using antibodies against Ubc9, 
Actin, and p53 at 72 hrs post-initial siRNA transfection.  (b) Suppression of Ubc9 does 
not affect cell viability.  Viability of Ctr. RNA and/or Ubc9 RNAi transfected 293T cells 
was analyzed using the BD ApoAlert Annexin V & Apo 2.7-PE kit following the 
manufacturer’s suggested protocol. The percentages of cells undergoing apoptosis were 
measured by flow cytometry.  (c) Ubc9 is not required for budding.  293T cells were 
either left untreated or transfected twice with Ubc9 siRNA or Ctr. RNA. Wild-type HIV-
1 proviral DNA (pNL4-3) was transfected 24 hrs following the second siRNA 
transfection.  Twenty-four hrs later (72 hrs post initial siRNA transfection), culture 
medium was collected and clarified.  Virions in the culture medium were pelleted through 
20% sucrose cushion and lysed with PSB.  Equal volumes of the lysates were separated 
by SDS-PAGE, and p24 levels were measured by immunoblotting using anti-p24 
antibodies.  (d) Ubc9 in virus producing cell is required for HIV-1 infectivity.  Equivalent 
amount of virus (normalized to pelletable p24) present in the medium from transfected 
293T cells was used to infect TZM-BL indicator cells for 36 hrs.  The numbers of 
infectious events were analyzed counting the number of cells that were positive for X-gal 
staining. 
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Figure 4 
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Figure 4:  Biochemical composition of viral particles.  The relative levels of viral RNAs 
and proteins packaged into equivalent amounts of defective and infectious virions 
(normalized to p24 content) were analyzed.  (a) Viral RNA Packaging. RNA from 
pelleted virions was extracted, reverse transcribed using oligo (dT)12-18, and quantified 
by real-time PCR using vRNA specific primers.  Real-time PCR data from three 
independent experiments is shown as the amount of vRNA packaged into virions relative 
to that of vRNA packaged into virions produced from cells transfected with pNL4-3 only.  
(b) Packaging of cellular and HIV-1 regulatory proteins.  Levels of cellular (Cyclophilin 
A) and viral regulatory proteins (Vif, Vpr, Vpu) packaged into virions were analyzed by 
immunoblotting.  The bands were quantified using The Discovery Series Quantity One 
software.  (c) Glycoprotein packaging into virions.  Envelope packaging into virions was 
analyzed by immunoblotting using polyclonal anti-HIV-1 and monoclonal anti-gp41 
antibodies.  (d) Glycoprotein production in cell lysates.  Envelope production inside 
transfected cells was analyzed by immunoblotting using polyclonal anti-HIV-1 
antibodies.  (e) Decreases in virion infectivity are not due to defects in the early post-
entry events.  Cells were transfected with RNAs as in previous experiments, followed by 
DNA transfections with pNL4-3-!E-EGFP and pHyg-VSV-G or pNL4-3 !Env alone.  
Media containing pseudotyped virions were harvested and clarified 24 hrs post-DNA 
transfections.  Virion infectivity was carried out as before using TZM-bl target cells. 
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Figure 5 
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Figure 5:  Gag and Env processing in the absence of Ubc9.  (a and b) Viral protein 
assembly kinetics.  293T cells were transfected with NL4-3, NL4-3 + Ctr. RNA, NL4-3 + 
Ubc9 RNAi, or left untransfected (U).  Cells were pulsed (P) with [
35
S] methionine for 45 
min and then chased for 2 and 4 hrs.  HIV-1 proteins in the cell lysates (a) and the culture 
supernatants (b) were immunoprecipitated with pooled AIDS patient serum, separated by 
SDS-PAGE, and detected by fluorography. The viral protein bands from multiple pulse 
chase experiments were quantified and analyzed using The Discovery Series Quantity 
One software. (c) Ratio of cellular gp120/Pr55. (d) Ratio of gp120/p24 released into the 
media. 
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Figure 6 
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Figure 6:  Env processing in the absence of Gag and Ubc9 expression.  (a) Ubc9 does not 
directly affect Env processing.  293T cells were transfected with LTR-Env, LTR-Env + 
Ctr. RNA, LTR-Env + Ubc9 RNAi, or left untransfected (U).  Cells were pulsed (P) with 
[
35
S] methionine for 45 min and then chased for 2 and 4 hrs.  HIV-1 proteins were 
immunoprecipitated from cell lysates with AIDS patient serum.  (b) Immunoprecipitated 
gp160 and gp120 bands were quantitated using The Discovery Series Quantity One 
software and the % of gp160 processed was calculated at 2 and 4 hours.  (c) Table 
summarizing proteins involved in Env processing defect. 
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Figure 7 
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Figure 7:  Ubc9 may function independently of its E2 SUMO conjugating activity during 
HIV-1 assembly.  (a) Myc-C93A is a trans-dominant negative active site mutant and 
suppressed SUMOylation of cellular proteins.  293T cells were co-transfected with 
pEGFP-SUMO-1 and either pCMV-Tag3A (lane 2) or Myc-C93A (lane 3), with pCMV-
Tag3A alone (lane 4), or left untransfected (lane 1).  Cells were washed with PBS, lysed 
in SUMO lysis buffer, and boiled for 10 minutes.  Lysates were assayed by 
immunoblotting using antibodies against SUMO-1 and Ubc9.  (b) Overexpression of 
Myc-Ubc9 or Myc-C93A does not affect virion budding.  293T cells were co-transfected 
with pNL4-3 and either PCMV-Tag3A (sample set 1), Myc-Ubc9 (sample set 2), or Myc-
C93A (sample set 3).  Media was harvested and virions were pelleted through a 20% 
sucrose cushion.  Virion budding and release was assayed by immunoblotting using 
antibodies against p24.  Transfected cells were lysed directly in PSB and protein 
expression was analyzed by immunoblotting using antibodies against Ubc9 and Actin.  
(c) Overexpression of Myc-Ubc9 or Myc-C93A does not affect HIV-1 infectivity.  
Medium from transfected cells was harvested and equal amounts of virus were used to 
infect TZM-bl indicator cells as in previous experiments.  (d) HIV-1 Gag and Myc-C93A 
does not affect Gag trafficking or co-localization with Ubc9 at perinuclear sites.  
Transfected 293T cells were fixed and processed for immunofluorescence analysis by 
confocal microscopy, using anti-Ubc9 pAb (1) and anti-p24 mAb (2).  Cy5-conjugated 
donkey anti-mouse and Cy2-conjugated donkey anti-rabbit antibodies were used as 
secondary antibodies.  Co-localization was analyzed using 0.3-um optical-sections.  
Representative medial sections are shown.  Yellow arrows and white arrows indicate 
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areas of Ubc9 and Gag co-localization at perinuclear puncta and near the plasma 
membrane respectively. Scale bar represents 10 "m. 
 
 76 
Chapter III 
 
 
Human Ubc9 is involved in intracellular HIV-1 Env stability 
after trafficking out of the trans-Golgi network in a Gag 
dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
Unpublished data 
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Abstract 
 We have previously shown that Ubc9 is important for the production of fully 
infectious HIV-1 virions.  We demonstrated that Ubc9 was a Gag interaction partner and 
Ubc9 expression was important for the stability of mature intracellular Env levels and 
packaging into the released virions.  We have continued to characterize the defect in the 
intracellular mature Env levels in Ubc9 knockdown cells to further understand how Ubc9 
and Gag contribute to intracellular Env stability and packaging into the assembled 
virions.  We found that gp160 stability in the endoplasmic reticulum (ER) was unaffected 
and that gp160 trafficked to the trans-Golgi network (TGN) in Ubc9 knockdown cells 
normally.  We examined the stability of a gp160 cleavage mutant (MUT 511) and found 
that it was unaffected in Ubc9 knockdown cells.   These results combined with data that 
showed gp160 stability was not affected when cleavage and trafficking from the TGN 
was blocked, indicated that the decreased intracellular mature Env levels in Ubc9 
knockdown cells were due to selective degradation of mature Env gp120 after it is 
trafficked out of the TGN and cleavage from gp160.  Decreased levels of Gag and mature 
Env were found to be associated with the plasma membrane and lipid rafts, which 
suggest that mature Env was degraded before insertion into the plasma membrane and 
association with lipid rafts.  We also demonstrated that the defect in virion infectivity due 
to the knockdown of Ubc9 expression was not isolate specific.  Virions produced from 
Ubc9 knockdown cells transfected with the HIV-1 pSG3.1 proviral clone also exhibited 
decreased infectivity. 
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Introduction 
Assembly of infectious HIV-1 virions requires a variety of viral and host factors 
that function in a coordinated manner to co-traffic the essential viral and cellular factors 
to the site of assembly on the plasma membrane (PM), and in some cases exclude the 
factors, such as tetherin and APOBEC3G from the assembling virions (64, 263).  A large 
number of host factors have been identified to interact with viral proteins to direct their 
correct trafficking to the assembly site.  These include KIF3A (15),  KIF3C (41), KIF4 
(242), POSH (8), SOCS1 (315), Rab9 and Rab11a (260), AP-1 (51, 271), AP-2 (19, 30), 
AP-3 (93), Tip47 (20, 29, 224), Staufen (56), GGA and ARF (174), SNARE proteins 
(173), ABCE1 (218), CD81 (135), phosphatidylinositol (4,5) bisphosphate (274), lipid 
rafts, (276), and Clathrin (298).  Once correctly trafficked to the PM, the viral and 
cellular factors are retained at the assembly site as the nascent virion is assembled and 
released from the cell surface through a process called budding.  The budding and release 
of progeny virions utilize the host vacuolar protein sorting pathway through direct 
interactions with TSG101 (122) or AIP1 (347).  During or shortly after release, the 
immature virion core undergoes viral protease-dependent cleavage maturation where the 
Gag proteins are cleaved and the virions mature into their infectious forms (assembly 
reviewed in 71). 
Gag (Pr55) is the predominant structural protein of HIV-1, which can drive the 
assembly of virus like particle in the absence of other viral proteins because the 
functional domains necessary for assembly are encoded within the Gag polyprotein 
precursor.  Gag is subsequently cleaved into matrix (MA), capsid (CA), nucleocapsid 
(NC), p6, and two small spacer peptides (SP1 and SP2).  The domains needed for proper 
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viral assembly include: the M-domain in MA, it is responsible for Gag targeting and 
binding to specific host cell membranes; the I-domain sequences within CA and NC 
which are involved in Gag multimerization, and the L-domain within p6 which directs 
budding and release of newly assembled virions.  Gag is translated on free ribosomes in 
the cytoplasm.  It then traffics to the site of assembly on the PM, multimerizes, and 
initiates the budding process as the immature capsid assembles. Gag also specifically 
binds and packages the viral genome through the zinc-finger motifs in NC and is 
responsible for packaging the viral protease and replication enzymes: Protease, Reverse 
Transcriptase, and Integrase.  These enzymes are initially expressed as a Gag-Pol fusion 
protein and packaged through Gag-Gag interactions mediated by the I-domain of the Gag 
precursor Pr55 and Pr160.  The replication enzymes are cleaved into the mature forms 
along with Pr55 during virion maturation events (Gag function reviewed in 113, 352, 
387). 
The Envelope glycoprotein is another essential viral structural protein that is 
packaged into the assembling virions, and is responsible for virion binding and entry into 
a target cell.  Envelope is expressed as an immature precursor protein (gp160) within the 
lumen of the endoplasmic reticulum (ER).  The gp160 is highly glycosylated, forms 
trimers within the ER, and is then trafficked to the Golgi complex.  As gp160 traffics 
through the Golgi, the sugar moieties are extensively modified and gp160 undergoes 
proteolytic cleavage into gp120 and gp41.  Cleavage of gp160 is believed to be mediated 
by Furin, a host encoded protease located in the trans-Golgi network (TGN).  After 
cleavage, the mature fusion competent Env, a trimer of gp120 and gp41 heterodimers is 
then formed and traffics through the unregulated secretory pathway to the PM where it is 
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packaged into assembly virions.  Alternatively, the Env in the PM can be endocytosed 
and recycled back the TGN (29, 99, 271).  Currently, the mechanism leading to Env 
packaging is still not fully understood.  However, there is evidence to suggest that under 
normal conditions, sequences within the cytoplasmic tail (CT) of Env interact with the 
MA domain within Gag, resulting in the specific packaging of the mature fusion 
competent Env (reviewed in 58, 167). 
We have previously reported that the host factor Ubc9 interacts with Gag, and 
plays an important role in the HIV-1 assembly pathway (159).  Ubc9 is an E2 SUMO 
conjugase which normally interacts with target proteins which are modified post-
translationally by the addition of SUMO (SUMOylation reviewed in 124, 405).  
SUMOylation generally leads to altered protein function.  However, a growing list of 
proteins were found to interact with Ubc9 without being targeted for SUMOylation, even 
though the physical interaction with Ubc9 altered the function of these interacting 
proteins (11, 54, 136, 199, 220, 282, 318, 357).  Ubc9 and SUMOylation have been 
shown to play important roles in the replication cycles of both DNA and RNA viruses, 
and some of these viruses deregulate the host SUMOylation pathway to enhance their 
replication (31, 32, 388).  We previously reported that Ubc9 is a HIV-1 Gag interaction 
partner and when the endogenous Ubc9 expression was knocked down in HIV-1 producer 
cells, it resulted in the production of virions with decreased infectivity.  The defect in 
infectivity was found to be due to decreased levels of mature intracellular Env which 
resulted in a reduced amount of Env being packaged into the released virions.  
Interestingly, the decreased intracellular Env levels in Ubc9 knockdown cells were 
dependent upon Gag expression, as intracellular Env levels were not affected in the 
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absence of Gag and Ubc9 expression.  Experiments with the trans-dominant negative 
Ubc9 (C93A), that lacks SUMO conjugase activity, suggested that the enzymatic activity 
of Ubc9 did not play a role in Gag dependent reduction in intracellular Env levels in 
Ubc9 knockdown cells.  However, Zamborlini et al. recently demonstrated that Ubc9 
may be important during HIV-1 infection as they have found that HIV Integrase is 
SUMOylated at a low level by SUMO-2.  They were also able to detect a small amount 
of SUMOylated Gag-Pol cleavage products in cells over expressing SUMO-2, indicating 
that Gag-Pol may be SUMOylated in producer cells, however, SUMOylated viral 
proteins were undetectable in the virion (401). 
In this study, we continued to examine the role of Ubc9 during HIV-1 assembly in 
the context of a fully infectious provirus, specifically determining how the knockdown of 
a Gag interacting partner can lead to the decrease in mature intracellular Env, resulting in 
less infectious virions.  We also examined which step(s) in the assembly pathway might 
be affected by a knockdown of Ubc9 thus leading to a reduction in Env.  We report here 
that in Ubc9 knockdown cells, the decreased intracellular mature Env is not due to an 
increase in gp160 instability in the ER, or a defect in subsequent trafficking of gp160 to 
the TGN compartment.  We found that mature Env gp120 is selectively targeted for 
degradation after cleavage, maturation and transport out of the TGN.   Less Gag and 
mature Env were found to be associated with the PM and lipid rafts, which suggested that 
in Ubc9 knockdown cells, less Gag and Env are associated with microdomains known to 
be important for virion assembly, and that the degradation of mature Env likely occurred 
before trafficking to the PM. 
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Materials and Methods 
Cell culture and transfection.  293T cells were obtained from the American Type 
Culture Collection, they were cultured and transfected as previously reported (159).  
TZM-bl indicator cells were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, 
Dr. Xiaoyun Wu and Tranzyme Inc.  
Plasmids.  The infectious HIV-1 proviral clone pNL4-3 and psG3.1 were obtained from 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 
pNL4-3 from Dr. Malcolm Martin (4) and pSG3.1 from Drs. Sajal Ghosh, Beatrice Hahn, 
and George Shaw (125).  The cleavage defective Envelope mutant  (pNL4-3 MUT 511) 
was a kind gift from Dr. Valerie Bosch and has been previously described (36). 
HIV-1 infectivity assays.  Virion infectivity assays were carried out as previously 
described (159).  Briefly, medium from transfected 293T cells containing infectious HIV-
1 virions were used to infect TZM-bl cells for approximately 36 hours.  TZM-bl cells 
were assayed for HIV-1 infection by staining for "-galactosidase activity and counting 
positive cells.  Infectivity was normalized to pelletable p24 levels in the media as 
determined by immunoblot. 
Metabolic labeling, immunoprecipitation, and Endoglycosidase treatments.  
Metabolic labeling experiments were carried out as previously reported with differences 
in labeling times with [
35
S] methionine/cysteine (>1,000 Ci/nMol; NEN) (159).  Briefly, 
transfected and untransfected 293T cells were pulse labeled for 30 minutes, 1 hour, or 4 
hours with 300 "Ci, 600 "Ci, or 2.0 mCi respectively.  For pulse chase experiments, 
labeling media were removed and chased for 2 and 4 hours in complete culture media.  
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The culture media was removed, clarified by centrifugation (13,000 RPM for 2 min), and 
adjusted to 1x lysis buffer (320).  Cells were lysed with 1X lysis buffer containing Halt 
protease inhibitors cocktail (Pierce) and clarified by centrifugation.  Viral proteins were 
immunoprecipitated using AIDS patient sera and ultralink A/G beads (Thermo 
Scientific).  The beads were washed 4X with lysis buffer and the viral proteins were 
released from the beads by boiling for 5 minutes in 0.04% SDS and 200mM 2-
mercapitoethanol (319).  The solublized proteins were split into two equal volumes and 
treated with Protein N-Glycosidase F (PNGase F) or Endoglycosidase Hf  (Endo 
Hf)(NEB) per manufacturers suggestions for 3.5 hours, or left untreated.  All samples 
were adjusted to 1X protein sample buffer (PSB), separated by SDS-PAGE, and 
visualized by phosphor imaging.  Band intensities were quantified using Discovery Series 
Quantity One software (Bio-Rad).  
Unfolded protein response.  Activation of the unfolded protein response was analyzed 
by XBP-I splicing as previously described with slight modifications (163).  Briefly, 
transfected and untransfected 293T cells were treated with 5mM dithiothreitol (DTT) for 
3 hours or left untreated.  Total RNA was extracted from 293T cells using the RNeasy 
mini kit (Qiagen) and treated with DNase I amplification grade (Invitrogen) per 
manufacturer’s protocol.  Three micrograms of RNA was reverse transcribed using oligo 
(dT) and SuperScript III (Invitrogen) per manufacturer’s protocol.  XBP-1 cDNA was 
amplified using standard PCR techniques with primers that flank the splice site (5’-
CCTTGTTGAGAACCAGG-3’ and 5’-CTAAGACTAGGGGCTTGGTA-3’). 
Lipid raft/detergent resistant membrane isolation.  Lipid raft isolations were 
preformed as previously described with slight modifications (25). Transfected 293T cells 
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were radiolabeled for 4 hours with 2.0 mCi [
35
S] methionine/cysteine.  The labeling 
media was removed and the cells were lysed on ice with 500 "l of TNE buffer (10 mM 
Tris [pH 7.5], 100 mM NaCl, 10 mM EGTA) containing 0.5% Triton X-100 (TX-100) 
for 30 min.  Lysates were collected and homogenized with 10 strokes through a 25-G 
needle and clarified by low speed centrifugation at 10,000 RPMs at 4°C for 10 minutes.  
Post nuclear lysates were adjusted to 60% sucrose by adding 1.5 ml of 80% sucrose TNE 
(w/v).  The lysates were layered over 500 "l of 80% sucrose TNE, followed by 2 ml of 
50% sucrose TNE, 6ml of 38% sucrose TNE, and 1.5 ml of 10% sucrose TNE.  The 
sucrose gradients were centrifuged at 100,000 X g at 4°C for at least 18 hrs in a Beckman 
SW41 rotor.  11 fractions were collected using a piston gradient fractionator (Biocomp).  
Densities of each fraction were determined by the refractive index of each sample.  
Fractions were adjusted to 1X lysis buffer and viral proteins were immunoprecipitated 
with pooled patient serum, separated by SDS-PAGE, and visualized by phosphor 
imaging.  Cellular proteins were precipitated from each fraction by 
methanol/chloroform/water precipitation (381) and then analyzed by immunoblotting to 
identify which sucrose fractions contained lipid rafts (LR), detergent resistant membranes 
(DRM), and/or detergent soluble membranes (DSM). 
Immunoblotting.  Samples were lysed in lysis buffer as described above and normalized 
by BCA assays (Thermo), or samples were directly solublized in 2x PSB.  Proteins were 
separated by SDS PAGE, transferred to nitrocellulose (GE Water & Process 
Technologies), and analyzed by immunoblotting as previously described (159) or with a 
LI-COR Odyssey infrared imaging system. 
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Antibodies.  Anti-Ubc9 (N-15) goat polyclonal antibodies (PAb), anti-Actin goat PAb, 
anti-Flotillin (K-19) goat PAb, anti-E-Cadherin (H-108) rabbit PAb, anti-TGN38 (H-300) 
rabbit PAb, HIV-1 anti-gp120 (1994) monoclonal antibodies (MAb), HIV-1 anti-gp41 
(10E9) MAb, horseradish peroxidase (HRP)-conjugated chicken anti-goat, and HRP-
conjugated donkey anti-mouse PAbs were purchased from Santa Cruz Biotechnology, 
Inc.  HIV-1 anti-gp120 goat PAb was purchased from Affinity BioReagents.  Anti-human 
transferrin receptor monoclonal antibodies were purchased from Invitrogen.  Rabbit anti-
p17 PAbs was obtained from the NIH AIDS Research and Reference Reagent Program.  
Alexa Fluor 488 conjugated donkey anti-mouse, Alexa Fluor 488 conjugated donkey 
anti-rabbit, Alexa Fluor 647 conjugated donkey anti-sheep, Alexa Fluor 647 conjugated 
donkey anti-mouse, and Alexa Fluor 647 conjugated donkey anti-rabbit PAbs were 
purchased from Molecular Probes. IRDye 800CW conjugated donkey anti-goat and 
IRDye 680LT conjugated donkey anti-rabbit PAbs were purchased from LI-COR.  
Pooled AIDS patient sera were obtained from a patient cohort.    
Confocal.  293T cells were cultured on sterile, poly-L-lysine coated glass coverslips and 
transfected as previously reported (159).  24 hours post transfection with NL4-3, medium 
was removed, and the cells were fixed with 4% paraformaldehyde in phosphate buffered 
saline (PBS) for 20 minutes at room temperature.  The coverslips were washed with PBS, 
and when necessary, permeabilized with 0.2% TX-100 in PBS for 5 minutes at room 
temperature.  The coverslips were washed again in PBS followed by blocking for 1 hour 
with 2% bovine serum albumin (BSA) in PBS.  Cover slips were incubated with primary 
antibodies in 2% BSA for 2 hours at room temperature followed by 3X washes with 2% 
BSA for 10 minutes.  Cover slips were incubated with secondary antibodies in 2% BSA 
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in PBS for 45 minutes at room temp followed by 2X washes in 2% BSA for 10 minutes, 
and a final wash in PBS.  Cover slips were mounted to slides and analyzed by confocal 
microscopy (Olympus FV500 with an upright BX Olympus fluorescence microscope).  
Cellular and viral proteins were detected using antibodies against Gag (PAb anti-p17), 
Env (MAb anti-gp120 and MAb anti-gp41), and TGN (PAb anti-TGN38).  Alexa Fluor 
488 conjugated donkey anti-mouse, Alexa Fluor 488 conjugated donkey anti-rabbit, 
Alexa Fluor 647 conjugated donkey anti-sheep, Alexa Fluor 647 conjugated donkey anti-
mouse, and Alexa Fluor 647 conjugated donkey anti-rabbit PAbs were used as secondary 
antibodies.  The 0.3 µm optical z-sections were analyzed with Fluoview imaging 
software (Olympus). 
Results 
Effect of Ubc9 on viral infectivity is not unique to a specific isolate of HIV-1.   We 
have previously demonstrated that in the context of NL4-3, an infectious proviral clone, 
the endogenous Ubc9 expression in HIV-1 producer cells was important for the 
production of fully infectious HIV-1 virions. Knockdown of Ubc9 expression in producer 
cells using Ubc9 specific RNAi techniques reduced the specific infectivity of the released 
virions approximately 10-fold as compared to virions produced in the presence of Ubc9.  
Pseudotyping experiments using VSV-G demonstrated that the decreased infectivity of 
virions produced in Ubc9 knockdown cells was likely due to a reduced level of mature 
Env gp120 packaged into the virions, and the reduction was reflected in a decrease in the 
intracellular Env level in the virus producing cells (159).  To confirm that the effect of 
Ubc9 was not HIV-1 strain specific we have repeated the virion infectivity assay using a 
different HIV-1 strain, SG3.1. The SG3.1 Gag and Env are 6% and 16% divergent at the 
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amino acid level when compared with NL4-3 Gag and Env respectively.  The pSG3.1 
provirus lacks Vpu, however it can produce highly infectious/pathogenic virions, and can 
readily replicate in chimpanzees and SCID-hu mice (125).  To assess the infectivity of 
SG3.1 virions produced in the presence or absence of Ubc9 expression, 293T cells were 
transfected with pSG3.1 alone, or in combination with control siRNA or Ubc9 siRNA.  In 
the absence of Ubc9, SG3.1 virions did not exhibit any significant defects in the amount 
of virions released into the media, as quantified by the amount of pelletable p24 in the 
media with immunoblotting (Fig. 1a).  However, the specific infectivity of viruses 
produced from cells in which Ubc9 expression was knocked down by Ubc9 siRNA was 
decreased by more than 60% (Fig. 1b).   This data confirmed that Ubc9 expression in 
HIV-1 SG3.1 producing cells is important for the production of fully infectious HIV-1 
virions, and that the decrease in HIV-1 infectivity in the absence of Ubc9 expression is 
not specific to the HIV-1 NL4-3 isolate. 
No evidence for endoplasmic reticulum associated degradation (ERAD), or 
activation of the unfolded protein response (UPR) as a factor in gp120 stability in 
the absence of Ubc9 expression.  The decrease in intracellular mature Env (gp120 and 
gp41) in Ubc9 knocked down cells could be caused by a number of mechanisms.  
Decreased intracellular gp120 levels could be due to: a defect in intracellular gp160 
stability; a defect in gp160 trafficking to the TGN and maturation into gp120 and gp41; 
gp120 might be mistargeted for degradation as it traffics out of the TGN before reaching 
the plasma membrane assembly site; or gp120 may be incorrectly endocytosed from the 
plasma membrane and then degraded.  We have previously hypothesized that the 
decrease in intracellular mature Env levels was not likely due to an overall decrease in 
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stability of gp160 prior to cleavage into gp120 and gp41.   This was based on data from 
pulse chase experiments where the levels of intracellular gp160 decreased over time at 
similar rates regardless of whether the cells were transfected with Ubc9 siRNA, control 
RNA, or no RNA (159).  However it could not be ruled out that the decrease in 
intracellular gp120 was not due to a defect in the endoplasmic reticulum (ER) leading to 
an increase in gp160 degradation. 
To examine if gp160 stability was affected in the ER in Ubc9 knockdown cells, 
we examined two major ER degradation pathways that could lead to gp160 degradation.  
The ERAD is an ER based pathway that can degrade gp160, but under certain conditions 
it can cause gp160 to migrate at a molecular weight (MW) similar to gp120 and affect the 
quantitation of the gp160 and gp120 levels experimentally (76, 163).  Therefore, the 
effect of Ubc9 knockdown on gp160 ERAD was further examined by assaying the MW 
of viral glycoproteins after treatment with PNGase F (Fig. 2a), which hydrolizes nearly 
all forms of N-linked glycans between the asparagines and N-acetyl-D-glucosamine 
(100).  As expected, the viral glycoprotein was expressed as gp160 during the pulse-
labeling period.  During the chase, gp120 could be detected in cells transfected with NL4-
3 alone, or in combination with control RNA.  However, cells transfected with Ubc9 
siRNA contained less gp120.  When the lysates from the pulse period were treated with 
PNGase F, the band corresponding with glycosylated gp160 disappeared and a band with 
a MW of approximately 90 kDa appeared.  The 90 kDa band correlates with the expected 
MW of deglycosylated gp160.  When the chase samples were treated with PNGase F, the 
gp160 band shifted down as expected to approximately 90 kDa.  The band corresponding 
to gp120 disappeared, and a band with a MW of approximately 60 kDa appeared, which 
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correlates to the expected weight of deglycosylated gp120. The 60 kDa band could be 
seen throughout the chase period when samples were treated with PNGase F, and it was 
much less evident in cells transfected with Ubc9 siRNA as expected.  A band with a MW 
of approximately 30 kDa also appeared in these samples, which correlates with the 
expected size of deglycosylated gp41.  The presence of the 60 kDa band in Ubc9 siRNA 
transfect cells indicated that the band around 120 kDa was in fact gp120, and not a 
partially deglycosylated form of gp160 undergoing ERAD.  More importantly, gp160 
was not preferentially degraded in Ubc9 knockdown cells compared to control cells.  
Extreme over exposure of the gels did not show any unique or excess banding between 
90 and 60 kDa, ruling out the possibility that gp160 was undergoing degradation (data 
not shown). 
With no evidence for ERAD gp160 degradation in Ubc9 knocked down cells, we 
examined if another ER degradation pathway, the unfolded protein response (UPR), was 
triggered and involved in the decrease of intracellular gp120 through degradation of 
gp160.  The UPR is triggered when improperly folded proteins accumulate in the ER, and 
UPR activation is a marker for overall ER stress and cellular dysfunction.  Upon UPR 
activation the X-box binding protein 1 (XBP-1) mRNA is alternatively spliced, leading to 
a frame-shift that increases the transcriptional activity of XBP-1, resulting in the 
upregulation of chaperones in the ER (UPR reviewed in 329).  To examine ER stress and 
activation of UPR, XBP-1 splicing in Ubc9 knocked down cells was determined using 
total cellular RNA extracted from transfected 293T cells, either treated or untreated with 
dithiothreitol (DTT), an UPR activating agent.  A 450 bp unspliced XBP-1 mRNA 
product was detected in untreated cells and upon addition of DTT, a 26 bp smaller spliced 
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XBP-1 mRNA PCR product was detected, indicating that the UPR was activated (Fig 
2b).  However, neither HIV-1 gene expression nor knockdown of Ubc9 by siRNA 
activated the UPR.   Replicate plates transfected with control RNA, Ubc9 siRNA, or left 
untransfected were lysed and immunoblotted for Ubc9 and actin levels to confirm 
knockdown of Ubc9 (Fig. 2c).  Taken together, the decrease in intracellular gp120 levels 
did not appear to be due to gp160 instability in the ER as an outcome of Ubc9 
knockdown. 
Gp160 was trafficked to the trans-Golgi network normally in the absence of Ubc9 
expression.  With no evidence implicating that the decreased intracellular gp120 levels 
were due to ER dysfunction and associated gp160 degradation in the Ubc9 knockdown 
cells, we next determined whether there was a defect in gp160 trafficking to the TGN, 
and whether cleavage and maturation could be involved in the decreased levels of 
intracellular gp120.  To determine if Ubc9 knockdown caused defects in gp160 TGN 
trafficking, we tracked Env movement through the secretory pathway of Ubc9 
knockdown cell and control cells by pulse chase analysis following Endo Hf treatments 
(Fig. 3a).  HIV-1 gp160 is extensively modified with N and O-linked oligosaccharides in 
the ER, which are highly sensitive to removal by Endo Hf, an endoglycosidase which 
primarily cleaves high-mannose sugars (233).   As Env proteins trimerize in the ER and 
traffic through the TGN, the polyprotein oligosaccharides are substantially modified and 
the susceptibility to Endo H f cleavage decreases.  As gp160 traffics through the TGN it is 
cleaved into its mature forms (gp120 and gp41) (23, 321, 343 reviewed in 71).  During 
the pulse period (P), only gp160 could be detected, in control cells that were transfected 
with NL4-3 proviral DNA alone (Fig. 4a, left panel), in cells co-transfected with NL4-3 
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and control RNA (middle panel), or in cells co-transfected with NL4-3 and Ubc9 siRNA 
(right panel).  Cells co-transfected with control or Ubc9 siRNA consistently produced on 
average 5-6% less gp160 than control cells.  Treatment of the pulse samples with Endo Hf 
led to the disappearance of the band of 160 kDa (gp160) and the appearance of a band 
with an approximate MW of 90 kDa.  The 90 kDa band correlated with the expected MW 
of gp160 with its N-linked glycans removed by Endo Hf (gp160s).  Susceptibility to Endo 
Hf indicated that during the pulse period, all the gp160 was located in the ER because it 
has only been glycosylated with high-mannose sugars.  As expected, during the chase 
period, gp160 levels decreased, and gp120 appeared along with a very diffuse band with 
an approximate MW of 170-180 kDa.  This diffuse band correlated to a population of 
gp160 that had trafficked to the Golgi and had been modified with more complex sugars, 
giving it a larger molecular weight as has been reported previously (119, 138).  When the 
chase samples were treated with Endo Hf, gp160, gp120, and the 170-180 kDa bands 
disappeared, and bands with approximate MW of 130, 90, and a smear around 80 kDa 
appeared.  The band at around 130 kDa is consistent with the migration pattern of a 
partially Endo Hf resistant gp160 (gp160r), the population of gp160 that would have 
trafficked out of the ER with its high mannose sugars modified to more resistant complex 
sugars in the Golgi complex.  The band at approximately 90 kDa is a population of gp160 
that still resides in the ER (gp160s).  The band/smear around 80 kDa is consistent with 
forms of gp120 that have undergone extensive glycosylation modifications in the Golgi 
and were partially resistant to Endo Hf  (gp120r) (211). 
Upon transfection with siRNA to knockdown Ubc9, or with control RNA, levels 
of partially Endo H f resistant forms of gp160 (gp160r) could be detected beginning at 
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two hours.  Detection of similar amounts of gp160r in cells where Ubc9 expression was 
knocked down indicated that gp160 was able to trimerize and traffic out of the ER (98, 
386).  Mature Env gp120 and gp120r were detected at similar levels in cells transfected 
with NL4-3, or in combination with control RNA.  In contrast, gp120 and gp120r were on 
average reduced by 50-60% in cells transfected with Ubc9 siRNA (Fig. 3a).  Similar 
levels of gp160 were found to traffic out of the ER to the Golgi complex and total gp160 
decreased at similar rates during the chase times, suggesting that slower gp160 trafficking 
and cleavage in the TGN could not account for the lower levels of intracellular gp120.  
As expected, the lower intracellular gp120 in the absence of Ubc9 expression resulted in 
less gp120 packaged into the virion (Fig. 3a, lower panels). 
Normal Env trafficking to the TGN in the absence of Ubc9 expression was further 
confirmed using confocal microscopy.  TGN staining by TNG38 antibodies (red) 
appeared as cytoplasmic puncta that grouped together near the periphery of the nucleus 
regardless of whether the cells were transfected with RNA and/or NL4-3, or left 
untransfected (Fig. 4a-c, e, h, and k).  Cells transfected with NL4-3 alone (d-f), or in 
combination with control RNA (g-i) or Ubc9 siRNA (j-l) showed typical intracellular 
HIV-1 Env (green) patterns, which are known to be associated with the secretory and 
endocytosis pathways.  When the signals for Env and TGN38 from the same optical z-
section were merged, distinct areas of co-localization could be seen in the cytoplasm 
(Fig. 2 f, i, and l), which confirmed that Env trafficked to the TGN even in Ubc9 
knockdown cells.  Taken together, the knockdown of Ubc9 expression did not affect 
gp160 oligomerization, trafficking out of the ER to the TGN, oligosaccharide 
modification in the TGN, or gp160 maturation. 
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Gp120 and not gp160 was specifically degraded in the absence of Ubc9.   Our data so 
far has suggested that the reduced level of intracellular gp120 in Ubc9 knocked down 
cells was not due to defects associated with gp160 functions, and the expression of both 
Ubc9 and Gag were required for normal levels of intracellular gp120.  To examine 
whether gp120 was specifically degraded after gp160 cleavage in Ubc9 knockdown cells, 
we examined the stability of an Env cleavage mutant (MUT 511) in the presence and 
absence of Ubc9, in the context of a complete provirus.  MUT 511 has a point mutation at 
position 511 (Arg to Ser) in gp160, which blocks its cleavage into gp120 and gp41.  Mut 
511 is not efficiently packaged into virions, but still traffics to the plasma membrane (36, 
97).  If gp120 is specifically targeted for degradation, MUT 511 stability should be 
unchanged as it trafficks through the secretory pathway to the plasma membrane.  
Transfected 293T cells were again assayed by pulse chase experiments to assess MUT 
511 stability in Ubc9 knockdown cells and control cells.  Cells were pulse chased and 
treated with Endo Hf as in previous experiments to track MUT 511 stability and 
trafficking through the TGN (Fig 5a).  As expected, only gp160 was observed, and it was 
not processed into gp120 and gp41 because of the mutation.  During the pulse period, 
gp160 resided in the ER and was completely Endo Hf sensitive as observed earlier (Fig. 
3a).  At the two-hour chase time a band with an approximate MW of 180 kDa appeared 
and persisted through the 4-hour chase period.   Endo Hf treatment resulted in the 
appearance of band of 90 kDa (gp160s), a partially resistant Endo Hf gp160 (gp160r) as 
observed earlier (Fig. 3a), confirming that MUT 511 was trafficking through the 
secretory pathway even in Ubc9 knockdown cells.  Intracellular Env levels remained 
stable during the chase in cells that were transfected with either Ubc9 siRNA or control 
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RNA, indicating that the decrease in gp160 observed over time in previous experiments 
was due to gp160 maturation into gp120/gp41 and not due to degradation.  Taken 
together our results suggest that the decreased intracellular gp120 in Ubc9 knockdown 
cells was due to specific degradation of gp120. 
Ubc9 knockdown did not affect Furin activity or endogenous E-cadherin stability.  
To further confirm that the increase in gp120 degradation in Ubc9 knockdown cells is 
specific to mature Env, and not due to a more generalized decrease in overall stability of 
proteins trafficking through the secretory pathway, we assayed the maturation and 
stability of endogenous cellular E-cadherin.  E-cadherin is a cellular, type-1 
transmembrane adhesion factor and its biosynthetic pathway is very similar to that of 
HIV-1 Env.  E-cadherin is translated in the ER as a glycosylated inactive proprotein that 
undergoes a post-translational maturation step.  E-cadherin is cleaved into its functional 
subunits as it moves through the secretory pathway, presumably by Furin in the TNG, as 
it traffics to the plasma membrane.  Equal amounts of whole cell lysates from Ubc9 or 
control siRNA transfected, and untransfected 293T cells were analyzed for E-cadherin 
expression.  Pro E-cadherin (135kDa) and mature E-cadherin (120 kDa) can be detected 
in whole cell lysates, with cells transfected with Ubc9 siRNA containing on average 19-
23% less total E-cadherin (immature and mature forms) compared to control cells.  The 
lower E-cadherin expression was not unexpected as previous studies have shown that the 
over expression of Ubc9 led to an increase in miR-200b, which targets and causes the 
down regulation of E-cadherin transcriptional repressors, ZEB-1 and ZEB-2 (65, 190, 
284, 409).  Even though less total E-cadherin was expressed in the Ubc9 knocked down 
cells, the mature E-cadherin represented 43% of total cellular E-cadherin when 
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normalized to the levels of actin regardless of Ubc9 expression (Fig. 6).  Our results 
indicate that in Ubc9 knockdown cells, there was no evidence of a general decrease in 
stability of proteins such as E-cadherin, while trafficking through the secretory pathway, 
and that only gp120 was affected.  In addition Furin activity was not affected since pro E-
cadherin was properly cleaved by Furin, suggesting that the lower levels of gp120 in 
Ubc9 knockdown cells is not due to a defect in cleavage of gp160 by Furin. 
Degradation of intracellular mature Env in the absence of Ubc9 required trafficking 
out of the TGN.  Taken together, our data indicates that in Ubc9 knockdown cells, Env 
trafficked to the TGN as expected and that gp120 was specifically degraded after 
cleavage.  To examine if gp120 degradation requires trafficking out of the TGN, we 
examined Env stability and trafficking through the secretory pathway when cultured at 
20°C.  Incubating cells at 20°C inhibits the budding of immature secretory vesicles from 
the TGN, effectively blocking transport out of the TGN and leads to an accumulation of 
proteins in the TGN (244).  For this study, we carried out pulse chase experiments as 
before.  After metabolically labeling at 37°C, cells were shifted to 20°C and chased for 2 
and 4 hours.  We found that when transfected cells were shifted to/and incubated at 20°C, 
gp160 cleavage was significantly inhibited and remained stable during the chase period.  
Interestingly, an extremely faint Endo Hf resistant band with a MW of approximate 140-
150 kDa (gp160r*) was detected during the 2-hour chase time on over-exposed images, 
and the intensity of this band increased to become more easily detectable at the 4 hours.  
This Endo Hf resistant band could represent a fraction gp160 that has trafficked to the 
TGN and undergone aberrant glycosylation modifications because of the altered 
trafficking kinetics through the secretory pathway when cultured at 20°C.  Gag cleavage 
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and virion assembly was also slowed significantly as Pr55 was more stable over time and 
less p24/p25 was cell associated (Fig. 7).   This data supports previous data indicating 
that gp120 was specifically degraded and that degradation of gp120 occurred after Env 
trafficked out of the TGN as it migrated through the secretory pathway. 
Degradation of gp120 occurred before transport to the plasma membrane and the 
lipid rafts.  Our results have so far indicated that gp160 stability, trafficking from the ER 
to the TGN and cleavage were normal, and the degradation of gp120 occurred after 
transport out of the TGN in Ubc9 knockdown cells.  In a normal cell, after Env cleavage 
maturation occurs, the trimmer consisting of the gp120 and gp41 is trafficked to the PM.  
The mature Env is then either packaged into assembling virions, or it is quickly 
endocytosed by the cellular endocytosis machinery through interactions with adaptor 
protein complexes, primarily through AP-2 binding (21, 30, 271).  It is possible that in 
the absence of Ubc9, gp120 stability is affected prior to reaching the PM or may be 
affected only after endocytosis.  To further delineate when the degradation of gp120 
occurred in the ubc9 knockdown cells, we conducted experiments to examine the amount 
of gp120 associated with the PM and lipid rafts.  To examine the levels of mature Env 
(gp120) associated with the PM, Ubc9 or control siRNA transfected 293T cells were 
metabolically labeled and chased for 1.5 and 2.5 hours (Fig. 8a).  During the pulse, very 
little Env proteins appeared to be associated with the PM fraction in any samples.  At 1.5 
and 2.5 hours, gp160 and gp120 can be readily detected in the PM fraction of cells 
transfected with NL4-3 alone, or with NL4-3 and control RNA.   Cells transfected with 
NL4-3 and Ubc9 siRNA showed a decrease of 83% in the levels of gp120 associated with 
the PM fraction as compared to the control cells (Fig. 8b).  This result suggests that the 
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effect on gp120 stability in the absence of Ubc9 likely occurred before insertion into the 
PM and that a more thorough examination of the PM and PM microdomains would be 
needed to further confirm this hypothesis. 
 To further examine the localization of HIV-1 Gag and Env at the surface of the 
cell, immunofluorescent confocal microscopy was utilized.  293T cells were grown on 
coverslips, transfected as in previous experiments, fixed, and examined using polyclonal 
Abs against HIV-1 p17 and in combination with either monoclonal Abs against HIV-1 
gp120 (Fig. 9a-c) or gp41 (Fig. 9d-f).  Cells transfected with NL4-3 alone, or in 
combination with control RNA, showed that both Env (red) and Gag (green) can be 
detected in transfected cells, and showed co-localization in areas along the periphery of 
the cell (Fig.9a,b,d, and e).  Cells transfected with NL4-3 and Ubc9 siRNA showed 
indistinguishable Gag staining from the control cells, however, less Env was detected at 
the cell surface and less co-localization between Gag and Env was observed (Fig. 9c and 
9f).  This result supports the preliminary PM isolation experiment.  Together, they 
suggested that in Ubc9 knockdown cells, less Env is present at the plasma membrane and, 
gp120 stability was affected prior to its insertion into the PM. 
 To more extensively examine the amount of Gag and Env associated with the PM 
during the assembly process we analyzed their association with lipid rafts (LR). Multiple 
lines of evidence have implicated that lipid rafts are important microdomains of the PM 
that facilitate virion assembly.  To examine viral protein association to lipid rafts in Ubc9 
knockdown cells, metabolic labeling combined with lipid raft floatation experiments 
were utilized.   Transfected 293T cells were metabolically labeled and cell lysates were 
fractioned, and analyzed for the presence or absence of viral and cellular proteins.  
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Flotillin-1 is a cellular LR protein marker and was only detected at the top of the gradient 
in fractions 1 and 2.  Transferrin receptor (TfR), a protein excluded from detergent 
resistant membranes (DRM) and lipid rafts, was only detected in the bottom of the 
gradient in fractions 9, 10, and 11, indicating that there was a good separation between 
LR, DRM, and detergent soluble membranes (DSM) (Fig. 10a).   The densities of each of 
the fractions across all samples were assayed and showed that the gradients were 
consistent and reliably reproduced among samples (Fig. 10b).  DSM fractions from 
transfected cells were combined and immunoblotted for Ubc9 expression. (Fig. 10c).  
The majority of Gag and Env were detected in the DSM factions, with very small amount 
found in the DRM and LR fractions regardless whether the cells were co-transfected with 
control RNA, Ubc9 siRNA, or with NL4-3 alone (Fig. 10d-f).   In cells transfected with 
NL4-3, or in combination with control RNA, gp160, gp120, and Gag were detected in the 
DSM and LR fractions.  Viral proteins associated with DRM decreased as the sucrose 
density decreased towards the top of the gradient, then increased again when the fractions 
were enriched with LR.  The ratios of Pr55 with gp160 and/or gp120 in LR fractions 
were similar between control cells.  Interestingly, cells co-transfected with NL4-3 and 
Ubc9 siRNA showed altered levels of viral proteins associated with the DSM and LR 
factions.  Ubc9 siRNA transfected cells showed about a 5-fold reduction in the amount of 
gp120 associated with LR fractions.  However, similar LR Pr55/gp160 ratio was found 
when compared to control cells, suggesting that the amount of gp160 associated with the 
LR was not affected by Ubc9 expression levels even though there was a reduction in 
gp120 level (Fig. 10g).  The percentage of Gag associated with LR was also examined, as 
previous reports have suggested that Env trafficking to LR is dependent upon Gag co-
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trafficking to LR (26, 285).  We found that in the absence of Ubc9 expression, Pr55 
association with LR was decreased by almost 50% compared to the control cells (Fig. 
10h).  In summary, our data suggests that Gag and Env trafficking and association with 
lipid rafts in the absence of Ubc9 is altered, and that gp120 stability is affected prior to 
the trafficking of gp120 to the PM and to the lipid raft microdomain in Ubc9 knockdown 
cells. 
Discussion 
 We have previously demonstrated that when endogenous Ubc9 expression was 
knocked down by Ubc9 specific siRNA in HIV-1 producer cells, HIV-1 specific 
infectivity was reduced 10-fold when compared to control cells.  The defect in infectivity 
was found to be a defect in mature, intracellular Env production and subsequently 
reduced Env packaging into assembling virions.  In this study, we have continued to 
examine HIV-1 assembly in Ubc9 knockdown cells in an effort to further characterize the 
decrease in intracellular Env levels, and to further understand how Ubc9 and Gag 
contribute to mature, intracellular Env stability and packaging into assembling virions.  
Our data indicated that in Ubc9 knockdown cells, there was no increase in ERAD or 
activation of UPR, and Env stability and trafficking from the ER to the TGN appeared to 
proceed normally.  We also found that in Ubc9 knockdown cells, gp160 trafficked as 
expected to the Golgi apparatus, suggesting that glycosylation, oligomerization, transport 
out of the ER, and modification of the high mannose carbohydrates to complex 
carbohydrates occurred as in control cells expressing Ubc9.  However, we found that 
mature Env was being selectively targeted for degraded after transport out of the TGN in 
Ubc9 knockdown cells.  Examination of the surface expression of viral proteins by 
 100 
various approaches demonstrated that in Ubc9 knockdown cells, Gag and Env displayed 
altered trafficking and association with the cell surface and PM microdomains, 
suggesting that the defect in Env stability occurred after being transported out of the ER, 
but before trafficking to the PM (Fig. 11). 
 HIV-1 assembly predominantly takes place at the plasma membrane (156, 175), at 
sites where viral and host derived factors co-localize and interact to assemble infectious 
viral particles.  There are a number of intracellular sites where important viral and host 
factors interact during the assembly of an infectious virion (126).  However, the timing 
and location of where most these proteins interact during the viral assembly pathway are 
still not well understood.  One essential gap is when and where Gag and Env first interact 
during the assembly process to facilitate Env packaging into the released virions. Various 
mechanisms have been proposed for Env packaging, however specific interactions, either 
directly or indirectly, between amino acids within MA and the cytoplasmic tail of Env 
results in the selective packaging of the viral Env seems most likely to occur under 
normal conditions (mechanisms reviewed in 58, 167).  Confocal microscopy data 
examining the site of colocalization between Gag and Env suggested that Gag and Env 
may interact at the PM, as they primarily co-localize at the PM (143, 224).  However 
various lines of evidence have suggested that the interaction may occur before virion 
assembly at the PM, either through direct or indirect interactions, resulting in the active 
incorporation of mature Env into the assembling virions (80, 86, 221, 222, 224, 280, 
323).  Regardless of where Gag and Env first interact, there was evidence to suggest that 
both Gag and Env can influence the stability and trafficking of each other (99, 143, 171, 
203, 210, 221, 222, 374).   
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Based on our results, there are three potential mechanisms that may explain how 
interrupting the interaction between Gag and the cellular host factor Ubc9 may lead to 
gp120/gp41 instability and its decreased packaging into the assembling virions (Fig. 11).  
First is the altered trafficking of Gag, either at an early or late stage of assembly.  In Ubc9 
knockdown cells, Gag displayed altered trafficking and association with lipid rafts, a 
microdomain important during the very late stages of virion assembly (reviewed in 273, 
370).  It is possible that other earlier stages of Gag trafficking may have also been 
disrupted in Ubc9 knockdown cells.  Ubc9 has been identified as a host factor localized 
to the Gag perinuclear clusters (GPC) which were hypothesized to be early intermediate 
Gag trafficking sites (242).  In Ubc9 knockdown cells, Gag may not be targeted correctly 
through the cytoplasm if Ubc9 is not present at the GPC.  It is also possible that Ubc9 
interacts with Gag at a later stage of trafficking, as we have also observed that Gag co-
localized with Ubc9 in close proximity to the PM, which suggests that this interaction is 
important during the later stages of virion assembly (159).  If Env and Gag first interact 
and influence each other at an intracellular site, at or near the TGN or recycling 
endosomes (8, 20, 224, 323), an alteration of Gag trafficking through the interruption of 
Gag-Ubc9 binding, Gag and Env interactions and co-trafficking to the site of assembly 
may also be disrupted.  This disruption could lead to Env being mistrafficked/sorted and 
targeted for degradation instead of trafficking to the normal virion assembly site (Fig. 11 
green arrow).   
The second potential mechanism to explain these observations is that if the site of 
interaction between Gag and Env is at the site of assembly on the plasma membrane, 
altering Gag trafficking to the site of assembly by Ubc9 knockdown may in turn alter the 
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ability of Gag to stabilize Env on the PM (99, 210).  Without Gag dependent Env 
stabilization at the PM, Env would be quickly endocytosed and might then be targeted for 
degradation instead of recycling to the TGN (Fig. 11 violet arrows).  Interestingly, Ubc9 
and SUMOylation have been previously shown to be involved in the endocytic pathway 
by modulating the endocytosis of cellular proteins at the plasma membrane (251, 395).  
Lastly, it is possible that by interrupting Gag and Ubc9 interactions, it may have altered 
the trafficking or function of yet other unknown cellular factor(s) that are involved in Env 
stability and packaging into assembling virions, since the host factors and pathways used 
during assembly are not fully understood.   
Our study cannot rule out any of the proposed models, but our results seem to 
favor the first model, where Gag undergoes aberrant trafficking in Ubc9 knockdown 
cells, which then interrupts interactions with Env at an intracellular site.  The altered 
Gag/Env interaction, directly or indirectly causes the mistargeting of the Env containing 
secretory vesicles for degradation before trafficking to the PM. This is supported by 
reports implicating that Ubc9 involvement in TGN protein sorting, leading to aberrant 
trafficking within the cell.  Studies with GLUT4, an insulin-regulated glucose transporter, 
have shown that Ubc9 plays a role in regulating GLUT4 stability and trafficking.  In 
Ubc9 knockdown cells, GLUT4 levels decreased by approximately 50% and this was 
found to be due to an increase in its degradation.  It was hypothesized by Liu et al. that 
Ubc9 may function by interacting with Arf-binding proteins (GGA), which function in 
sorting proteins that move through the secretory pathway and are involved with the 
formation of GLUT4 storage vesicles.  Alternatively, Ubc9 may function to negatively 
regulate the trafficking of secretory vesicles from the TGN to sites of degradation (220).  
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Interestingly, GGA and Arf proteins have been shown to be important host factors that 
regulate HIV-1 assembly and release, and GGA2 appeared to play a role in Env 
maturation, however the mechanism of how it is involved is not understood (174). 
It has been previously reported that interactions between cellular factor p14
ARF
 
and Ubc9 enhanced the SUMOylation of p14
ARF
 binding partners.  This demonstrated 
that cellular factors, that are Ubc9 binding partners, may act as a “tether” to retain the 
SUMO-Ubc9 complex in close proximity to other unmodified target proteins, which 
increases the efficiently by which they are SUMOylated (308).  A similar model has been 
proposed for dynamin and SUMOylation mediated endocytosis (251) At this point it 
cannot be ruled out that SUMOylation mediated by Ubc9 may also be involved.  We had 
previously reported that over expression of the catalytically inactive trans-dominant 
negative Ubc9 mutant (C93A) did not lead to a decrease in infectivity of the HIV-1 virion 
produced. However a total block in SUMOylation was unlikely (159), and it is possible 
that only a very low level of SUMOylation was needed during the assembly process. 
Recently, Zamborlini et al. demonstrated that HIV-1 Gag-Pol cleavage intermediates are 
SUMOylated with SUMO-2 in a cell line that over expressed SUMO-2.  However, they 
could not detect SUMO-2 associated with the virion, suggesting that SUMOylation may 
even play a role during assembly but its effect my be very transient and not detectable in 
the mature virion (401). 
If Ubc9 is involved with Gag and Env interactions, directly or indirectly, it is 
most likely dependent upon sequences in matrix and the cytoplasmic tail of gp41, as 
these domains have been previously reported to be important for Gag dependent Env 
packaging into the assembling virions (115, 117, 257, 258).  It has been previously 
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hypothesized by Salzwedel et al. that the CT of mature Env may undergo a 
conformational change after cleavage to allow it to be preferentially packaged over 
gp160, presumably through interaction with MA (321).  A similar mechanism in Ubc9 
knockdown cells involving the CT may be involved with the selective degradation of 
mature Env when both mature Env, and uncleaved gp160 are both trafficking through the 
secretory pathway, yet only mature Env is degraded.  Experiments are underway to 
further clarify the potential role of endocytosis or altered TGN sorting/trafficking as 
mechanisms for the increase in degradation of mature Env in Ubc9 knockdown cells.   
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Figures and Figure Legends 
 
 
Figure 1 
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Figure 1.  HIV-1 molecular clone pSG3.1 assembly and virion infectivity is reduced by 
Ubc9 knockdown in producer cells.  (a) Ubc9 is not required for virion budding and 
release.  293T cells were transfected with pSG3.1 alone, or in combination with Ctr. 
RNA or Ubc9 siRNA.  24 hour after DNA transfection, medium was collected, clarified, 
and virions were pelleted through a 20% sucrose cushion.  Pelleted virions were lysed 
directly in PSB, separated by SDS PAGE, transferred to nitrocellulose, and assayed by 
immunoblotting using anti-p24 PAb.  p24 was quantified using the LI-COR Odyssey 
infrared imaging system using  680LT conjugated donkey anti-rabbit PAbs as secondary 
antibodies.  (b) Specific infectivity of virions produced in the presence or knockdown of 
Ubc9 expression.  Clarified medium from transfected 293T cells were used to infected 
TZM-bl indicator cells and were assayed 36 hours post infection for "-galactosidase 
activity.  Infectivity was normalized by p24.  Infections were carried out in triplicate. 
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Figure 2 
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Figure 2 (continued) 
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Figure 2:  The decrease in HIV-1 Env stability in of Ubc9 knockdown cells is not due to 
degradation pathways associated with endoplasmic reticulum stress responses.  (a) 
Molecular weights of deglycosylated Env proteins in the presence or near absence of 
Ubc9 expression.  293T cells were transfected with pNL4-3 alone, or in combination with 
either non-silencing RNA (Ctr. RNA) or siRNA directed against Ubc9 (Ubc9 RNAi), or 
left untransfected (Un).  Cells were pulse (P) labeled with [
35
S] methionine/cysteine for 1 
hour and chased for 2 and 4 hours.  Cell associated viral proteins were solublized and 
immunoprecipitated with pooled AIDS patient sera, split equally, and incubated for 3.5 
hours at 37° C in the presence, or absence of N-glycosidase F (PNGase F).  Samples were 
separated by SDS PAGE and visualized by phosphorimaging using The Discovery Series 
Quantity One software.  A representative, over-exposed gel is shown so that partially 
Endo Hf resistant Env can be more easily visualized.  The identity and position of 
PNGase F untreated viral proteins are labeled on the left of the gel.  Deglycosylated, 
PNGase F sensitive, viral proteins are labeled on the right and are denoted with a (s) to 
identify the position of gp160s, gp120s, and gp41s in the gel after PNGase F treatment. 
(b) Unfolded protein response activation state in the presence or knockdown of Ubc9 
expression.  Total RNA was extracted from transfected 293t cells that were either treated 
with 5mM DTT for 3 hours to induce UPR, or left untreated.  Total mRNA was reverse 
transcribed with oligo (dT) followed by PCR amplification of XBP-1 cDNA using 
primers that flank an alternative splicing site with in the XBP-1 mRNA.  (c) Immunoblot 
of Ubc9 expression in whole cell lysates.  Untransfected (lane 1), Ctr. RNA (lane 2), and 
Ubc9 RNAi (lane3) 
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Figure 3 
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Figure 3 (continued) 
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Figure 3:  HIV-1 gp160 traffics to the Golgi network in Ubc9 knockdown cells.  (a)  Env 
trafficking through the secretory pathway.  293T cells were transfected with pNL4-3 
alone, or in combination with either Ctr. RNA or Ubc9 siRNA (Ubc9 RNAi), or left 
untransfected (Un).  Cells were pulse (P) labeled with [
35
S] methionine/cysteine for 30 
minutes and chased for 2 and 4 hours.  Cell and media associated viral proteins were 
solublized and immunoprecipitated with pooled AIDS patient sera, split equally, and 
incubated for 3.5 hours at 37° C in the presence, or absence of Endo H f.  Samples were 
separated by SDS PAGE and visualized by phosphorimaging using The Discovery Series 
Quantity One software.  A representative, over-exposed gel is shown so that partially 
Endo Hf resistant Env can be more easily visualized. Viral proteins and their positions in 
the gel are labeled on the left.  The identity of Endo Hf, untreated viral proteins and their 
positions in the gel are labeled on the right.  Deglycosylated Endo Hf sensitive forms of 
gp160 residing in the ER are labeled as gp160s.  Partially deglycosylated, Endo Hf 
resistant forms of gp160 and gp120 that have undergone glycan modification in the TGN 
are labeled as gp160r and gp120r.  gp160r in Endo Hf untreated samples is labeled as 
gp160*.  (b) The gp160 trafficking to TGN.  The ratio of gp160r/total gp160 during the 
2-hour chase period, normalized to NL4-3. 
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Figure 4 
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Figure 4:  HIV-1 Envelope proteins traffic to the TGN in Ubc9 knockdown cells.   (a) 
Untransfected 293T cells, transfected with (b) Ctr. RNA, or transfected with (c) Ubc9 
siRNA (Ubc9 RNAi).  (d-f) 293T cells transfected with pNL4-3.  (g-i) 293T cells 
transfected with pNL4-3 and Ctr. RNA.  (j-l) 293T cells transfected with pNL4-3 and 
Ubc9 siRNA.  Cells were fixed, permeabilized, and prepared for immunofluorescence 
assays using anti-TGN38 PAb and anti-gp120 MAb.  Cy2-conjugated donkey anti-mouse 
and Cy5-conjugated donkey anti-rabbit antibodies were used as secondary antibodies to 
visualize subcellular localization by confocal microscopy.  Medial, 0.3-µm representative 
optical z-sections are shown.  Scale bars, 10-µm. 
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Figure 5 
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Figure 5:  Stability of gp160 is unchanged in Ubc9 knockdown cells. (a) 293T cells were 
transfected with pNL4-3 MUT 511 alone, or in combination with Ctr. RNA or Ubc9 
siRNA (Ubc9 RNAi), or left untransfected.  Cells were pulse (P) labeled with [
35
S] 
methionine/cysteine for 1 hour and then chased for 2 and 4 hours.  Cell associated viral 
proteins were solublized and immunoprecipitated with pooled AIDS patient sera, split 
equally, and incubated for 3.5 hours at 37° C in the presence, or absence of 
Endoglycosidase H f (Endo H f).  Samples were separated by SDS PAGE and visualized 
by phosphorimaging using The Discovery Series Quantity One software. A 
representative, over-exposed gel is shown so that partially Endo Hf resistant Env can be 
more easily visualized. The identity of Endo Hf, untreated viral proteins and their 
positions in the gel are labeled on the right.  Deglycosylated Endo Hf sensitive forms of 
gp160 residing in the ER are labeled as gp160s.  Partially deglycosylated, Endo Hf 
resistant forms of gp160 that have undergone glycan modification in the TGN are labeled 
as gp160r.  These forms of gp160 denoted as gp160* in Endo Hf untreated samples.  
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Figure 6 
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Figure 6:  Furin activity is not dependent upon Ubc9 expression.  293T cells were 
transfected with pNL4-3 alone, or in combination with either Ctr. RNA or Ubc9 siRNA 
(Ubc9 RNAi), or left untransfected.  Cells were lysed 24 hrs post transfection with pNL4-
3, separated by SDS-PAGE and transferred to nitrocellulose.   Membranes were 
immunoblotted with antibodies against Ubc9, Actin, and E-Cadherin.   Immature, 
uncleaved E-Cadherin is designated as pro E-Cadherin. 
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Figure 7 
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Figure 7.  HIV-1 Env processing and stability in Ubc9 knockdown cells during a TGN 
trafficking temperature block at 20°C.  293T cells were transfected with Ubc9 siRNA and 
pNL4-3 as in previous experiments.  Cells were pulse (P) labeled with [
35
S] 
methionine/cysteine for 1 hour, shifted to 20°C, and chased for 2 and 4 hours.  Cell 
associated viral proteins were solublized and immunoprecipitated with pooled AIDS 
patient sera, split equally, and incubated for 3.5 hours at 37° C in the presence, or absence 
of Endoglycosidase H f (Endo H f).  Samples were separated by SDS PAGE and 
visualized by phosphorimaging using The Discovery Series Quantity One software.  A 
representative, over-exposed gel is shown so that partially Endo Hf resistant Env can be 
more easily visualized.  The identity of Endo Hf, untreated viral proteins and their 
positions in the gel are labeled on the right.  Deglycosylated Endo Hf sensitive forms of 
gp160 residing in the ER are labeled as gp160s.  Partially deglycosylated, Endo Hf 
resistant forms of gp160 that have undergone glycan modification in the TGN are labeled 
as gp160r and gp160r*. 
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Figure 8 
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Figure 8 (continued) 
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Figure 8:  HIV-1 proteins exhibit altered trafficking to the plasma membrane in Ubc9 
knockdown cells.  (a) 293T cells were transfected with pNL4-3 alone, or in combination 
with either Ctr. RNA or Ubc9 siRNA, or left untransfected (Un).  Cells were pulse (P) 
labeled with [
35
S] methionine/cysteine for 30 minutes and chased for 1.5 and 2.5 hours.  
At indicated times, cells were quickly cooled on ice.  Medium was removed from the 
culture dishes and cells were collected in ice-cold sucrose buffer (16% by weight), 
ruptured with 100 strokes in a dounce homogenizer, and followed with Benzonase 
treatment (50 units) for 0.5 hours.  Samples were centrifuged at 4°C, for 20 hours at 
34,500 RPMs in a ML-130 rotor.  Supernatants were carefully collected leaving behind 
the pellet containing cellular organelles and adjusted to 1X lysis buffer.  Viral proteins 
were immunoprecipitated with patient serum, separated by SDS PAGE, and visualized by 
phosphorimaging using The Discovery Series Quantity One software.  (b) Quantitation of 
viral proteins associated with the plasma membrane. Pr55/gp120 ratios of the PM fraction 
during the 2 hour and 4 hour chase times. 
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Figure 9 
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Figure 9: Gag and Env exhibit altered surface staining in Ubc9 knockdown cells. 293T 
cells were transfected with pNL4-3 alone (a and d), or in combination with either Ctr. 
RNA (b and e) or Ubc9 siRNA (c and f).  Cells were fixed with 4% paraformaldehyde 
and processed for immunofluorescence using a combination of anti-p17 PAb and anti-
gp41 MAb (a-c), or anti-p17 PAb and anti-gp120 MAb (d-f).  Cy-2 conjugated donkey 
anti-rabbit (green) and Cy-5 donkey anti-mouse were used as secondary antibodies.  
Surface colocalization was visualized by confocal microscopy.  Representative 0.3-"m 
medial sections are shown.  Yellow scale bar, 10-"m. 
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Figure 10 
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Figure 10 (continued) 
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Figure 10 (continued) 
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Figure 10:  HIV-1 Gag and Env exhibit altered association with lipid rafts in Ubc9 
knockdown cells.  (a) Lipid raft isolation.  Representative immunoblot of sucrose 
fractions for lipid raft markers Flotillin-1 and non-raft marker transferrin receptor 1 
(TfR).  Fractions containing lipid raft markers (LR), detergent soluble membranes (DSM; 
raft excluded), and detergent resistant membranes (DRM; non DSM).  (b) Average 
density of all sucrose fractions prior to being adjusted to 1X lysis buffer.   (c) 
immunoblot of transfected cell lysates.  293T cells were transfected with pNL4-3 alone 
(d), or in combination with either Ctr. RNA (e) or Ubc9 siRNA (f).  Cells were labeled 
with [
35
S] methionine/cysteine for 4 hours.  Cells were placed on ice and transferred to a 
4°C cold room where they were lysed with ice cold TNE buffer for 30 minutes on ice 
followed by homogenization with a 25G needle.  Lysates were clarified in a cooled micro 
centrifuge and then adjusted to 60% sucrose and overlaid with a discontinuous sucrose 
gradient and centrifuged at 100,000 X g at 4C for at least 18 hrs.  Gradients were 
fractioned into 11 equal samples using a Biocomp piston fractionator and adjusted to 1x 
lysis buffer.  Viral proteins were immunoprecipitated with patient serum, separated by 
SDS PAGE, and visualized by phosphorimaging using The Discovery Series Quantity 
One software.  Lipid raft floatation experiments were carried out in triplicate.  
Representative, over-exposed gels are shown so that viral proteins associated with lipids 
rafts can be more easily visualized.  (g) Ratio of Gag and Env proteins associated with 
lipid rafts.  (h) Percent of total cellular Gag associated with lipid rafts. 
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Figure 11 
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Figure 11.  Models for mature Env degradation in Ubc9 knockdown cells.  In Ubc9 
knockdown cells HIV-1 Env trafficking from the ER to the TGN is normal (black arrow).  
After cleavage into gp120/gp41 and transport out of the TGN, Env may be directly 
targeted for degradation instead of the assembly site at the PM.  Mistrafficking of Env for 
degradation could be due to altered interactions with Gag, as Gag itself is mistrafficked to 
the assembly site in Ubc9 knockdown cells (green arrow).  Another potential mechanism 
could be due to Gag being mistrafficked to the assembly site in Ubc9 knockdown cells, 
Gag may not stabilize Env at the PM and mature Env may be quickly endocytosed.  In 
Ubc9 knockdown cells, a portion of endocytosed Env may then be targeted for 
degradation instead of recycling back to the TGN (violet arrows).  Alternatively, the 
trafficking or function of yet unknown cellular factor(s) that are involved in Env stability 
and packaging into assembling virions may have been disrupted by altering Gag/Ubc9 
interactions.  (gray question mark). 
 
 
 
 
 
 
 
 
 
 
 
 132 
Chapter IV 
 
 
 
 
 
Mature HIV-1 Env is degraded through the lysosomal pathway 
in Ubc9 knockdown cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unpublished data 
 133 
Abstract  
We previously have shown that Gag and Ubc9 are important for mature 
intracellular Env stability.  We found that in Ubc9 knockdown cells, Env underwent 
increased degradation at an intracellular site prior to insertion into the plasma membrane, 
but only after Env was trafficked out of the trans-Golgi network and cleaved.  We have 
continued to examine the effect that Ubc9 knockdown has on intracellular Env stability to 
further understand the underlying mechanism.  Env stability in Ubc9 knockdown cells 
was examined and compared to control cells in the presence or absence of specific 
inhibitors of known cellular pathways that lead to degradation.  We found that the 
proteasome inhibitor MG132, or the clathrin-dependent endocytosis inhibitor 
chlorpromazine (CPZ), did not restore intracellular gp120 levels to those of control cells. 
Intracellular gp120 levels were restored to that of control cells with the treatment of Ubc9 
knockdown cells with a combination of lysosome inhibitors; however, inhibition of 
gp120 degradation did not restore Env packaging into released virions. Since lysosomal 
degradation is linked with autophagy, we examined autophagy in Ubc9 knockdown cells 
and found that autophagy was increased approximately 3-fold when compared to control 
cells.  Commonly used autophagy inhibitors were not able to inhibit autophagy in Ubc9 
knockdown cells and it is not clear whether intracellular mature Env is degraded in the 
lysosome through an autophagy dependent or independent mechanism.    
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Introduction 
 
The HIV-1 assembly pathway is a complex web of viral and cellular interactions 
that makes use of a wide range of cellular pathways to traffic the essential viral 
components and correctly assemble then into immature virions on the plasma membrane 
of HIV-1 producer cells.  The assembly process culminates in the release and maturation 
of nascent infectious HIV-1 particles capable of infecting new target cells.  During virus 
assembly, various viral proteins have been shown to evade or use the host degradative 
pathways to their advantage in order to complete virion assembly and release of 
infectious virions.  One such pathway is the ubiquitin-dependent pathway. 
 The ubiquitin dependent proteasome pathway has been shown to be an important 
pathway utilized by the HIV-1 in multiple ways.  The proteasome pathway is the 
predominant ubiquitin-dependent degradation pathway of short-lived proteins in 
eukaryotic cells. The proteasome functions in both the cytoplasm and nucleus.  The 26S 
proteasome is a large multi-subunit complex that degrades proteins that are damaged, 
misfolded, or unneeded by the cell.  The covalent attachment of polyubiquitin chains to a 
target protein is the molecular signal for degradation by the proteasome.  Ubiquitin is a 
small globular protein and its covalent addition to target proteins is regulated by the E2-
Ubiquitin conjugating enzymes and the E3-Ubiquitin ligases.  The E2 and E3 bind with 
the target protein, E3 then covalently transfers the ubiquitin from the E2 to the target 
protein and the transfer continues until a chain of multiple ubiquitins is formed, the 
ubiquitinated protein is then targeted to the proteasome for degradation.  Ubiquitination 
and degradation occur constitutively at a basal level in a highly regulated manner.  
However, this process can be upregulated rapidly in a response to various stimuli, such as  
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during the cell cycle, cell stress and damage, and virus infection and replication 
(reviewed in 207, 302, 368). 
It has been shown that blocking the ubiquitin dependent proteasome pathway with 
inhibitors led to defects in Gag maturation and release at the late stage of budding (331).  
Gag is known to be ubiquitinated, and the ubiquitin ligase POSH has been shown to play 
an important role during assembly (8).  However, the exact mechanism of how ubiquitin 
regulates the late stages of assembly is not yet fully understood, although it has been 
shown to involve the endosomal sorting pathway (reviewed in 240).  In addition, there 
are HIV-1 accessory proteins such Vif and Vpu that have been shown to utilize the 
proteasome pathway.  Vif has been shown to utilize the proteasome pathway to degrade 
apoplipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G) 
to limit its packaging into the released virions (346).  APOBEC3G is a host restriction 
factor that blocks HIV-1 replication at multiple steps during early events (reviewed in 
127).  Vpu has been demonstrated to utilize the proteasome to degrade CD4 in the ER to 
prevent CD4 expression on the cell, and to prevent premature interactions of CD4 with 
HIV-1 Env as it passes through the secretory pathway (239, 330). 
In addition to the proteasome pathway, the endocytic/endosomal pathway is also 
an essential cellular sorting and degradation pathway.  It is involved in the transport of 
vesicles and their contents through the cytoplasm, and has been implicated to play 
essential roles during HIV-1 assembly.  The endocytic/endosomal pathway includes a set 
of functionally distinct membrane vesicles that are involved in the sorting and trafficking 
of various non-cytoplasmic proteins.  The vesicles involved in the endosomal pathway 
can be broadly classified as early endosomes, recycling endosomes, multivesicular 
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bodies, and late endosomes.  These vesicles are classified by shape, intracellular location, 
and the presence of specific host factors/markers.  Proteins in the endocytic pathway can 
be targeted to recycling endosomes and trafficked back to the TGN or plasma membrane, 
to their intracellular sites of function, to be sequestered in storage vesicles, or they can be 
trafficked to late endosome and/or lysosomes for degradation (reviewed in 69, 70, 177, 
361, 390).  Proteins can enter the pathway either through endocytosis from the cell 
surface or they can be trafficked directly into the endocytic pathway from the trans-Golgi 
network (TGN).  Numerous cellular factors are involved with the pathway, and function 
by regulating the assembly of vesicles, selecting their contents/cargo, trafficking of the 
vesicle through the cell, and vesicle-vesicle fusion. 
The HIV-1 Gag protein has been shown to localize to various endosomal 
compartments and utilize the endosomal pathway during assembly (93, 172, 253).  Virion 
assembly is dependent upon a large number of cellular factors involved in the endosomal 
pathway.  For example, Rab9 and Rab11a are proteins involved with protein sorting from 
the late endosome to TGN, and then to plasma membrane (260).  The heterotetrameric 
adaptor protein complexes AP-1, AP-2, and AP-3 that are involved with protein sorting 
between organelles, have been found to bind the matrix domain within Gag, and are 
involved with Gag transport to the assembly site and budding from the cell surface (19, 
51, 93).  In addition, TSG101, AIP1, and various proteins involved with endosomal 
sorting complex required for transport (ESCRT complex) have been shown to be 
essential in virus budding from the cell surface (122, 347, reviewed in 27, 66, 340).  The 
kinesin family of motor proteins, involved with vesicular movement across microtubules 
have also been shown to play an important part in Gag trafficking and assembly (15, 41, 
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242).   The endocytic pathway has been also shown to interact with the cytoplasmic tail 
of Env, which is involved with trafficking Env through the cell.  AP-1, AP-2, AP-3, and 
Tip47 were found to interact with the cytoplasmic tail of Env to regulate trafficking to the 
plasma membrane, endocytosis, and recycling back to the TGN (21, 29, 271).  The Nef 
accessory protein also interacts with and alters the protein trafficking and sorting 
pathways resulting in the down regulation of CD4 and MHC-I through degradation in the 
lysosome (reviewed in 312).  Vpu has been shown to antagonize tetherin, another host 
restriction factor involved with blocking virion release at a very late state of budding.  
Vpu binds tetherin and targets it for degradation in the lysosome, however the mechanism 
is not fully elucidated and the proteasomal degradation has also been implicated to be 
involved (94, 158, 237). 
The third pathway involved in protein degradation is autophagy, which has also 
been shown to play a role in HIV-1 assembly.  Autophagy is normally induced in 
response to cellular stress or activation of the cell signaling pathways.  Unregulated 
autophagy activation is believed to eventually lead to apoptosis.  Autophagy is a 
degradation/recycling pathway that degrades long-lived proteins, damaged organelles, 
and cytoplasm.  Old or damaged organelles and the surrounding cytoplasm are engulfed 
in a double, or multi-membrane vesicle known as the autophagosome, which fuses with 
lysosome to form the autophagolysosome.  The contents of the autophagolysosome are 
degraded and recycled for anabolic cellular metabolism. The formation of an autophagic 
vacuole requires a sequential cascade of various protein-protein interactions and protein-
lipid interactions leading to the formation of the double membraned autophagic vacuole.  
The upregulation of autophagy is commonly initiated by cellular stress through inhibition 
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of mTOR kinase activity, which activates the phosphatidylinositol 3-kinase (PI3K) and 
Atg1/ULK complex at the phagophore assembly site followed by phagophore elongation.  
Phagophore elongation involves a series of steps where Atg12 is conjugated to Atg5, 
which then forms a complex with Atg6 at the edges of the elongating phagophore.  
During this time, LC3-I is lipidated by Atg4, forming LC3-II to associate with the 
elongating phagophore.  LC3-II levels correlate well with the induction and formation of 
autophagosomes and it is commonly used as a marker for autophagy (178). The 
phagophore elongates and curves around to form an enclosed vesicle forming the double 
membraned autophagosome, which fuses with the lysosome for degradation of the 
internal contents of the autophagosome.  (autophagy reviewed in 95, 230, 231, 252, 289).  
Autophagy is highly regulated and is constitutively active at a basal level in cells.   
HIV-1 Gag and Nef have been shown to interact with LC3 and Beclin-1 
respectively, which are important components in the autophagy pathway.  It was 
demonstrated that when autophagy was blocked through the use of inhibitors, or siRNA 
against autophagy structural components, there was decreased virion assembly and 
infectivity.  In addition, Nef was shown to interact with Beclin-1 and block the fusion of 
the autophagosomes with the lysosome to inhibit autophagic degradation.  It was 
hypothesized that the formation of autophagic vacuoles were important for increased 
levels of assembly and release of infectious HIV-1 virions (201).  However, the exact role 
of autophagy in affecting HIV-1 infection is still not clear, as Zhou and Spector have 
demonstrated that HIV-1 infection leads to decreased autophagy in target cells (406). 
We have previously shown that in Ubc9 knockdown cells, intracellular mature 
Env levels (gp120/gp41) were decreased in a Gag dependent mechanism.  We found that 
 139 
the decreased intracellular levels of mature Env was not due to altered gp160 trafficking 
or stability in Ubc9 knockdown cells, but due to selective degradation of the mature Env 
after it trafficked out of the TGN.  We also found that both Gag and mature Env showed 
altered trafficking and association with the plasma membrane and lipid rafts, which are 
domains found to be important for virion assembly (reviewed in 273, 370).  This led us to 
hypothesize that Env is mistargeted for degradation, through an unidentified pathway, 
potentially due to altered Gag and Env interactions within the cell, either at the assembly 
site on the plasma membrane or at an intracellular site where Gag and Env co-trafficked.  
We hypothesized that the altered Gag and Env interactions could be due to an altered 
intracellular Gag trafficking as a result of interrupted Gag/Ubc9 interaction in the 
knockdown cells. 
 In this study we have examined the functional role of Ubc9 during HIV-1 
assembly.  Using a wide variety of degradation inhibitors, we systematically examined 
which degradative pathway(s) are responsible for mature Env degradation in Ubc9 
knockdown cells using pulse chase experiments. We have shown that MG132 (26S 
proteasome inhibitor), chlorpromazine (CPZ) (endocytosis inhibitor), 3-MA and 
wortmannin (autophagy inhibitors) were unable to restore intracellular Env levels.  
However, a combination of E63d, Pepstatin A, and Leupeptin (lysosome) were able to 
restore intracellular gp120 to wild type levels, indicating that the lysosome is the 
predominant pathway that degrades mature Env in Ubc9 knockdown cells.  We also 
observed that LC3-II levels were increased approximately 3-fold in Ubc9 knockdown 
cells compared to control cells, suggesting that Ubc9 may also play a role in autophagy.  
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However, whether increased autophagy played an active role in Env degradation and 
lysosomal degradation of Env needs to be further elucidated. 
Materials and Methods 
Cell culture and transfections.  293T cells were cultured and transfected as previously 
described (159).    
Immunoblotting.  Cells were lysed directly in lysis buffer as previously described (159).  
Total protein content from whole cell lysates, or post-immunoprecipitation cellular 
lysates were normalized by BCA assays (Thermo) and equal amounts of total protein 
were solublized in 2x protein sample buffer (PSB) unless other wise described, separated 
by SDS PAGE, and transferred to nitrocellulose (GE Water & Process Technologies).  
Immunoblotting was performed as previously described (159), or with a LI-COR 
Odyssey infrared imaging system using the appropriate IRDye conjugated secondary 
antibodies for detection. 
Antibodies.  Anti-Ubc9 (N-15) goat polyclonal antibodies (PAb), anti-actin goat PAb, 
HIV-1 anti-gp41 (10E9) MAb, horseradish peroxidase (HRP)-conjugated chicken anti-
goat PAb were purchased from Santa Cruz Biotechnology, Inc.  Anti-LC3B PAb were 
purchased from Abcam.  IRDye 800CW conjugated donkey anti-goat PAb were 
purchased from LI-COR.  Pooled AIDS patient sera were obtained from a patient cohort.   
Metabolic Labeling, immunoprecipitation, and Endoglycosidase treatments. 
Metabolic labeling experiments were carried out as previously reported but with different 
metabolic labeling times with [
35
S] methionine/cysteine (>1,000 Ci/nMol; NEN) (159).  
Briefly, transfected and untransfected 293T cells were pulse labeled for either 30 minutes 
or 1 hour with 300"Ci and 600 "Ci respectively.  For pulse chase experiments, labeling 
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medium were removed and chased for 2 and 4 hours in complete culture medium.  The 
culture medium was removed, clarified by centrifugation (13,000 RPM for 2 min), and 
adjusted to 1x lysis buffer (320).  Cells were lysed with 1X lysis buffer containing Halt 
protease inhibitors cocktail (Pierce) and clarified by centrifugation.  Viral proteins were 
immunoprecipitated from the culture supernatant and cell lysates, using AIDS patient 
sera and ultralink A/G beads (Thermo Scientific).  The beads were washed 4X with lysis 
buffer.  Following the final wash, the viral proteins were eluted from the beads by boiling 
for 5 minutes in 0.04% SDS and 200mM 2-mercapitoethanol (319), split into two equal 
volumes, and treated with Endo Hf (NEB) per manufacturers suggestions for 3.5 hours, or 
left untreated.  All samples were adjusted to 1X PSB, analyzed by SDS-PAGE, and the 
proteins were visualized by phosphor imaging.  Alternatively, viral proteins were 
solublized directly from the A/G beads using 2X PSB, boiled, separated and examined as 
above. 
Inhibitor treatments.   Transfected and untransfected cells were treated with various 
protease inhibitors:  proteasome inhibitor MG132 (10 µM), endocytosis inhibitor 
Chlorpromazine (CPZ) (10µg/ml), autophagy inhibitors 3-MA (10mM) or wortmannin 
(50 nM), and lysosome inhibitors E63d (10 µg/ml), Pepstatin A (10 µg/ml), Leupeptin (5 
µg/ml), or NH4Cl (20 mM).  All inhibitors were purchased from Sigma.  Cells were 
pretreated with the appropriate inhibitors for various times prior to metabolic labeling and 
maintained throughout the pulse-chase experiment.  Pulse-chase samples were processed 
and analyzed as above. 
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Results 
Intracellular gp120 in Ubc9 knockdown cells was not degraded through the 
proteasome pathway.  We have previously shown that in Ubc9 knockdown cells there 
was a defect in HIV-1 assembly that led to the production of virions with lower specific 
infectivity.  We had determined that the defect in infectivity was due to an increase in 
intracellular degradation of mature Env (gp120/gp41).  To further understand how Env 
stability is affected in Ubc9 knockdown cells, we examined whether any of the 
predominant degradation pathways are involved.  For these experiments we examined 
which inhibitors impeded the degradation of mature Env in an effort to determine which 
degradative pathway was involved with Env degradation in Ubc9 knockdown cells. 
To examine the potential participation of the proteasomal degradation pathway, 
MG132 (10µM) was used to inhibit the ubiquitin dependent 26S proteasome, and Env 
stability was assayed by pulse-chase experiments.  We began by examining the 
proteasome as it has been previously demonstrated that the proteasomal pathway plays a 
crucial role during virion assembly and release (331).  Schubert et al. found that when the 
proteasomal degradation pathways were disrupted in HIV-1 producing cells, the amount 
of virions released into the media was decreased by approximately 3-fold and the 
released virions were up to 50-fold less infectious.  Interestingly, no significant changes 
in Env maturation or stability was observed in the presence of the inhibitors, even though 
it has been reported by Bultmann et al. that a small fraction of Env is ubiquitinated and is 
degraded through the proteasome pathway (47).  In cells transfected with Ubc9 siRNA 
and NL4-3, in the presence of MG132, Gag displayed an assembly phenotype similar to 
what was described by Schubert et al. when cells were treated with proteasome inhibitors 
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(Fig. 1).  Less Env and Gag proteins were expressed.  Gag processing was slightly slower 
than in the untreated cells, less cell associated p24/25, and virion release was decreased 
by approximately 3.5-fold in the presence of MG132 (data not shown).  However, no 
alteration in the Endo H resistant forms of gp160 (gp160r) or gp120 (gp120r) was 
observed, indicating that the viral glycoproteins trafficked out of the endoplasmic 
reticulum (ER) and to the TGN where the high mannose sugars were modified into 
complex forms.  Env expression levels did not appear to be altered in the presence of 
MG132, suggesting that the proteasome may not be the major degradation pathway 
involved in affecting the stability of intracellular gp120 in the absence of Ubc9.   
Endocytosis inhibitor chlorpromazine did not restore intracellular Env levels in 
Ubc9 knockdown cells.   We previously hypothesized that Env was degraded before 
reaching the plasma membrane, however we could not exclude the possibility that the 
increase in Env degradation could be through an upregulation of the endocytosis 
pathway.  To examine the possibility that an increase in endocytosis was the cause of 
decreased Env levels, we examined Env trafficking and stability in the presence of 
chlorpromazine (CPZ).  The CPZ was shown to inhibit clathrin-dependent endocytosis by 
disrupting AP-2 and clathrin at the plasma membrane (reviewed in 157).  Transfected 
293T cells were treated with CPZ (10µg/ml) for 2 hours prior to and during the pulse 
chase experiment.  Interestingly, less intracellular p24/25 was detected in CPZ treated 
cells (Fig. 2) without significant changes in intracellular Pr55 or p24 levels in the culture 
supernatants when compared to untreated cells.  We observed a decrease in intracellular 
p24/25 levels regardless of whether cells were transfected with control RNA or Ubc9 
siRNA (data not shown).  This suggests that a portion of the intracellular p24/25 levels 
 144 
were degraded when endocytosis was disrupted by treatment with CPZ.  We did not 
observe an increase in virion release as reported by Molle et al., when they used 
monensin or a dominant-negative dynamin to block the endocytic pathway (253).  
However, the use of different cell lines and methods of inhibition are possible reasons for 
the discrepancies.  Unexpectedly, in CPZ treated Ubc9 knockdown cells, very little 
gp160 cleavage was observed in cells transfected with either Ubc9 siRNA (Fig. 2) or 
control RNA (data not shown) during the duration of the chase.   In addition, no Endo Hf 
resistant forms of gp160 or gp120 could be detected throughout the chase after treatment 
with CPZ, which suggested that gp160 did not traffic out of the ER to the TGN.  We did 
however, detect a band that migrated slightly faster in the gel than gp120 (Fig. 2) during 
the chase, and we hypothesize that this band could be the partially deglycosylated form of 
gp160 undergoing degradation, possibly through endoplasmic reticulum associated 
degradation (ERAD), since gp160 is being trapped for a longer period of time in the ER.  
It is unknown at this time how CPZ may affect gp160 transport out of the ER. 
Intracellular gp120 was degraded through the lysosomal pathway in the absence of 
Ubc9.  The demonstration that proteasome and endocytosis inhibitors were unable to 
restore intracellular Env levels, prompted us to examine the potential role of the 
lysosomal degradation pathway.   The lysosome pathway has been previously implicated 
as having a role in HIV-1 Env degradation and virion assembly.  A combination of 
specific lysosomal protease inhibitors, E64d, Pepstatin A, and Leupeptin (10, 245, 307) 
were used to determine if lysosomal degradation was involved in Env degradation in 
Ubc9 knock down cells.  Lysosomal inhibitors were added to the culture medium 2 hours 
prior to the pulse chase experiment followed by metabolic labeling as in previous 
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experiments.  Since newly synthesized viral aspartyl proteases may affect the inhibition 
of lysosomal aspartyl proteases by Pepstatin A, concentrations of Pepstatin A were 
increased 5X during the pulse chase (334).  Interestingly, in the presence of these 
lysosome inhibitors, the intracellular gp120 levels were restored to levels similar to the 
control cells, (92-98%) at the 4-hour chase time in cells transfected with Ubc9 siRNA 
(Fig. 3a upper panels and 3b).  However even with the restoration of in intracellular 
gp120 to normal levels in Ubc9 knockdown cells, this did not completely restore the 
packaging of gp120 into released virions to the control levels.  This suggests that even 
though the mature Env degradation was blocked, the fraction of Env that was targeted for 
degradation in Ubc9 knockdown cells was not capable of being packaged into the 
assembling virions.  Inhibition of the lysosome also did not appear to have any affect on 
Gag function as similar levels of p24 were released into the media (Fig. 3a middle 
panels).  
To confirm the role of the lysosome in mature Env degradation in Ubc9 
knockdown cells, we used another lysosome inhibitor NH4Cl, which is a classical 
lysosomotropic endosomal-lysosomal acidification inhibitor that is functionally different 
from the effects of E64d, Pepstatin A, and Leupeptin.  NH4Cl is a weak base that 
functions by blocking lysosomal pH-dependent degradation by raising the pH within the 
secretory and endocytosis-lysosomal system.  Transfected cells were incubated for 2 
hours prior to the pulse chase experiments and maintained in NH4Cl continuously 
throughout the experiment. Using a low dose of NH4Cl, we found that in the absence of 
Ubc9, gp160 cleavage was completely blocked (Fig. 3c).  Over exposure of the gels did 
not indicate any partially Endo Hf resistant forms, suggesting that gp160 did not traffic to 
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the TGN.  However it has been shown previously that treatment with NH4Cl can cause 
the redistribution of glycosyltransferases from the TGN to endosomal-like vesicles (14), 
which might change the glycosylation patterns, alter glycosylation trafficking, and 
cleavage of HIV-1 Env (79, 105, 386), or its susceptibility to Endo Hf.  We did however 
detect a band that migrated slightly faster in the gel than normal gp120, which was likely 
to be the deglycosylated forms of gp160 undergoing degradation, possibly though ERAD. 
Autophagy pathways were upregulated in Ubc9 knockdown cells.  Our data using 
lysosomal inhibitors strongly suggests that gp120 is degraded via the lysosomal pathway 
in Ubc9 knockdown cells.  Since the lysosomal degradation is linked to the autophagy 
pathway (253, 385), it is possible that the autophagy pathway is affected by Ubc9 
knockdown to lead to degradation of gp120.  To determine the affect of Ubc9 knockdown 
on autophagy, the conversion of LC3-I to LC3-II was measured in Ubc9 siRNA and 
control RNA transfected 293T cells (Fig. 4a).  We found that cells transfected with Ubc9 
siRNA alone or in combination with NL4-3, exhibited a 3-fold increase in the amount of 
LC3-II (Fig. 4b), suggesting that Ubc9 either directly or indirectly regulated autophagy 
through a PI3K independent manner.  It is unlikely that the increase in autophagy in Ubc9 
knockdown cells is non-specific, as cell transfected with control RNA did not show a 
similar increase in LC3-II under identical conditions (Fig. 4 and b).  Increased LC3-II 
levels in Ubc9 knockdown cells could be due to either an increase autophagy, or a defect 
in the degradation and accumulation of autophagosomes.  Autophagosomes that can 
complete autophagy are degraded through the fusion with lysosomes to form 
autophagolysosomes.  Comparing LC3-II levels in the presence or absence of lysosome 
inhibitors can therefore determine if increased LC3-II levels was due to increased 
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autophagy, or defects in autophagolysosome formation and degradation (185).  We found 
that LC3-II levels were stabilized in the presence of a combination of lysosome 
inhibitors, which indicated that the increased LC3-II levels in Ubc9 knockdown cells 
were due to increased autophagy and not because of defects in autophagolysosome 
formation and the accumulation of autophagosomes (Fig. 4c). 
To further understand if Env degradation in Ubc9 knockdown cells was indeed 
due to an induction of autophagy, we treated transfected 293T cells with autophagy 
inhibitor 3-MA (PI3K inhibitor) for 2 hours prior to, and during the pulse-chase 
experiments.  Cells treated with 3-MA did not show a decrease in p24 released into the 
media, similar to what was observed with HIV-1 infected macrophage treated with 3-MA 
(data not shown) (201).   However, in Ubc9 siRNA transfected cells, the intracellular Env 
was not restored to the levels of control RNA transfected cells in the presence of 3-MA 
(Fig. 5a and 5b).  When LC3-II levels were assayed to examine the efficiency of 3-MA 
inhibition of autophagy, it was found that LC3-II levels were still elevated in Ubc9 
knockdown cells, and treatment with 3-MA did not inhibit autophagy based on LC3-II 
conversion levels (Fig. 6).  Therefore, it is likely that the inability of 3-MA to inhibit Env 
degradation may be due to its inability to inhibit autophagy with the concentration used in 
the experiments. 
Similar results were obtained with another PI3K inhibitor for autophagy, 
wortmannin.  When wortmannin was used at concentrations previously published to 
efficiently block autophagy in complete medium (50nM) (394), it was able to block 
autophagy activation under amino acid and serum starvation conditions in control cells 
(Strv.) (Fig. 7), but did not block Env degradation (data not shown), or autophagy when 
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Ubc9 expression was knocked down.  Interestingly, we also observed a gradual increase 
in LC3-II levels in wortmannin treated cells after 5 hours of treatment, which may 
indicate that wortmannin was losing its effect with time, or it may have induced 
autophagy after a prolonged incubation with the cells. 
Discussion 
In this study we have continued to examine the role of Ubc9 during HIV-1 
assembly and the mechanism in which mature Env is selected for degradation in a Gag 
dependent manner in Ubc9 knockdown cells.  There are four possible mechanisms by 
which Env degradation may have occurred upon Ubc9 knockdown: the first is 
degradation via the proteasome pathway; the second is the recycling of Env from the 
plasma membrane into the endosome and degradation in the lysosome; the third is the 
direct Env trafficking from the TGN to the lysosome for degradation; and fourth is the 
induction and degradation through the autophagy pathway.  Based on our findings, we 
suggest that the lysosomal pathway is mostly likely involved in increased Env 
degradation in Ubc9 knockdown cells.  Inhibition of the proteasome and endocytic 
pathways in Ubc9 knockdown cells failed to restore intracellular Env levels to those 
found in control cells.  However, inhibition of the lysosome stabilized intracellular Env 
levels, yet it did not increase the amount of Env packaged into released virions.  This 
suggests that once targeted for degradation, Env can no longer be packaged into the 
assembling virions.  This is most likely due to the sequestering of Env in vesicles that 
cannot be trafficked to the assembly site.  However, we did not observe an increase in 
virion release as described by Molle et al. when they blocked lysosomal degradation with 
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chloroquine.  This could be due to the use of different cell lines and methods of 
lysosomal inhibition (253).  
Interestingly, we found that autophagy had increased by approximately 3-fold in 
Ubc9 knockdown cells.  The finding that autophagy had increased over steady state levels 
in Ubc9 knockdown cells supports the possibility that mature Env is degraded in Ubc9 
knockdown cells.  The observed degradation of Env was specific because viral gp160 and 
Pr55, cellular Actin, p53, and mature E-cadherin were unaffected (159), suggesting that 
additional factors may have been involved in the specific degradation of Env if the 
autophagy and lysosomal pathway are involved.  However, the autophagy inhibitors 
tested were unable to inhibit autophagy or restore intracellular Env to wild type levels in 
Ubc9 knockdown cells, therefore we were not able to determine if increased Env 
degradation in the lysosome was due to increased autophagy, or if degradation occurred 
in spite of an increase in autophagy. 
Our data, if further substantiated would suggest that Ubc9 and/or SUMOylation 
down regulates or inhibits the activation of autophagy in wild type cells under normal 
growth conditions.  The possible mechanism involved is unknown at this time, but it is 
possible that in Ubc9 knockdown cells, autophagy regulation can be affected by either 
negatively affecting cellular factors that normally repress autophagy, or Ubc9 knockdown 
deregulated pro-autophagy factors that led to the activation of the autophagy pathway.  
The simplest interpretation of our data would be that in the Ubc9 knockdown cells, 
autophagy inhibition is deregulated at, or downstream of Vps34 activation, as inhibition 
of Vps34 PI3K activity by wortmannin or 3-MA did not appear to block autophagy, even 
though similar levels of inhibitors were found to inhibit the PI3K activity (28, 394).  The 
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condition was also sufficient to inhibit autophagy in control cells where autophagy was 
induced by serum and amino acids starvations.  This data also does not support the notion 
that an altered mTOR activity in Ubc9 knockdown cells could have led to the increase in 
autophagy, because mTOR acts upstream of Vps34 in the activation of autophagy.  Other 
autophagy triggers such as reactive oxygen species (17, 33, 38, 92, 228, 328, 365), 
increased free Ca
2+ 
(89, 151), altered cell signaling through the MEK/ERK pathways 
(198, 364, 371), activation of phosphorylation pathways (PKA, PKB, PKC, and AMPK) 
(12, 45, 77, 165, 209, 214, 249, 344), or toll-like receptor signaling (196, 197, 278, 305, 
359), could all be potentially altered or involved in Ubc9 knockdown cells.  Interestingly, 
all these pathways intersect with the SUMOylation pathways at some point, either 
directly or indirectly.  Based on what is known about potential autophagy regulation 
pathways and their intersections with the SUMOylation pathway, some of these potential 
autophagy regulation pathways may or may not be involved in the upregulation of 
autophagy in Ubc9 knockdown cells. Given the far-reaching role of Ubc9 in cellular 
metabolism and replication, it is likely that one or a combination of a number of potential 
mechanisms may contribute to the increased autophagy in Ubc9 knockdown cells.  To 
our knowledge, there are no other reports demonstrating that Ubc9 or SUMOylation 
having an effect on on the proteins that are involved with autophagic vesicle elongation 
or fusion with the lysosome (Atg3, Atg4, Atg5, Atg7, Atg9, Atg12, Atg16, Atg18, or 
LC3).  Further experiments will be needed to decipher the mechanisms involved in 
increased autophagy in Ubc9 knockdown cells. 
Although autophagy is commonly recognized as a catabolic pathway, the 
autophagy pathway has been shown to be an important pathway involved in the 
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replication of a number of viruses, including HIV-1 (96, 152, 201, 243, 246, 267, 299, 
311, 326, 338, 350, 379, 391, 398, 404).  Autophagy has been implicated as a pathway 
that enhances HIV-1 assembly in macrophages.  It was demonstrated that inhibition of 
autophagy resulted in a 2 -to 3-fold decrease in virus released and a 3-fold decrease in 
infectious virions.  Nef was found to be important for this phenotype by blocking the 
formation of autophagolysosomes.  In our study we did not observe an obvious increase 
in autophagy in the presence of HIV-1 NL4-3 as observed by others in macrophage, nor 
did we detect any changes in the levels of virus released from the cell (159).  Our data 
would suggest that autophagy is detrimental for HIV-1 assembly in Ubc9 knockdown 
cells, which is in contrast to what Kyei et al. have demonstrated in macrophage (201).  
The difference may be due to the use of different cell types and methods used to analyze 
the affects of autophagy on the assembly of HIV-1 virions.  
Based on our findings we can propose several pathways leading to the lysosome 
being the site of Env degradation and the potential involvement of autophagy in Ubc9 
knockdown cells (Fig. 8).  Degradation of Env in the lysosome could potentially occur 
through three mechanisms.   In Ubc9 knockdown cells Env could be directly targeted to 
the lysosome after trafficking out of the TGN, but before reaching the plasma membrane.  
Alternatively, Env could traffic to the plasma membrane, where it can be quickly 
endocytosed.  Once Env enters the endocytic pathway, it could be trafficked through the 
late endosome for degradation in the lysosome, instead of recycling to the TGN.  Lastly, 
Env could be degraded in the lysosome through the induction of the autophagy pathway, 
as the contents of the autophagolysosome are degraded and recycled in the lysosome.  It 
is possible that Env could enter the autophagy pathway either directly after transport from 
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the TGN by selective autophagosome engulfment of Env containing secretory vesicles 
through crinophagy, or autophagosomes could engulf the Env containing endocytic 
vesicles and to degrade Env in the lysosome.  Crinophagy is the degradative process 
where secretory vesicles are redirected to lysosomes instead of the plasma membrane 
(91).  Crinophagy is not well understood in 293T cells, and its potential role in HIV 
assembly is unknown. 
 Our data supports the previously proposed model where the interruption of Ubc9-
Gag interactions altered Gag trafficking to the assembly site, thus affecting Gag-Env 
interactions to enhanced Env degradation at an intracellular site that we have now 
identified as the lysosome (Fig. 8).  The direct involvement of autophagy is a likely 
possibility, even though our data cannot confirm that an induction of autophagy directly 
leads to Env degradation, in spite of a 3-fold increase in autophagy in Ubc9 knockdown 
cells.  Our data still can not completely rule out other alterative mechanisms involved, 
such as a mechanisms were Env is not stabilized at the assembly site on the plasma 
membrane by interactions with Gag, and is quickly endocytosed and degraded in the 
lysosome.  Further experiments are underway to examine if Gag dependent Env 
degradation in the lysosome is due to an increase in autophagic flux in Ubc9 knockdown 
cells, or if Env degradation is occurring in an autophagy independent lysosomal 
mechanism. 
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Figures and Figure Legends  
Figure 1 
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Figure 1:  HIV Env stability and Gag assembly in Ubc9 knockdown cells in the presence 
of proteasome inhibitor MG132.  293T cells were transfected with Ubc9 siRNA and 
pNL4-3 as in previous experiments.  MG132 (10uM) was added to the culture media for 
1 hour prior to pulse chase experiments and was maintained throughout the experiment. 
Cells were pulse (P) labeled with [
35
S] methionine/cysteine for 1 hour and then chased for 
2 and 4 hours.  Cell and media associated viral proteins were solublized and 
immunoprecipitated with pooled AIDS patient sera, split equally, and incubated for 3.5 
hours at 37° C in the presence, or absence of Endoglycosidase H f (Endo H f).  Samples 
were separated by SDS PAGE and visualized by phosphorimaging using The Discovery 
Series Quantity One software. A representative, over-exposed gel is shown so that 
partially Endo Hf resistant Env can be more easily visualized.  Viral proteins and their 
positions in the gel are labeled on the left.  The identity of Endo Hf, untreated viral 
proteins and their positions in the gel are labeled on the right.  Deglycosylated Endo Hf 
sensitive forms gp160 residing in the ER are labeled as gp160s.   Partially 
deglycosylated, Endo Hf resistant forms of gp160 that have had their glycans modified in 
the TGN are labeled as gp160r.  Forms of gp160 that have undergone glycan 
modification in the TGN but have not been cleaved are denoted as gp160* in Endo Hf 
untreated samples.  
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Figure 2 
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Figure 2:  HIV Env processing and stability in Ubc9 knockdown cells in the presence of 
endocytosis inhibitor chlorpromazine.  293T cells were transfected with Ubc9 siRNA and 
pNL4-3 as in previous experiments.  Chlorpromazine (CPZ, 10ug/ml) was added to the 
culture media for 2 hour prior to pulse chase experiments and was maintained throughout 
the experiment.  Cells were pulse (P) labeled with [
35
S] methionine/cysteine for 1 hour 
and then chased for 2 and 4 hours.  Cell associated viral proteins were solublized and 
immunoprecipitated with pooled AIDS patient sera, split equally, and incubated for 3.5 
hours at 37° C in the presence, or absence of Endo H f.  Samples were separated by SDS 
PAGE and visualized by phosphorimaging using The Discovery Series Quantity One 
software. A representative, over-exposed gel is shown so that partially Endo Hf resistant 
Env can be more easily visualized. Viral proteins and their positions in the gel are labeled 
on the left.  The identity of Endo Hf, untreated viral proteins and their positions in the gel 
are labeled on the right.  Deglycosylated Endo Hf sensitive forms gp160 residing in the 
ER are labeled as gp160s.   Partially deglycosylated, Endo Hf resistant forms of gp160 
that have had their glycans modified in the TGN are labeled as gp160r.  Forms of gp160 
that have potentially undergone partial deglycosylation are denoted as gp160^ in Endo Hf 
untreated samples.  
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Figure 3 
 
 
 
 158 
Figure 3 (cont.) 
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Figure 3 (cont.) 
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Figure 3:  HIV-1 gp120 is degraded through the lysosomal pathway in Ubc9 knockdown 
cells.  293T cells were transfected with Ubc9 siRNA and NL4-3 as in previous 
experiments.  (a) A combination of E64d (10µM), Pepstatin A (10µM), and Leupeptin 
(5µM), was added to the culture media 2 hours, or 45 minutes prior to pulse chase 
experiments.  The amount of Pepstatin A was increased to 50 µM during the pulse chase 
experiment, while the amounts of E64d and Leupeptin were maintained at 10 µM and 5 
µM respectively. Cells were pulse (P) labeled with [35S] methionine/cysteine for 1 hour 
and then chased for 2 and 4 hours.  Cell and media associated viral proteins were 
solublized and immunoprecipitated with pooled AIDS patient sera.  Samples were 
separated by SDS PAGE and visualized by phosphorimaging using The Discovery Series 
Quantity One software.  (b) Quantitation of intracellular gp120/Pr55 ratios of Ubc9 
siRNA knockdown cells compared to control cells.  The gp120/Pr55 ratios of controls 
cells were normalized to 1.   (c) HIV Env processing and stability in Ubc9 knockdown 
cells in the presence of Lysosome acidification inhibitor NH4Cl.  Pulse chase experiments 
were carried out as before after a 45 minute pretreatment with NH4Cl.  A representative, 
over-exposed gel is shown so that partially Endo Hf resistant Env can be more easily 
visualized. Viral proteins and their positions in the gel are labeled on the left.  The 
identity of Endo Hf, untreated viral proteins and their positions in the gel are labeled on 
the right.  Deglycosylated Endo Hf sensitive forms gp160 residing in the ER are labeled 
as gp160s.   Partially deglycosylated, Endo Hf resistant forms of gp160 that have had 
their glycans modified in the TGN are labeled as gp160r. Forms of gp160 that have 
potentially undergone partial deglycosylation are denoted as gp160^ in Endo Hf untreated 
samples.  
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Figure 4 
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Figure 4 (continued) 
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Figure 4:  Ubc9 is involved in the regulation of autophagy.  (a) Immunoblot for Actin, 
LC3, and Ubc9 levels in Ubc9 knocked downed cells.  239t cells were transfected with 
Ctr. RNA, or siRNA in combination with pNL4-3, RNA alone, pNL4-3 alone, or left 
untransfected.  24 hours after transfection with pNL4-3, cells were lysed in lysis buffer, 
and protein concentration in the lysates was assayed by BCA assays.  Proteins were 
separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted for Actin, 
Ubc9, and LC3 expression.  Unequal loading of whole cell lysates for LC3 
immunoblotting, approximately 1/3 less Ubc9 RNAi transfected cells lysates compared to 
control cells (upper panels).  Equal loading of whole cell lysates for Ubc9 
immunoblotting (lower panels).  (b) Ratio of Actin/LC3-II levels normalized to 
untransfected cells.  (c) Autophagosomes complete autophagy by fusing with lysosomes 
to form autophagolysosomes.  Immunoblot of cellular actin and LC3-II levels in cell 
lysates from pulse-chase experiments using a combination of lysosome inhibitors E64d, 
Pepstatin A, and Leupeptin. 
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Figure 5 
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Figure 5:  HIV Env processing and stability in Ubc9 knockdown cells in the presence of 
autophagy inhibitor 3MA (PI-3K inhibitor).  293T cells were transfected with pNL4-3 in 
combination with Ctr. RNA (a) or Ubc9 siRNA (b) as in previous experiments.  3MA 
(10mM) was added to the culture media for 2 hours prior to pulse chase experiments and 
was maintained throughout the experiment.  Cells were pulse (P) labeled with [
35
S] 
methionine/cysteine for 1 hour and then chased for 2 and 4 hours.  Cell associated viral 
proteins were solublized and immunoprecipitated with pooled AIDS patient sera, split 
equally, and incubated for 3.5 hours at 37° C in the presence, or absence of Endo H f.  
Samples were separated by SDS PAGE and visualized by phosphorimaging using The 
Discovery Series Quantity One software. A representative, over-exposed gel is shown so 
that partially Endo Hf resistant Env can be more easily visualized.  Viral proteins and 
their positions in the gel are labeled on the left.  The identity of Endo Hf, untreated viral 
proteins and their positions in the gel are labeled on the right.  Deglycosylated Endo Hf 
sensitive forms gp160 residing in the ER are labeled as gp160s.  Partially deglycosylated, 
Endo Hf resistant forms of gp160 and gp120 that have had their glycans modified in the 
TGN are labeled as gp160r and gp120r.  
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Figure 6 
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Figure 6:  Efficiency of autophagy inhibitor 3-MA (PI-3K inhibitor) to inhibit autophagy 
in Ubc9 knockdown cells.  Immunoblot of LC3, actin, and Ubc9 in cell lysates from 
pulse-chase experiments using autophagy inhibitor 3-MA (10mM). 
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Figure 7 
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Figure 7:  Efficiency of autophagy inhibitor Wortmannin (PI-3K inhibitor) to inhibit 
autophagy in Ubc9 knockdown cells.  293T cells were transfected with Ubc9 siRNA and 
pNL4-3 as in previous experiments. Wortmannin (50nM) was added to the culture media 
for 2.  (b) Immunoblot of Actin, LC3 and Ubc9 expression in whole cell lysates.  Cells 
were cultured in PBS for 2.5 to activate autophagy through FBS and amino acid 
starvation (Strv.). 
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Figure 8 
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Figure 8.   Revised models for mature Env degradation by the lysosome in Ubc9 
knockdown cells.  In Ubc9 knockdown cells HIV-1 Env trafficking from the ER to the 
TGN is normal (black arrow).  After cleavage into gp120/gp41 and transport out of the 
TGN, Env may be directly targeted for degradation in the lysosome instead of the 
assembly site of the plasma membrane. This mistrafficking of Env for degradation could 
be due to altered interactions with Gag, as Gag itself is mistrafficked to the assembly site  
on the plasma membrane in Ubc9 knockdown cells (green arrow).  Another possibility is 
that because Gag is mistrafficked to the assembly site in Ubc9 knockdown cells, and may 
not stabilize Env at the plasma membrane and may be quickly endocytosed.  In Ubc9 
knockdown cells, a portion of endocytosed Env may then be targeted for degradation in 
the lysosome instead of recycling back to the TGN (violet arrows).  Alternatively, the 
trafficking or function of yet unknown cellular factor(s) that are involved in Env stability 
and packaging into assembling virions may have been disrupted by altering Gag/Ubc9 
interactions (gray question mark).  With the observation that autophagic flux is increased 
in Ubc9 knockdown cells, autophagy could be an additional mechanism that results in 
degradation of mature Env in the lysosome (blue arrows).   
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Summary of results 
The role of Ubc9 in late events of HIV-1 infection. 
In the previous chapters, we have identified Ubc9 as a HIV-1 Gag interacting 
partner and have found that it is an important host factor involved in the assembly of fully 
infectious HIV-1 virions.  We have examined the role of Ubc9 during HIV-1 assembly, 
specifically showing how Ubc9 functions with Gag to stabilize mature intracellular Env 
and package it into assembling virions.  Using various biochemical and microscopic 
imaging techniques, we showed that in Ubc9 knockdown cells, gp160 stability, 
glycosylation, and oligomerization in the endoplasmic reticulum (ER) was unaffected and 
that gp160 trafficked out of the ER to the trans-Golgi network (TGN) normally.  
However, after Env underwent cleavage maturation by Furin, and trafficked out of the 
TGN, gp120/gp41, the lack of Ubc9 caused Env to be specifically degraded in the 
lysosome.  Env degradation likely occurred before Env was trafficked to the plasma 
membrane.  Interestingly, during the course of these experiments, we serendipitously 
found that Ubc9 knockdown cells undergo increased autophagic flux.  However, we were 
unable to block autophagy using common autophagy inhibitors (3-MA and wortmannin) 
did not block autphagy, thus we could not conclude if the increased autophagy in Ubc9 
knockdown cells played a direct role in mature intracellular Env degradation in the 
lysosome, or if Env degradation occurred in spite of the increased autophagy. 
We have proposed a mechanism that when interactions between Gag and Ubc9 
are disrupted in knockdown cells, the Ubc9-dependent Gag function was uncoupled, 
resulting in the mistargeting of Env to the lysosome.  This model is based on our 
observations that Env biosynthesis was normal until trafficked out of the TGN, and that 
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Gag and Env were observed to have altered association with the plasma membrane and 
lipid rafts.  There are multiple reports in the literature demonstrating that Gag and Env 
affect the co-trafficking and stability of each other at the assembly site (99, 143, 171, 
203, 210, 221, 222, 374).   However, our data cannot rule out a mechanism where Env 
and Gag are both targeted to the plasma membrane, but because of the interruption of 
Gag and Ubc9 interactions in knockdown cells, Gag does not stabilize Env at the 
assembly site and it is quickly endocytosed, trafficked through the late endosome (LE), 
and subsequently degraded in the lysosome. 
Future experiments to study the role of Ubc9 in HIV-1 late infection 
events. 
In order to refine these models, I would first perform experiments to determine if 
endocytosis and recycling of Env is involved in the decreased intracellular levels of 
mature Env in Ubc9 knockdown cells.  I would examine the surface expression and 
stability of Env in Ubc9 knockdown cells using Env mutants that have been demonstrated 
to inhibit endocytosis from the plasma membrane.  Mutation of the tyrosine at position 
712 in the dominant endocytosis signal in the cytoplasmic tail (CT) of gp41 (Y/C, 
tyrosine to cysteine) has been previously shown to decrease the endocytosis of Env by up 
to 2-fold (382).  If Gag affects Env stability and trafficking to the lysosome at an 
intracellular site before co-trafficking to the plasma membrane, we would expect that in 
Ubc9 knockdown cells, intracellular Env (Y/C) stability and expression at the cell surface 
would still be disrupted when compared to control cells.  However, if Env degradation in 
Ubc9 knockdown cells is dependent upon increased endocytosis, due to defects in the 
ability of Gag to stabilize Env on the surface of the cells, we would expect the levels of 
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Env (Y/C) on the plasma membrane to be higher relative to wild type Env in Ubc9 
knockdown cells.  We might also hypothesize that these mutations would increase Env 
stability, since less Env would undergo endocytosis, leading to less being trafficked 
through the late endosome and degraded in the lysosome.  Results from these 
experiments could also be further confirmed by examining surface expression and 
stability of WT Env in Ubc9 knockdown cells in the presence of endocytosis inhibitors 
other than chlorpromazine (CPZ), which we found to have affected Env biosynthesis in 
the endoplasmic reticulum leading to defects in transport to the TGN.  Inhibitors such as 
Chloroquine, Methyl-b-cyclodextrin, bafilomycin A1, or dynosore would be some 
alternatives to test. 
I would also perform experiments that could confirm our hypothesis that 
interactions between the cytoplasmic tail (CT) of Env and the Matrix domain of Gag are 
important for the degradation of Env in Ubc9 knockdown cells.  These experiments could 
be carried out in Ubc9 knockdown cells using Env CT deletion mutants (CT-del-63 or 
CT-del-144-2) (117, 258).  We would hypothesize that if sequences within the CT of 
HIV-1 Env are important for stability in a Gag and Ubc9 dependent manner, deleting the 
CT should make the mutant Env insensitive to degradation in Ubc9 knockdown cells, and 
a similar amount of mutant Env should be packaged into virions compared to virions 
produced in control cells.  We would also hypothesize that the CT mutants would restore 
specific infectivity of virions produced in Ubc9 knockdown cells compared to virions 
produced in control cells.  These results could strengthen our published data using VSV-
G pseudotyped virions, where we demonstrated that neither the packaging of VSV-G, a 
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heterologous viral glycoprotein, into assembling virions nor the infectivity of the 
pseudotyped virions was affected by Ubc9 knockdown (159). 
As mentioned earlier, we observed that Ubc9 knockdown cells were undergoing 
increased autophagy and that neither of the autophagy inhibitors tested, 3-MA nor 
wortmannin, were able to inhibit autophagy in Ubc9 knockdown cells.  These results 
cannot determine if autophagy plays a direct role in the degradation of mature 
intracellular Env in Ubc9 knockdown cells. 50nM of wortmannin might not be efficient 
in blocking a 3-fold increase in autophagy and we may have used sub-optimal 
concentrations.  However, 50nM of wortmannin was sufficient to block serum and amino 
acid starvation induced autophagy in control cells.  Thus experiments should be carried 
out to determine optimal wortmannin concentrations to use to inhibit autophagy in Ubc9 
knockdown cells.  We have planned to examine if increasing the concentration of 
autophagy inhibitors might block autophagy in Ubc9 knockdown cell and if Env levels 
could be restored to normal levels. If autophagy activation in Ubc9 knockdown cells is 
dependent upon PI3K activity, we would expect that higher concentrations of the 
inhibitors would lead to a decrease in LC3-II levels as compared to untreated Ubc9 
knockdown cells.  Once the concentration that blocks autophagy is optimized, these 
experiments should be able to clarify whether autophagy is involved in Env degradation 
in Ubc9 knockdown cells.  These experiments would also determine if the initiation of 
autophagy is activated through PI3K dependent, or independent pathways. 
Alternatively, if increased inhibitor concentrations are found not to inhibit 
autophagy, we would perform experiments to determine if increased autophagy might be 
playing a role in the lysosomal degradation of Env in Ubc9 knockdown cells.  We are in 
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the process of utilizing confocal microscopy to examine potential co-localization between 
Env and autophagic vacuoles to determine if there is an increase in their co-localization 
in Ubc9 knockdown cells.  For these experiments we are using 293 cell lines, which 
stably express LC3-GFP.  Cells undergoing autophagy should show increased punctate 
staining correlating with LC3-GFP lipidation and increased formation of autophagic 
vacuoles.  The number of GFP positive puncta has been found to be an indicator of the 
levels of cellular autophagy (185).  If we observe an increase in co-localization or close 
association between Env and LC3-GFP puncta in Ubc9 knockdown cells, it would 
support the hypothesis that HIV-1 Env is degraded through the upregulated autophagy 
pathways.  However, if Env is found not to co-localize with punctate LC3-GFP, it would 
suggest that autophagy is not involved with Env degradation and Env may be degraded in 
the lysosome in an autophagy independent mechanism.  We will also carry out these 
experiments in the presence of lysosome inhibitors, since Env turnover might be too 
dynamic to capture by microscopy.  We could also examine the potential co-localization 
of Gag and punctate LC3-GFP.  We have demonstrated that Gag trafficking was altered 
in Ubc9 knockdown cells, and it is not known whether altered Gag trafficking has an 
effect on Gag-LC3-GFP colocalization.  If the hypothesis that Env is degraded through 
increased autophagy in Ubc9 knockdown cells, we would also expect an increase in Gag 
association/co-localization with LC3-GFP as Env degradation is Gag dependent.   
Furthermore, if we find an increase in Env and Gag co-localization with punctate 
LC3-GFP in Ubc9 knockdown cells, we would use thin-section electron microscopy 
(EM) to further substantiate the confocal co-localization data.  Using EM with 
immunogold labeling techniques to identify Env and Gag localization to the autophagic 
 178 
vacuoles would support the hypothesis that autophagy is involved in Env degradation in 
Ubc9 knockdown cells.  
 Another possible limitation of our data is that they were obtained using 293T cells 
because these are easily manipulatable with high transfection efficiencies and can express 
high levels of exogenous proteins, as well as very efficient Ubc9 knockdown.  However, 
the natural target cells for HIV-1 are primarily T-cells and macrophages, and using more 
relevant cell types to confirm our findings in 293T cells is important.   Nevertheless, 
there have been many discoveries about the retroviral replication cycles through the use 
of common laboratory cell lines that were later confirmed in more relevant HIV-1 target 
cells.  Some examples are the Late domains and the role of TSG101 in budding, Env 
packaging signals, role of restriction factor Tetherin, function of various host factors 
involved with replication, and general characteristics of Env and Gag function (3, 41, 83, 
98, 122, 128, 258, 341).  
The role of Ubc9 in early events during HIV-1 infection. 
The early events of the HIV-1 replication cycle begin by the attachment of the 
virus to the target cell through interactions between the host CD4 and viral Env.  After 
attachment and engagement with the host co-receptor, the viral Env undergoes 
conformational changes, facilitating the fusion of the viral membrane with the host 
plasma membrane.  The fusion of the membranes releases the viral core into the 
cytoplasm, where the viral RNA is uncoated and is reverse transcribed into viral DNA 
(vDNA).  The viral DNA in complex with viral proteins is transported into the nucleus.  
In the nucleus, the vDNA is integrated into the host chromosome by the viral integrase, 
and the viral genes are expressed using the host transcriptional and translational 
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machinery (early events reviewed in 71).  During these early events, the viral proteins 
utilize specific host proteins to their advantage and avoid others that are detrimental to 
complete the infection of new target cells (reviewed in 349, 262, 202). 
The role of Ubc9 in HIV-1 target cells has not been examined, however 
SUMOylation had been implicated to be involved in the early infection events of 
replication (137, 400).  These studies were done with infectious retroviral clones that 
contained lysine mutations that where shown to block SUMOylation of p30 in MoMuLV, 
p6-GFP in HIV-1, or HIV-1 Integrase.  We have begun experiments to examine if Ubc9 
is also an important host factor during HIV-1 early infectious events.  Our experiments 
are potentially more far reaching because we will be determining if Ubc9 expression is 
needed in target cells during infection and not just the role of lysine mutations and 
potential SUMOylation of viral proteins during early events. 
For these experiments, we have examined the ability of HIV-1 to complete the 
early steps of the replication cycle and express new proteins from the integrated provirus 
in Ubc9 knockdown cells.  Ubc9 knockdown cells were infected with VSV-g 
pseudotyped NL4-3-green fluorescent protein (GFP) and assayed for the expression of 
GFP in the infected cell by flow cytometry.  NL4-3-GFP is an infectious proviral clone 
that had GFP cloned in-frame 5’ of the Nef open reading frame.  VSV-G pseudotyped 
virions were used because 293T cells do not express the HIV-1 receptor and co-receptor, 
and thus cannot support HIV-1 Env dependent entry.  Pseudotyping NL4-3-GFP with 
VSV-G is a common technique used by the HIV-1 field to increase virion infectivity and 
expand cell tropism for early infectious event studies (18). 
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To examine the role of Ubc9 in HIV-1 early events, 293T cells transfected as in 
previous knockdown experiments, or left untransfected and were infected with equal 
amounts of VSV-G pseudotyped NL4-3-GFP at either 24 or 48 hours after the second 
Ubc9 siRNA transfection.  We allowed the virus to infect the cells for approximately 30 
hours before the cells were fixed in 4% paraformaldehyde for 20 minutes at room 
temperature, washed 3-times with phosphate buffered saline (PBS), and analyzed for 
GFP expression by flow cytometry.  The percentage of cells that expressed GFP after 
being infected 24 hours after the second Ubc9 siRNA transfection were decreased 
approximately 3-fold in Ubc9 knockdown cells compared to control cells (Fig. 1a).  The 
percentage of GFP positive cells decreased by approximately 6-fold compared to control 
cells when cells were infected 48 hours after the second siRNA transfection (Fig. 1b). 
During the course of the experiment, Ubc9 was efficiently knocked down compared to 
control cells (Fig. 1c).  These results suggest that Ubc9 is important for HIV-1 early 
infectious events leading to the integration of vDNA and the LTR based expression of 
GFP.   
Interestingly, LC3-II levels increased over time, which correlated with a decrease 
in infection and GFP expression (Fig. 1c).  These results suggest that increased 
autophagy may play a role in the decreased completion of early infectious events in Ubc9 
knockdown cells, however further experiments are needed to confirm the observation, 
and determine if autophagy is the cause of decreased infectivity.  However, our 
preliminary finding do not support those of other groups, demonstrating that the 
autophagy components Atg7, Atg8, Atg12, and Atg16L2 were required for HIV-1 
infection (41).    
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Other than autophagy, there are other possible mechanisms that might explain the 
observed decrease in infection by pseudotyped HIV-1 in Ubc9 knockdown cells.  First, 
the defect could be directly related to Ubc9 expression levels, and Ubc9 knockdown will 
result in an interruption of its interactions with viral components during early infectious 
events.  Second, the defect could be due to changes in SUMOylation of viral or host 
proteins, and these changes may have altered their functions (SUMOylation reviewed in 
124, 405).  Third, defects could be due to the alteration of the mRNA of the host or viral 
mRNA transcriptional levels, including miRNA, which might have affected the 
expression of host factors utilized by the virus to enter the host cell and complete early 
events.  Lastly, Ubc9 knockdown could increase the expression of host restriction factors. 
Future experiments to investigate the role of Ubc9 in early events of 
viral infection. 
As stated above, there could be a number of mechanisms involved with the 
decrease in HIV-1 infectivity in Ubc9 cells.  Recently, Zamborlini et al. described lysine 
mutations in HIV-1 Integrase that affected SUMOylation by SUMO-2 and led to defects 
in viral integration (401).  Our data is in agreement with the report by Zamborlini et al.  
Based on their results, we would expect a decrease in Integrase SUMOylation in Ubc9 
knockdown cells, which could lead to the defects in integration and transduction of GFP 
in Ubc9 knockdown cells.  However, our knockdown system might also affect HIV-1 
infection at various early events if Ubc9 plays a role in these events in addition to 
integration, such as nuclear import of the pre-integration complex (PIC).  Zamborlini et 
al. reported that there was no change in nuclear import of the PIC, which suggests that the 
SUMOylation of integrase is not involved with nuclear import, however Ubc9 could play 
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a role in nuclear import independent of the SUMOylation of integrase.  Ubc9 is known to 
also localize to the nuclear pore (402), an alteration in nuclear pore composition and 
function in Ubc9 knockdown could be another mechanism to explain the decrease in 
infectivity because of defects in nuclear import of the pre-integration complex (PIC).  
However, nuclear pore function did not appear to be affected as viral and host transcripts 
were expressed and translated at normal levels.  The potential role of Ubc9 in nuclear 
import could be tested by assaying for the completion of the various steps of reverse 
transcription in infected Ubc9 knockdown cells.  If Ubc9 plays a role in nuclear import of 
the PIC, we would expect to detect lower levels of 2-LTR circles, which were used as a 
marker for nuclear localization of the PIC.  If 2-LTR levels are found to be unchanged, 
this would suggest that the defect is occurring during integration of the provirus, and 
would be in agreement with the results of Zamborlini et al.  However, if lower levels of 
2-LTRs are detected, we would need to examine the completion of the earlier steps in 
reverse transcription, since defects earlier in reverse transcription would also lead to 
lower 2-LTR levels.  Further work will need to be carried out to fully understand how 
Ubc9 is involved in the early events of the HIV-1 replication cycle. 
Potential role of Ubc9 in autophagy regulation and potential 
mechanisms involved. 
During the course of the autophagy inhibitor experiments we found that 
autophagy was increased in Ubc9 knockdown cells by approximately 3-fold based on 
LC3-II levels.  It was also interesting to find that the commonly used inhibitors 3-MA 
and wortmannin, which inhibit autophagy by inhibiting PI3K, did not block autophagy 
under these conditions. It is possible that the concentrations of the inhibitors used were 
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not optimized and thus further experiments will be need to examine if higher amounts can 
lead to the inhibition of autophagy.  Alternatively, Ubc9 knockdown can activate, or 
deregulate autophagy in a PI3K independent manner.  Interestingly, an abstract by Rao et 
al. suggested that Vps34, a PI3K involved in autophagy activation, is SUMOylated with 
SUMO-1 by E3 SUMO ligase KAP1, and that SUMOylation is important for autophagy 
initiation.  It is possible that the SUMOylation function of Ubc9 is involved in the 
regulation of autophagy.  
To our knowledge, there are no published reports implicating that Ubc9 or 
SUMOylation can directly affect the cellular proteins, which are involved with 
autophagic vesicle elongation or fusion with the lysosome such as Atg3, Atg4, Atg5, 
Atg7, Atg9, Atg12, Atg16, Atg18, or LC3. The mechanism behind increased autophagy 
in Ubc9 knockdown cells is not known, and many of the proteins that have been 
demonstrated to play a role in regulating autophagy are also part of the 
Ubc9/SUMOylatio pathway.  Given the far reaching role of Ubc9 in cellular metabolism 
and replication, it is likely that more than one of the potential mechanisms contributes to 
increased autophagy in Ubc9 knockdown cells, and a combination of one or all of them 
could be contributing to the induction of autophagy in Ubc9 knockdown cells.   
Future experiments to examine the role of SUMOylation in the 
induction of autophagy by Ubc9 knockdown. 
We will further examine the role of SUMOylation in the activation of autophagy 
in Ubc9 knockdown cells through various methods.  To examine if the enzymatic E2 
SUMO conjugase activity of Ubc9 is involved in autophagy regulation, the trans-
dominant negative Ubc9 mutant (C93A) will be used to study its effect on autophagy.  
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C93A is a point mutation in the enzymatic active site that blocks Ubc9 function as an E2 
SUMO conjugase.  If SUMOylation is a key factor in regulating autophagy, autophagy 
would be reduced in the presence of the C93A mutant.  Autophagy activation could also 
be examined when SUMOylation is knocked down using siRNA specific for SUMO-1, 
SUMO-2, SUMO-3, and SUMO-4 individually and in combination with each other.  If 
SUMO knockdown by siRNA leads to increased autophagy, this would support the 
hypothesis that SUMOylation of host factors regulate autophagy activation and would 
also be in agreement with our Ubc9 knockdown data.  However, detection of endogenous 
SUMOylation is already difficult, and the detection of knocked down SUMOylation 
could be more difficult.  The SUMO siRNA experiments might also be difficult to 
interpret, because Ubc9 itself is SUMOylated and SUMOylation causes changes in 
binding characteristic with target proteins (144, 186).  Alternatively, gain of function 
experiments can be carried out, where autophagy activation would be monitored in cells 
that have undergone endogenous Ubc9 knockdown, and then restore Ubc9 expression 
with either exogenous Ubc9 or C93A that is resistant to siRNA knockdown.  We would 
hypothesize that if SUMOylation were important in the upregulation of autophagy in 
Ubc9 knockdown cells, we would expect that autophagy will be induced upon expression 
of the SUMOylation minus Ubc9 mutant in knockdown cells.  However, if SUMOylation 
is not important for the activation of autophagy in Ubc9 knockdown cells, we would 
expect that the expression of resistant C93A would block the activation of autophagy in 
Ubc9 knockdown cells similar to endogenous Ubc9.  Another experiment that could be 
carried out is to overexpress the various SUMO isoforms, either individually or in 
combination to examine autophagy activation.  If SUMOylation is important for 
 185 
autophagy regulation, we would hypothesize that with excess SUMOylation, the 
excessive SUMOylation of repressors may inhibit the activation of autophagy upon 
exogenous stimulation, since intracellular SUMO levels are the limiting factor in protein 
SUMOylation (87).  
If SUMOylation is found to be an important factor for autophagy regulation, it 
will still be very difficult to identify which cellular protein(s) may be involved with the 
activation of autophagy in Ubc9 knockdown cells.  Examining the activation state of 
known regulators of autophagy, such as some of the potential pathways detailed above, 
will first be carried out.  These will include examining the levels of ROS, activation of 
the MEK/ERK signal pathway, activation of the PKA, PKB and PKC pathways, 
activation state of c-Jun signal pathway, and Ca2+ release from the ER and mitochondria 
in Ubc9 knockdown cells.  If specific pathways are found to be activated in Ubc9 
knockdown cells, further analysis of the pathways by data mining to identify potential 
interaction/complex partners based on previously published results may reveal proteins 
that are already known to interact with Ubc9 and/or are known targets of SUMOylation.  
The known components of the pathway(s) could also be analyzed for potential 
SUMOylation consensus motifs in an effort to narrow down which components may be 
involved in the increased autophagy.  
Based on the outcomes of these proposed experiments, new experiments could 
then be designed to study the role of Ubc9 and the newly identified component, and its 
affect on autophagy regulation. 
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Figure 1.  Ubc9 expression is important during the early infectious events in HIV-1 
target cells.  24 (a) and 48 (b) hours post second RNA transfections, 293T cells 
transfected with Ctr. RNA, Ubc9 siRNA, or left untransfected were infected with VSV-G 
pseudotyped NL4-3-GFP virions.  Cells were infected for approximately 30 hours, fixed 
with 4% paraformaldehyde in PBS for 20 minutes, washed multiple times with PBS, and 
analyzed for GFP expression by flow cytometry. (c) Ubc9, and LC3-II expression in 
293T whole cell lysates at 1, 2, and 3 days post second RNA transfections. 
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